Trading Analysis Report: COHR¶

Analysis date: 2026-10-14
Rating: Underweight
Generated: 2026-10-14 17:39:24
TradingAgents 0.6.0: openai, deep gpt-6-astra, quick gpt-6.1-sol
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 263.32 Price As Of: 2026-10-14

COHR — Technical Market Analysis¶

Company: Coherent Corp. | Exchange: NYQ | Quote currency: USD Focus: Daily/swing trading, with weekly and monthly context.

Executive assessment¶

COHR is experiencing a sharp daily selloff within a weekly uptrend that remains intact—but is approaching its trailing-stop reference. The distinction matters: the evidence supports a tactically bearish assessment, but not yet a confirmed bearish reversal across all timeframes.

Three competing forces define the current setup:

Daily deterioration: COHR closed below both its 50-day and 200-day moving averages, with RSI below its neutral midpoint and OBV declining during the latest downswing.
Higher-timeframe support for the existing regime: Weekly and monthly SuperTrend remain UP. The weekly signal takes priority, although its trailing stop is relatively close to the latest close.
Increasing rebound risk: The daily Z-score is below −2, indicating statistical downside stretch. However, RSI is not conventionally oversold, and none of the TD-9 setups has completed.

Technical implication: Neither an unconditional dip-buy nor a fresh short chased near the latest low has compelling confirmation. COHR needs either a failed recovery that improves bearish trade structure or a sustained recovery that demonstrates buyers are regaining control.

1. Verified price action: a significant setback¶

The verified October 14 bar was:

Open: 281.13
High: 285.00
Low: 261.90
Close: 263.32
Volume: 6,769,516 shares

COHR closed just 1.42 above its session low, a weak finishing position within the day’s range.

The verified closing-price sequence also shows substantial damage:

2026-10-13: 289.98
2026-10-14: 263.32

That is a decline of 26.66, or approximately 9.2%, calculated from those two verified closes.

Over the broader recent downswing, COHR fell from a 338.36 close on October 6 to 263.32 on October 14, approximately 22.2%. The latest close is also below the 264.41 close on September 3, making it the lowest close in the snapshot’s supplied 30-session window.

These observations establish meaningful downside pressure. They do not, by themselves, establish capitulation or a durable bottom.

Moving-average structure¶

The verified averages are:

50-day SMA: 303.43
200-day SMA: 293.97

The current ordering is:

Price < 200-day SMA < 50-day SMA

This is unfavorable for immediate price momentum: both averages are now overhead recovery references.

However, the 50-day SMA remains above the 200-day SMA. There is no current death-cross configuration. The correct interpretation is that price has deteriorated substantially before the slower moving-average relationship has become fully bearish.

For COHR, recovering 293.97 would be an initial improvement. Recovering and holding 303.43 would provide stronger evidence of medium-term repair. Neither level should be treated as guaranteed resistance; they are dynamic reference points that will change with subsequent closes.

2. SuperTrend: the weekly regime is the key distinction¶

The dedicated SuperTrend tool reports:

Tier 1 — Weekly: UP; trailing stop 255.29
Tier 2 — Monthly: UP; trailing stop 228.67
Tier 3 — Daily: DOWN; trailing stop 340.94

The prescribed hierarchy is weekly > monthly > daily.

Weekly: still UP, but vulnerable¶

COHR’s close is only 8.03 above the weekly trailing stop of 255.29.

That is a narrow cushion relative to daily ATR of 22.50—approximately 0.36 daily ATR. This comparison does not predict a breach, but it shows that the weekly boundary is close relative to the stock’s recent trading range.

A confirmed weekly close through the then-current weekly SuperTrend stop would materially strengthen the bearish interpretation by aligning the primary weekly signal with the already-bearish daily signal.

Conversely, simply remaining above the weekly line is not sufficient evidence to buy. A higher low, improving momentum, and recovering participation would make a stronger case.

Monthly: the broader regime has not flipped¶

Monthly SuperTrend remains UP above its 228.67 trailing stop.

This provides longer-horizon context, not proof that a decline must stop there. If the weekly signal weakens, the monthly line becomes another regime-monitoring reference—not an automatically validated support level or price target.

Daily: a rebound would initially be countertrend¶

Daily SuperTrend remains DOWN, with its trailing stop at 340.94.

A rally toward the moving averages could therefore occur without reversing this daily signal. Distinguish between:

A short-lived oversold bounce.
A recovery through the moving averages.
A confirmed flip of the recalculated daily SuperTrend.

Those are different stages of improvement.

For execution, confirm weekly signals at the relevant weekly close rather than treating an intraday breach as a completed weekly reversal. All trailing-stop values should be refreshed as new bars arrive.

3. Momentum, stretch, and exhaustion: rebound risk without a confirmed bottom¶

RSI: bearish momentum, not conventional oversold¶

Verified RSI: 39.30

RSI is below 50, consistent with weak momentum. It is not below the conventional 30 oversold threshold.

For COHR, this means:

The selloff is substantial, but RSI alone does not identify an extreme momentum washout.
An RSI turn higher would be an early improvement.
A sustained recovery above 50 would provide stronger evidence of momentum repair than a small bounce while RSI remains below that midpoint.

Z-score: only the daily timeframe is statistically stretched¶

The dedicated Z-score tool reports:

Weekly: −1.33
Monthly: +0.63
Daily: −2.05

The daily reading meets the tool’s |Z| ≥ 2 stretch threshold.

The weekly reading is below its mean but not at that same extreme, while the monthly reading remains modestly above its mean. Consequently, this is daily downside stretch, not a uniformly oversold condition across the higher timeframes.

There is no contradiction between daily Z-score below −2 and RSI above 30. Z-score measures distance from an average; RSI measures the balance of recent gains and losses.

For COHR, the stretch increases rebound risk but does not establish that selling is finished. Statistical extremes can persist during directional moves.

TD-9: downside setups are developing, not complete¶

The dedicated TD-9 tool reports:

Weekly: +1, buy setup, 1 of 9
Monthly: +3, buy setup, 3 of 9
Daily: +5, buy setup, 5 of 9

A “buy setup” is an exhaustion-monitoring label—not an instruction to buy.

The daily count is developing, but it has not completed. More importantly, the primary weekly count is only at 1. None of these readings supplies a completed TD-9 reversal watch.

The counts can also reset. It would be inappropriate to assume the daily setup must reach 9 on a predetermined date.

4. Volume: recent selling confirmation, with a longer-window divergence watch¶

OBV provides a mixed but useful perspective:

From October 6 to October 14, OBV declined, confirming weaker participation during COHR’s latest price downswing.
October 14 OBV remains above its September 3 reading, even though COHR’s latest close of 263.32 is below the September 3 close of 264.41.

The second observation creates a potential positive divergence across that longer comparison window: price has made a slightly lower closing low without OBV making a corresponding lower reading.

That is worth monitoring, but it does not override the recent OBV downturn. A more persuasive recovery would involve COHR forming a higher price low while OBV begins rising again.

The latest volume of approximately 6.77 million shares does not, on its own, establish capitulation. No relative-volume benchmark or volume-climax confirmation was returned, and OBV does not identify which investor groups are buying or selling.

5. Conditional trading setups for COHR¶

These are technical scenarios for further trade assessment, not unconditional orders.

Scenario A: bearish continuation¶

Evidence that would strengthen this scenario includes:

Acceptance below the October 14 low of 261.90, rather than a brief intraday break.
A subsequent failed attempt to reclaim that area.
RSI remaining below 50 and OBV continuing lower.
Ultimately, a confirmed weekly loss of the recalculated weekly SuperTrend boundary.

The immediate complication is the nearby 255.29 weekly SuperTrend reference. It offers little initial distance from the current close.

Illustrative reward/risk—not an order: A hypothetical short at 263.32, with a stop at 285.00 and an initial cover reference at 255.29, would risk 21.68 for 8.03 of potential reward—approximately 0.37R, before costs.

That illustration does not rule out a much larger decline. It shows why chasing the latest low toward the nearest reference can produce poor trade geometry.

Scenario B: a recovery that fails¶

A rebound could create a more clearly defined bearish setup if COHR subsequently rejects an overhead reference area.

Potential areas to observe are:

285.00: October 14 session high.
288.02–289.98: October 12–13 closing-price area.
293.97 and 303.43: Current 200-day and 50-day SMAs.

These are reference areas, not historically validated resistance zones.

A bearish case would strengthen if COHR rallies into one of these areas, forms an actual rejection, and then weakens while RSI remains below 50 and OBV turns down again. Any stop should be based on the structure that actually forms, rather than assuming a precise rejection in advance.

Scenario C: a recovery worth evaluating on the long side¶

The daily statistical stretch makes a rebound plausible, but price confirmation is still needed.

A stronger sequence would be:

COHR stops making lower lows.
Price reclaims 285.00 and subsequently holds a higher low.
OBV turns upward.
RSI improves, with a sustained move above 50 offering stronger confirmation.
Price advances through the 293.97 and 303.43 moving-average references.

An early recovery would remain a countertrend daily trade while daily SuperTrend is DOWN. A later daily SuperTrend flip would represent a different, stronger stage of confirmation.

6. Risk management: volatility can dominate the setup¶

Verified ATR: 22.50, equivalent to approximately 8.5% of the latest close.

ATR is a recent true-range measure—not a forecast, a maximum daily move, or a probability estimate. Nevertheless, it highlights the danger of using an arbitrarily tight stop in COHR.

Practical implications:

Size positions from the actual entry-to-stop distance, not from a desired share count.
Check whether the proposed stop is sensible relative to ATR and the observed price structure.
Do not assume that the 8.03 distance to the weekly trailing stop represents the maximum risk of a long position. A weekly-close rule can permit substantial movement before confirmation.
Allow for gaps, slippage, and stop execution away from the intended price.
For short positions, incorporate rebound/squeeze risk, borrow availability, and carrying costs.

A basic sizing framework is:

Position size = maximum dollar risk ÷ absolute entry-to-stop distance

If a structure-aware stop requires more room, the response is a smaller position—or no trade—not an artificially tighter stop.

Bottom line¶

COHR’s daily evidence is bearish, while its primary weekly trend remains UP but increasingly vulnerable. Daily statistical stretch and a longer-window OBV divergence create rebound risk, yet neither RSI nor TD-9 currently confirms exhaustion.

The clearest technical approach is to wait for either a confirmed failed recovery or a sustained recovery with improving momentum and participation. The current close alone does not provide a well-confirmed entry in either direction.

Data integrity: Latest OHLCV, moving averages, RSI, ATR, and the cited recent closes come from the verified snapshot. SuperTrend, OBV, TD-9, and Z-score come from their dedicated indicator outputs; those fields were not included in the verification snapshot. Overlapping values agree after rounding. No backtest, fundamental assessment, or news-based explanation was supplied.

Selected indicators and key takeaways¶

Eight indicators were selected to distinguish medium- and long-term structure while covering momentum, volatility, participation, exhaustion, and statistical stretch.

Selected indicator	Latest COHR reading	Why selected / practical implication
`close_50_sma`	303.43	Medium-term structure. Price below it indicates repair is needed; a sustained recovery would improve the swing-trading picture.
`close_200_sma`	293.97	Long-term benchmark. Price is below it, but the 50-day SMA remains above it; no current death-cross configuration.
`supertrend`	Weekly UP: 255.29; Monthly UP: 228.67; Daily DOWN: 340.94	Separates primary regime from daily timing. Weekly takes priority and is the key boundary to monitor.
`rsi`	39.30	Momentum confirmation. Bearish below 50, but not conventionally oversold below 30.
`atr`	22.50	Volatility-aware sizing and stop assessment. Tight stops are vulnerable relative to recent ranges.
`obv`	Down October 6–14; above September 3 reading	Recent selling confirmation, with a longer-window positive-divergence watch—not an immediate reversal trigger.
`td_9`	Weekly +1; Monthly +3; Daily +5	Tracks developing downside exhaustion. All are incomplete buy setups; none has reached 9.
`z_score`	Weekly −1.33; Monthly +0.63; Daily −2.05	Identifies daily downside stretch without implying a higher-timeframe bottom. Rebound risk is elevated, but confirmation is required.

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 4.6/10) Confidence: Low

COHR sentiment report¶

Instrument: COHR — Coherent Corp., NYQ; Technology / Scientific & Technical Instruments. Window: 2026-10-07 through 2026-10-14; assessed as of 2026-10-14.

Bottom line: COHR sentiment is mixed, with a bearish near-term tilt. Selloff and AI-financing concerns dominate the immediate discussion, while capacity, backlog and long-term optical-networking demand sustain a competing bullish thesis. This is active disagreement, not neutral or absent sentiment. Confidence is low because Reddit was disabled, news is headline-only, and the retail sample is small and concentrated in the final two days.

1. Source-by-source breakdown¶

Yahoo Finance news: negative near-term framing, constructive longer-term themes¶

The feed contains 20 headlines, but they are not 20 independent COHR developments. Several concern peers, broad stock lists or unrelated businesses, and multiple headlines may describe the same selloff.

Four headlines explicitly put COHR in a trade-down or selloff narrative: StockStory's multi-stock decline report; 24/7 Wall St.'s AI-funding-fears report describing a 7% COHR slide; TIKR's report describing a nearly 8% COHR fall; and Stocktwits' report that the optical-networking selloff extended overnight. These are the strongest immediate negative signals. Without individual publication timestamps or market-price data, the reported percentage moves cannot be added together or treated as separate down sessions.
The positive counterweight is demand and capacity, not verified new financial results. Headlines ask whether COHR's AI data-center expansion can fuel long-term growth, compare COHR and Lumentum backlog quality, and discuss COHR following sold-out-capacity news. These support a constructive narrative, but the supplied material gives no order totals, capacity figures, backlog terms or conversion rates.
Valuation framing is restrained. Simply Wall St.'s description that COHR looks “about right” following sold-out-capacity news suggests strong demand may already be reflected in valuation; it is not an unambiguous undervaluation signal. The retrospective stock-run headline and the question about year-to-date outperformance do not independently establish future upside or verified performance figures.
Earnings is the clearest identifiable company catalyst. GlobeNewswire announces the timing of the COHR FY2027 first-quarter earnings release. The actual release date and time are absent from the supplied headline, so they cannot be specified here.

Peer headlines about optical demand, sharp share-price declines and large year-to-date gains provide sector context, not COHR-specific performance evidence. AXT inventory concerns cannot be assigned to COHR. The CIBC and waste-management headlines, and a stock-list headline that does not identify its constituents, receive no meaningful COHR sentiment weight. Editorial category labels in headlines do not override the supplied company classification. This news feed is evidence of media framing, not measured institutional positioning.

StockTwits: mildly bullish labels, more defensive message bodies¶

There are 30 messages: 6 bullish, 4 bearish and 20 unlabeled. Among the 10 explicitly labeled messages, the split is 60% bullish / 40% bearish, or 1.5 bullish posts per bearish post. That is a modest positive leading retail signal, not overwhelming bullish conviction. Bullish labels represent only 20% of all messages, while two-thirds are unlabeled; the labeled split should not be generalized to the entire sample.

The bodies reveal a more negative immediate trading environment:

Selling pressure and downside speculation recur. On October 14, @Ajux describes “none stop selling,” a “brutal sell off” and “free fall again.” @JFDI calls COHR a “juicy looking short.” @HeyBudWhatsYourProblem_ predicts further declines into the end of the week. These are opinions and observations, not verified prices, flows or short-position data.
Dip buyers remain visible. @Galaxy_Class_Investor describes buying opportunities across connectivity and optics; @Captain_Save_A_Stock reports adding COHR at $278 on October 13; and @loutrades reports opening a 10-share position on October 14. @carminefox anticipates a return to $300 by week-end. These show willingness to buy weakness but do not establish a bottom or verified transactions.
Structural optimism coexists with financing anxiety. @JoeDirty argues AI spending cannot stop and expresses a multi-year optical-sector thesis. Other messages attribute the selloff to AI-investment economics, yields, inflation and war-related concerns. Those macro explanations and predictions are unverified social claims. A relative-value comparison with Lumentum also appears, but its financial figures are not independently supported here. The ETF price projection in @JoeDirty's longer-horizon post is not a COHR price target.

Representativeness is limited: 20 messages are dated October 14 and 10 October 13, leaving no direct StockTwits coverage of October 7–12. Three of the four bearish-tagged messages come from one account, while two of the six bullish-tagged messages come from another. Repeated negative unlabeled comments also come from the same author. Message counts therefore overstate the number of independent viewpoints. Bare cashtags, an RSI question and an account-blocking remark carry little directional information.

Reddit: unavailable by configuration¶

Reddit collection was explicitly disabled. There are no supplied posts from r/wallstreetbets, r/stocks or r/investing, so their tone, substance and engagement cannot be assessed. This is missing coverage, not evidence of neutral sentiment or no discussion. The missing third source requires a low-confidence assessment.

2. Cross-source divergences and alignments¶

Alignment: Selloff headlines and numerous StockTwits bodies reinforce the same immediate concern: COHR is being discussed within a broader optical/AI-infrastructure de-risking episode. AI-financing fears recur in news framing and retail commentary. The supplied evidence does not establish a COHR-specific operating deterioration behind that concern.

Divergence: The 60/40 bullish labeled retail split and visible dip-buying contrast with negative near-term headlines. However, this is a limited divergence: it rests on only ten labeled messages, and much of the unlabeled conversation is defensive. It does not support calling retail overwhelmingly bullish.

Time horizon explains part of the conflict. Bears emphasize the next few sessions and potential technical damage, while some bulls emphasize demand through 2028–2029. Strong long-term industry expectations can coexist with weak short-term sentiment. Also, the Yahoo headline supplied by Stocktwits already includes a retail-rebound narrative; it is not fully independent corroboration of the message feed.

3. Dominant narrative themes¶

AI financing versus AI demand: The central dispute is whether financing concerns undermine the investment cycle despite continued expectations for optical bandwidth demand.
Strong demand does not automatically imply valuation upside: Sold-out-capacity and backlog headlines coexist with “about right” valuation framing and sharp reported declines.
Sector exposure dominates the discussion: COHR repeatedly appears alongside other optical and AI-infrastructure names, supporting a sector-sentiment interpretation rather than an exclusively company-specific explanation.
Dip-buying versus breakdown psychology: New-position and rebound posts compete with short ideas, repeated selling complaints and progressively lower hypothetical price levels.

4. Catalysts and risks surfaced by the data¶

COHR FY2027 first-quarter earnings: The announced release is a potential sentiment reset. If provided, demand, backlog conversion, capacity and outlook commentary could help distinguish durable operating strength from valuation optimism. The release date, consensus estimates and company guidance are not supplied.
AI-financing narrative: Further evidence supporting or challenging funding availability and spending economics could affect the sector narrative. The present headlines establish concern, not confirmed financing failures or COHR order cancellations.
Peer read-through: Optical-sector demand reports may support sentiment, while further sector selloff coverage could reinforce de-risking. Peer conditions should not be assumed to match COHR operations.
Crowd levels are not validated technicals: Posts cite $275 as a claimed 200-day average, possible downside toward $250 or $220–230, a conditional breach of $200 in a severe market decline, and a bullish return to $300. These are trader claims and scenarios, not verified indicators, support/resistance levels or this report's forecasts. No current quote, price history, volume or RSI data is supplied.
Sampling and repetition risk: Overlapping headlines, repeated users, incomplete social coverage and the missing Reddit source can exaggerate apparent consensus. Neither a capitulation signal nor a sustained rebound is established.

This report supplies sentiment evidence for another agent to weigh alongside independently verified fundamentals and technicals; it does not select a COHR trade or predict a price outcome.

5. Summary of key sentiment signals¶

Signal	Direction	Source	Supporting evidence and qualification
Immediate COHR selloff framing	Bearish	Yahoo Finance headlines	Four headlines explicitly describe COHR trading down or extending a selloff; reported declines of 7% and nearly 8% are not additive.
AI-financing concerns	Bearish	News and StockTwits	Funding fears in headlines; retail posts question AI-investment economics and cite macro pressures. Social causal claims remain unverified.
Optical demand, capacity and backlog	Bullish longer-term	News	AI expansion, sold-out-capacity and backlog-quality framing; no supporting operating quantities supplied.
Valuation after capacity news	Mixed / restrained	News	COHR described as looking “about right,” limiting the bullish implication of demand headlines.
Explicit retail sentiment labels	Mildly bullish	StockTwits	6 bullish versus 4 bearish: 60/40 among 10 labels, but only one-third of 30 messages are labeled.
Unlabeled selling commentary	Bearish near-term	StockTwits	Repeated “selling,” “sell off” and “free fall” remarks; some repetition comes from one account.
Dip-buying and rebound conviction	Bullish counterweight	StockTwits	Reported addition at $278, a new 10-share position and a $300 rebound opinion; not verified executions or forecasts.
Earnings announcement	Direction-neutral catalyst	GlobeNewswire headline	COHR FY2027 first-quarter release timing announced; actual date and time absent.
Breadth and independence of evidence	Low confidence	All supplied sources	Reddit disabled; news headline-only; 30 social messages cover October 13–14, with repeated users and many unlabeled posts.

News Analyst¶

COHR: Weekly News and Macro Research Report¶

As of October 14, 2026 | Review period: October 7–14, 2026 Company: Coherent Corp. | Exchange: NYQ | Classification: Technology / Scientific & Technical Instruments

Executive assessment¶

COHR faces a near-term conflict between an optimistic AI-optics demand narrative and deteriorating financing and valuation conditions. This week’s coverage shifted from optical-capacity constraints toward sharp, sector-wide selling attributed to AI funding concerns. Meanwhile, global headlines pointed to hotter inflation, rising sovereign yields, and oil-related uncertainty.

The key distinction for COHR is demand deterioration versus valuation compression. The retrieved headlines support concern about AI financing and sector sentiment, but do not establish that COHR has suffered order cancellations or reduced guidance.

Research conclusion: A COHR rebound thesis needs confirmation from both sector price action and funded customer demand. Positive capacity headlines alone are insufficient when discount rates and financing risks are moving against growth equities. This is a research assessment, not an execution decision.

Evidence limitations¶

The news tools returned headlines and links, not full article bodies. All requested FRED series—CPI, core PCE, unemployment, the federal funds rate, the 10-year Treasury yield, and the yield curve—were unavailable because the data service lacks an API key. Accordingly, macro figures below are either explicitly attributed to news headlines or identified as prediction-market prices; none are presented as independently verified official observations.

1. COHR: What changed this week?¶

October 7–11: Coverage emphasized optical-demand constraints¶

The earlier part of the review window included a Barron’s headline reporting that Lumentum could not keep up with AI demand, alongside commentary about tightening data-center bandwidth.

COHR relevance: Peer capacity constraints are consistent with a constructive optical-networking demand backdrop. They do not, by themselves, establish COHR’s order growth, pricing power, or profitability.

Source: Barron’s — optical-demand constraints.

October 12–13: Capacity optimism coexisted with sector selling¶

The COHR feed included:

A Simply Wall St. headline referencing “sold out capacity” news.
A TIKR headline reporting that COHR fell nearly 8%, alongside substantial declines in optical-networking peers.
Coverage explicitly attributing optical-stock weakness to AI funding fears.

Interpretation: Investors appeared to be distinguishing strong demand narratives from the financing and execution required to turn those narratives into cash flow. However, the retrieved material does not reveal capacity commitments, customer deposits, cancellation rights, or backlog conversion schedules.

Sources: COHR capacity commentary, COHR and peer selloff, AI funding concerns.

October 14: Further selling coverage and an earnings-calendar announcement¶

The October 14 feed contained:

A headline reporting COHR down approximately 7% as AI funding fears hit optical stocks.
An official GlobeNewswire announcement concerning the timing of COHR’s fiscal 2027 first-quarter earnings release.
Continued commentary on COHR’s AI data-center expansion.

Important distinctions:

The reported 7% and nearly 8% declines are article-specific snapshots. They should not be added together or treated as a verified weekly return.
The official scheduling headline is not an earnings result. The returned feed did not expose the release or conference-call date, so that date must be confirmed through COHR investor relations.

Sources: October 14 optical-stock selling, COHR earnings-timing announcement.

What this establishes—and what it does not¶

The headline set supports a sector-wide sentiment and financing-risk explanation for COHR weakness. It does not establish a COHR-specific earnings shortfall, guidance cut, or order-cancellation event. The absence of such a headline is not proof that no adverse development exists.

2. The macro environment relevant to COHR¶

A. Inflation and bond yields are the clearest valuation headwinds¶

Yahoo Finance headlines reported rising Treasury yields following hot inflation data, including one describing the 10-year yield as its highest since 2002. An additional secondary headline cited U.S. inflation at 3.7%, but the returned text did not establish the precise measure or reference period; that number is therefore not used here as a verified CPI observation.

COHR transmission channels:

Higher discount rates can reduce the valuation assigned to future AI-related earnings.
More expensive financing can pressure customers’ data-center investment economics.
Strong operating demand can coexist with a falling COHR share price if valuation multiples compress.

The magnitude of these effects cannot be quantified without verified yields, earnings estimates, and COHR valuation data.

Sources: Inflation and Treasury yields, Long-term Treasury yield headline.

B. Market leadership looks less supportive of speculative growth¶

The global feed described banks rising on earnings while chip stocks fell, technology weakening as oil increased, and an intermittent rebound as AI jitters eased.

COHR implication: Positive company or industry news may not be enough when broader flows favor other sectors. At the same time, the rebound headline cautions against assuming an uninterrupted selloff. COHR’s performance relative to optical peers is more informative than a single market-wide bounce.

Source: Banks versus chip stocks.

C. Oil and Middle East developments remain inflation-sensitive risks¶

One Yahoo Finance headline reported oil falling to $103 after President Trump said the U.S. would not attack Iran before the midterm elections. This is an intraperiod headline figure, not a verified current quote; the returned headline did not identify the oil benchmark.

COHR implication: De-escalation could ease inflation and rate concerns. Renewed disruption could produce the opposite effect. The principal COHR channel is the broader impact on financing costs, equity risk appetite, and customer investment—not a quantified direct oil exposure.

Source: Oil and Iran-related headline.

D. The bond-market issue is international¶

Coverage also described rising sovereign yields globally, with particular concern about France.

COHR implication: If the pressure reflects a broader increase in term premiums or sovereign financing risk, a favorable U.S. inflation release alone might not fully reverse it. That is a scenario to monitor, not a verified attribution of this week’s yield moves.

Source: Global sovereign-yield pressure.

3. What prediction markets are pricing¶

Source: Live Polymarket results retrieved for this report on October 14, 2026. These are contract prices, not official forecasts. Contract definitions, rounding, and liquidity matter; cumulative trading volume is not current order-book depth.

Federal Reserve: A material shift toward tightening risk¶

No rate change after the October 2026 meeting: 70%, down 13 percentage points over one week; approximately $11.73 million traded.
A 25-basis-point increase after the October meeting: 28%, up 13 percentage points; approximately $9.29 million traded.
An increase of at least 50 basis points: 1%.
No Fed rate cuts during calendar 2026: 97%, up 1.2 percentage points.

COHR interpretation: The notable change is the increased pricing of a hike, not simply diminished expectations for a cut. A COHR thesis relying on imminent monetary easing has little support in these retrieved contracts. The annual “no cuts” contract does not imply that rates cannot rise.

Recession: Low priced probability, but a short horizon¶

U.S. recession by the end of 2026: 8%, up 1 percentage point over the week; approximately $2.30 million traded.

COHR interpretation: The combination of low year-end recession pricing and higher hike pricing is more consistent with inflation/rate pressure than with an imminent recession-and-easing narrative. However, this contract covers only the remaining part of 2026; it does not establish low recession risk over the following 12 months.

Geopolitics: Narrow contracts should not be overinterpreted¶

U.S.–Iran final nuclear deal by December 31, 2026: 12%.
Formal U.S. declaration of war on Iran by year-end: 2%.
China invading Taiwan by year-end: 2%.
China–Taiwan military clash before 2027: 4%.

For COHR, low invasion or formal-war probabilities do not eliminate the possibility of limited strikes, shipping disruption, trade restrictions, or supply-chain interruptions.

4. Actionable research framework for COHR¶

Conditions that would strengthen a COHR rebound thesis¶

Rates stabilize: Verified Treasury yields stop rising rather than merely pause intraday.
Sector participation improves: COHR strengthens alongside optical peers, reducing the likelihood that a bounce is isolated or short-lived.
Demand is demonstrably funded: COHR disclosures or customer announcements support committed spending, shipment schedules, and backlog conversion.
Capacity converts into economics: Revenue, margins, and cash flow validate the capacity-expansion narrative.

Conditions that would strengthen the COHR downside-risk case¶

Continued Treasury-yield increases or additional repricing toward Fed tightening.
Concrete evidence of customer financing constraints or delayed projects.
Persistent COHR underperformance after optical peers stabilize.
Weaker guidance, slower backlog conversion, or disappointing cash generation.

Priority checks before an execution decision¶

Confirm COHR’s earnings date and call time. The scheduling announcement makes calendar verification the immediate priority.
Separate backlog quantity from quality. Establish delivery timing, cancellation provisions, customer concentration, and funding commitments where disclosed.
Review COHR cash conversion and investment requirements. Sold-out capacity does not automatically imply strong free cash flow.
Obtain live COHR market data. Adjusted OHLCV, spreads, and realized/implied volatility are needed before setting entries, stops, or position size.
Verify official macro releases. Current inflation, labor, policy-rate, and Treasury data remain essential missing inputs.

Bottom line: The available evidence supports heightened caution about COHR’s near-term sensitivity to financing conditions. It does not establish that its underlying AI-optics opportunity has broken, nor that the selloff has created a valuation bargain.

Key-point summary¶

Theme	Supporting evidence	COHR implication	Next confirmation needed
AI-optics demand	Capacity-constraint and data-center expansion headlines	Constructive demand narrative, but not verified earnings growth	Funded orders, delivery schedules, backlog conversion
Sector selling	Headlines reported COHR declines of roughly 7% and nearly 8% in separate coverage	Elevated sentiment and volatility risk; no verified weekly return	Live COHR prices, volume, and peer-relative performance
Earnings catalyst	Official FY2027 Q1 scheduling announcement appeared October 14	Upcoming disclosure may test the demand narrative	Exact release/call date and guidance
Inflation and yields	News reported hot inflation and rising Treasury yields	Valuation and customer-financing headwinds	Official inflation data and current yields
Fed repricing	October hold 70%; 25-bp hike 28%, up 13 percentage points	An easing-led COHR thesis has limited market support	Subsequent contract moves and Fed communications
Growth risk	Year-end U.S. recession contract priced at 8%	Low short-horizon recession pricing does not remove longer-term risk	Labor, activity, and customer spending data
Geopolitics and oil	Iran-related oil volatility; narrow conflict contracts remain low-priced	Indirect inflation, risk-appetite, and supply-chain exposure	Verified energy prices and concrete policy developments
Research handoff	No verified valuation, live price series, or FRED observations	Insufficient basis for a COHR price target or execution recommendation	Market-data, financial, and official macro verification

Fundamentals Analyst¶

COHR — Fundamental Research Report¶

Company: Coherent Corp. Exchange: NYQ Sector / industry: Technology / Scientific & Technical Instruments As of: October 14, 2026 Weekly review window: October 8–14, 2026, compared with information available on October 7.

Executive assessment¶

COHR’s operating recovery is substantial, but its cash generation does not yet support the improvement in reported earnings.

Revenue and gross margins are improving: FY2026 revenue reached $7.118 billion, up 22.5%, while calculated gross margin increased to 37.5% from 35.2%.
Cash conversion is the principal weakness: FY2026 operating cash flow fell to $80 million, against $1.103 billion of capital expenditure. Statement-derived free cash flow was therefore negative $1.023 billion.
The weekly comparison revealed changes in annual net-income figures: The date-filtered income-statement extracts show FY2026 net income declining from $805 million to $787 million, with changes to earlier years as well. Revenue, diluted EPS, and annual cash-flow figures were unchanged. The tools do not establish whether this reflects a filing revision, attribution difference, or data-mapping change.
Valuation depends heavily on forward earnings: The provider reports 63.9× trailing earnings versus 18.7× forward earnings. The forward EPS definition and forecast period are not supplied, so the lower forward multiple should not automatically be interpreted as cheap.
No current-week insider transactions appear in the supplied feed. Its latest listed transaction is September 11, making insider evidence stale for this week’s trading decisions.

Research conclusion: COHR presents a credible revenue-and-margin recovery, offset by weak cash conversion, elevated capital spending, and unresolved accounting-data reconciliation issues. Those issues should be resolved before another decision-maker treats the forward valuation as a reliable trading opportunity.

1. What changed during the past week?¶

I compared annual financial-statement extracts requested as of October 7 and October 14, together with quarterly income statements for both dates.

Changes visible in the income-statement extracts¶

USD millions

Annual net-income line	Available as of Oct. 7	Available as of Oct. 14	Change
FY2026	805	787	−18, or −2.2%
FY2025	49	30	−19, or −38.8%
FY2024	−156	−159	Loss increased by 3

The compared extracts showed no change in:

Annual revenue and cost of revenue.
Annual diluted EPS.
Annual balance-sheet figures.
Annual operating, investing, financing, and capital-expenditure cash flows.
The quarterly income-statement figures returned through March 2026.

How traders should interpret this¶

This is an observable change in the date-filtered financial data, but it is not sufficient evidence of a newly announced COHR restatement or earnings downgrade.

The unchanged EPS figures, alongside changed net-income figures, make it important to verify whether the figures represent:

Consolidated net income.
Net income attributable to COHR.
Income available to common shareholders.
Different treatment of noncontrolling interests or preferred securities.
A vendor extraction or classification change.

Actionable implication: Before trading COHR on an “earnings revision” interpretation, inspect the underlying filing and income-attribution reconciliation. The available tools do not identify the relevant filing accession, announcement, or reason for the changes.

Limits on the weekly comparison¶

The fundamentals vendor explicitly withheld an October 7 valuation snapshot because it does not maintain historical vintages. Consequently, this report cannot establish weekly changes in COHR’s market capitalization, valuation multiples, forward estimates, or share price.

No news-search tool was available, so the financial-data comparison is not a complete review of all company announcements during the week.

2. COHR company profile and business exposure¶

COHR operates in photonics, including lasers, optical components, and engineered materials used across communications and industrial/high-technology applications.

Relevant fundamental drivers include:

Optical communications and data-center investment: Demand can support higher volumes and favorable product mix.
Industrial and capital-equipment cycles: Customer spending and inventory adjustments can create volatility.
Manufacturing utilization and product mix: These influence gross margins and the economics of capacity expansion.
Capital intensity: Revenue growth creates shareholder value only if capacity investment eventually produces adequate cash returns.

The supplied tools do not provide current segment revenue, bookings, backlog, customer concentration, or product-level profitability. Accordingly, they do not establish how much of COHR’s recent growth came specifically from AI infrastructure or any individual product category.

The historical financial series shows considerable expansion: revenue increased from $1.362 billion in FY2019 to $3.317 billion in FY2022 and $7.118 billion in FY2026. Large changes in the asset base over that period mean this growth should not automatically be treated as entirely organic; an acquisition and divestiture bridge is unavailable.

3. Financial history: strong recovery in sales and reported profitability¶

Fiscal years end June 30. USD millions except EPS. Gross profit and gross margin below are calculated from revenue less cost of revenue because the statement tool did not return a separately tagged gross-profit series.

Fiscal year	Revenue	Revenue growth	Gross margin	Net income, latest extract	Diluted EPS
FY2022	3,317	6.8%	38.2%	235	$1.45
FY2023	5,160	55.6%	31.4%	−259	−$2.93
FY2024	4,708	−8.8%	30.9%	−159	−$1.84
FY2025	5,810	23.4%	35.2%	30	−$0.52
FY2026	7,118	22.5%	37.5%	787	$4.12

What the history shows¶

1. The recovery extends beyond one quarter. COHR has recorded two consecutive years of revenue growth above 20%, following the FY2024 contraction.

2. Gross-profit growth is outpacing revenue growth. Calculated gross profit increased from $2.043 billion in FY2025 to $2.669 billion in FY2026, up 30.6%. Gross margin improved approximately 233 basis points.

That is consistent with better operating conditions, mix, pricing, utilization, or cost execution—but the tools do not separate those drivers.

3. Reported profitability improved sharply. Using the latest annual net-income line, FY2026 net margin was approximately 11.1%, versus 0.5% in FY2025.

However, recent operating-income data are missing from the statement extracts. This prevents a full bridge between gross profit, recurring operating earnings, interest expense, taxes, and other income.

4. Net income and common-share EPS require reconciliation. FY2025 shows positive net income of $30 million but diluted EPS of negative $0.52. Preferred-security allocations, noncontrolling interests, or other attribution differences could explain this, but the supporting schedules are absent. It would be inappropriate to infer an exact common-share count by dividing the displayed net income by EPS.

4. Recent quarterly trajectory: accelerating revenue and rising gross margins¶

FY2026 quarter	Revenue, $m	Year-over-year growth	Calculated gross profit, $m	Gross margin
Q1: September 2025	1,581	17.3%	579	36.6%
Q2: December 2025	1,686	17.5%	623	37.0%
Q3: March 2026	1,806	20.6%	680	37.7%
Q4: June 2026, implied	2,045	33.7%	787	38.5%

Derivation: The tool’s quarterly income statement stops at March 2026. June-quarter revenue and cost of revenue are calculated as annual totals minus the first three quarters. The year-over-year comparison similarly uses an implied June 2025 revenue figure of $1.529 billion. These calculations assume consistent reporting scope.

Trading relevance¶

Revenue growth accelerated across FY2026.
Implied June-quarter revenue increased 13.2% sequentially.
Gross margin rose in each quarter, reaching an implied 38.5%, approximately 284 basis points above the comparable June 2025 quarter.

These are constructive operating indicators.

Nevertheless, gross-margin improvement is not proof that all earnings improvement is recurring. Quarterly net income was $226 million, $147 million, and $191 million in the first three FY2026 quarters, showing variability despite steadily increasing revenue.

Given the annual net-income changes identified in the weekly comparison, I would not treat an annual-minus-nine-month net-income residual as a confirmed June-quarter profit figure without reconciling the attribution basis.

Monitoring implication: The implied June-quarter revenue of $2.045 billion and gross margin of 38.5% provide useful historical benchmarks for future verified results—not management guidance.

5. Cash flow: COHR’s most significant fundamental concern¶

For consistency, free cash flow below is defined as:

Operating cash flow minus capital expenditure

USD millions

Fiscal year	Operating cash flow	Capital expenditure	Calculated free cash flow
FY2022	413	314	99
FY2023	634	436	198
FY2024	546	347	199
FY2025	634	441	193
FY2026	80	1,103	−1,023

Earnings quality deteriorated despite higher reported profit¶

Between FY2025 and FY2026:

Operating cash flow fell 87.4%.
Capital expenditure increased 150.1%, or approximately 2.5×.
Free cash flow deteriorated by $1.216 billion.
Capital expenditure rose from 7.6% to 15.5% of revenue.
Free-cash-flow margin fell to approximately negative 14.4%.

Operating cash flow represented only about 10% of the latest annual net-income figure.

That gap does not establish poor accounting or permanent deterioration. It does establish that the earnings recovery was not accompanied by comparable cash generation.

Cash outflow intensified during FY2026¶

The cash-flow tool mixes standalone and year-to-date periods. Correctly differencing the cumulative figures produces the following quarterly FCF estimates:

September quarter: −$58 million
December quarter: −$96 million
March quarter: −$383 million
June quarter: −$486 million

The implied June quarter generated approximately $70 million of operating cash flow, but capital expenditure was approximately $556 million.

External financing accompanied the cash-flow shortfall¶

FY2026 included:

$1.414 billion of net investing outflows.
$1.477 billion of net financing inflows, compared with a $452 million financing outflow in FY2025.

The tools do not break financing flows into borrowing, equity issuance, conversions, repayments, or other components. It would therefore be incorrect to describe the entire inflow as new debt.

Important source discrepancy¶

The fundamentals snapshot reports FCF of approximately negative $650 million, while annual statement-derived FCF is negative $1.023 billion.

The roughly $373 million difference is unresolved. Both figures indicate negative FCF, but the annual statement calculation is the appropriate basis for the historical comparison above.

Actionable implication: A convincing COHR fundamental thesis needs an explanation for both the decline in operating cash flow and the increase in capital spending. The tools do not establish whether these are temporary working-capital movements, productive growth investment, or a more persistent cash-return problem.

6. Balance sheet and liquidity¶

USD millions except ratios

Metric	June 2025	June 2026
Cash and equivalents	909	1,162
Current assets	3,927	6,925
Current liabilities	1,795	2,854
Net working capital	2,132	4,071
Current ratio, calculated	2.19×	2.43×
Total assets	14,911	18,300
Total liabilities	6,430	7,062
Reported stockholders’ equity	5,645	10,903

Positive features¶

Year-end cash increased $253 million.
Current assets exceeded current liabilities by $4.071 billion.
The annual current ratio improved to approximately 2.43×, consistent with the provider’s reported 2.427.

Reasons not to overstate liquidity strength¶

1. Most current-asset growth was not cash. Noncash current assets increased from $3.018 billion to $5.763 billion. Their composition is unavailable, so this cannot be attributed specifically to receivables, inventory, or investments.

2. Cash coverage of current liabilities declined. Cash/current liabilities decreased from approximately 0.51× to 0.41×, despite the higher current ratio.

3. June-quarter liquidity weakened sequentially. Between March and June 2026:

Cash fell from $1.593 billion to $1.162 billion, down 27.1%.
Current liabilities increased from $2.113 billion to $2.854 billion, up 35.1%.
The calculated current ratio declined from approximately 3.05× to 2.43×.

Capital-structure reconciliation is necessary¶

At June 2026:

Assets minus liabilities equal $11.238 billion.
Displayed stockholders’ equity is $10.903 billion.
The difference is $335 million.

The corresponding difference was $2.836 billion a year earlier. Noncontrolling interests or mezzanine/preferred capital could explain the gap, but the necessary classifications are absent.

Reported equity also increased $5.258 billion, far more than annual net income. That increase should not be characterized as purely retained earnings.

The snapshot reports debt/equity of 31.612%, but the statements do not separately identify interest-bearing debt, maturities, leases, or preferred obligations. Accordingly, precise net debt, interest coverage, and enterprise-value multiples cannot be responsibly established from these outputs.

7. Valuation: attractive only if the forward earnings basis holds¶

Provider snapshot requested as of October 14¶

Market capitalization: $51.86 billion
Trailing P/E: 63.91×
Forward P/E: 18.74×
Trailing EPS: $4.12
Forward EPS: $14.05
Price/book: 4.73×
Book value per share: $55.70
PEG: 0.92
Dividend yield: 0%
EBITDA: $1.423 billion
Operating margin: 11.83%
Return on equity: 7.98%
Return on assets: 3.39%

Market capitalization divided by reported trailing revenue implies approximately 7.28× sales.

The forward/trailing earnings gap is unusually important¶

Forward EPS of $14.05 is approximately 3.41× trailing EPS of $4.12.

Mechanically, that is a 241% increase, but it should not be presented as confirmed like-for-like earnings growth. The tool does not identify:

The forecast fiscal year.
GAAP versus adjusted EPS.
Consensus versus management guidance.
The estimate timestamp or revision history.

The PEG figure likewise lacks enough methodology to establish undervaluation independently.

Implied reference price—not an execution quote¶

Trailing P/E multiplied by trailing EPS implies approximately:

63.912624 × $4.12 = $263.32

Forward P/E × forward EPS and price/book × book value produce approximately the same reference.

However, the tool did not return a timestamped last-traded price. $263.32 is an inferred valuation reference, not a verified live quote.

Illustrative valuation sensitivity¶

Assuming the provider’s full $14.05355 forward EPS is achieved:

Illustrative P/E	Implied value	Difference from $263.32 reference
15×	$210.80	−19.9%
20×	$281.07	+6.7%
25×	$351.34	+33.4%

These are arithmetic scenarios, not price targets or peer-based fair values.

A 20% reduction in forward EPS, even with the reported forward multiple unchanged, would imply approximately $210.66. COHR therefore has meaningful sensitivity to estimate disappointment before considering multiple compression.

Market-risk context¶

The provider reports:

Beta: 2.113
52-week range: $108.19–$440.00
50-day average: $304.64
200-day average: $293.61

These figures suggest substantial historical volatility and market sensitivity. They do not establish COHR’s performance during the review week.

Additional earnings-data inconsistency¶

The snapshot reports net income of $769.9 million, versus $787 million in the latest annual statement extract. Its displayed profit margin of 11.309%, applied to reported revenue, implies approximately $805 million of profit.

These may reflect different attribution or period definitions, but no reconciliation is supplied. Valuation work should use a consistent earnings basis.

8. Insider activity¶

Current-week evidence¶

No transactions dated October 8–14 appear in the supplied feed. The most recent listed transaction is September 11, 2026.

That is not proof that no transactions occurred; feed coverage and reporting delays are unknown.

Most recent observable sale cluster¶

Between August 31 and September 11, the feed lists six sales totaling:

25,636 shares
Approximately $7.21 million

The sales involved the CTO, directors, and another officer. The largest was the CTO’s 13,077-share sale, valued at approximately $3.58 million.

The feed also shows August 28 equity awards. Grants, gifts, and option exercises should not be counted as open-market purchases.

No explicit open-market purchases appear in the supplied 2026 records. The latest explicit purchase shown is a CEO purchase in December 2024, far outside the current review window.

Interpretation: Recent listed insider activity provides no fresh buying confirmation for COHR. However, the absence of transaction-plan details, post-sale holdings, and ownership percentages prevents a strong bearish inference from the sales alone.

9. Specific monitoring priorities for the COHR trade decision¶

Evidence that would strengthen the fundamental case¶

Cash conversion improves: Operating cash flow rises meaningfully and quarterly FCF turns positive.
Capital-spending returns become visible: Management connects the elevated investment level to utilization, incremental profit, and cash generation.
Gross margins remain durable: Future verified results sustain margins near the recent 37%–38.5% range.
Revenue remains resilient: Results support the recent acceleration rather than revealing a temporary shipment surge.
Forward EPS is verified: The $14.05 forecast is tied to a defined period, accounting basis, and current estimate source.

Evidence that would weaken the case¶

Continued heavy FCF outflows after the recent investment surge.
Gross margin falling toward the FY2025 level of approximately 35%.
Repeated financing needs without improved operating cash generation.
Downward forward-EPS revisions.
Unresolved preferred-capital, ownership-attribution, or earnings-basis differences.

Priority checks before relying on valuation¶

The next researcher or trade decision-maker should obtain:

COHR’s latest full filing and any amendments.
The consolidated-to-common-shareholder income reconciliation.
Receivables, inventory, payables, and noncash-adjustment schedules.
Debt, lease, preferred-capital, and maturity details.
Capital-expenditure guidance and expected cash returns.
A timestamped quote and current consensus-estimate history.

Overall assessment: The revenue and gross-margin evidence is constructive. Cash-flow evidence is materially weaker. COHR should be evaluated as a growth recovery requiring cash-flow and accounting-basis verification—not simply as an inexpensive stock because its reported forward P/E is below 20×.

Sources and methodology¶

This report uses get_fundamentals, annual and quarterly get_income_statement, get_balance_sheet, get_cashflow, and get_insider_transactions. Annual statements were compared at October 7 and October 14; quarterly income statements were also compared at those dates. Statement tools describe their data as SEC EDGAR facts filed on or before the requested date. Full filings, filing accession numbers, footnotes, and contemporaneous news were not supplied. Calculations are rounded; implied June-quarter figures are identified separately.

COHR — Key points for the trade decision¶

Area	Supporting evidence	Practical implication
Weekly financial-data change	FY2026 net-income extract moved from $805m to $787m; EPS unchanged	Verify attribution and filing basis before treating this as an earnings-revision event
Revenue recovery	FY2026 revenue $7.118bn, up 22.5%	Supports a sustained growth-recovery thesis
Margin improvement	Annual gross margin 37.5%; implied June-quarter margin 38.5%	Favorable, but sustainability and recurring operating earnings need confirmation
Cash conversion	FY2026 operating cash flow only $80m	Reported earnings substantially exceeded cash generation
Capital intensity	FY2026 capex $1.103bn; calculated FCF −$1.023bn	Investment payback and future funding requirements are central risks
Liquidity	June current ratio 2.43×; cash $1.162bn	Aggregate coverage is reasonable, but sequential cash and liability trends weakened
Capital structure	Equity attribution gaps and incomplete debt/preferred schedules	Do not rely on unverified net-debt or enterprise-value calculations
Valuation	63.9× trailing P/E versus 18.7× forward P/E	Forward EPS definition and achievability drive the valuation case
Insider evidence	No current-week records; latest listed sale September 11	No fresh insider signal is established for this week
Research handoff	Positive operating momentum, negative FCF, unresolved data bridges	Resolve earnings, cash-flow, and capital-structure questions before selecting the COHR trade

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # COHR: Opening Bull Argument

As of October 14, 2026 | Reference price: $263.32

My opening position is straightforward: COHR’s operating recovery is stronger than its recent share-price action suggests. I am bullish on the investment opportunity, although I would build exposure selectively rather than assume this selloff has already found a bottom.

The bear’s strongest argument is weak cash generation—not collapsing revenue, deteriorating gross margins, or confirmed customer cancellations. That distinction matters. The evidence supports a business expanding its revenue and gross-profit capacity while facing a serious cash-conversion challenge. It does not yet establish a broken growth thesis.

1. The growth case is already visible in the financial statements¶

Let’s start with what COHR has delivered, rather than what investors hope AI might eventually produce:

FY2026 revenue reached $7.118 billion, up 22.5%.
That followed 23.4% growth in FY2025—two consecutive years above 20%.
Gross profit increased 30.6%, to $2.669 billion, outpacing revenue growth.
Gross margin improved approximately 233 basis points, reaching 37.5%.

That last point is particularly important. COHR is not merely generating more sales at unchanged economics; it is retaining more gross profit from each revenue dollar.

The exit momentum also looks constructive. The implied June-quarter revenue was $2.045 billion, up 33.7% year over year and 13.2% sequentially, with an implied 38.5% gross margin. These figures are derived from annual results less the first three quarters, rather than a separately returned quarterly statement.

Annualizing that implied quarter produces an $8.18 billion revenue run rate, approximately 15% above FY2026 revenue. That is not guidance or a forecast—it ignores seasonality and assumes consistent reporting scope—but it illustrates the strength of the latest operating baseline.

My challenge to the bear: explain why accelerating revenue and expanding gross margins should be treated as evidence of business deterioration. A falling share price alone does not answer that question.

2. COHR has a credible competitive position in a consequential market¶

COHR supplies optical components, lasers, and engineered materials across communications and industrial applications. Its investment case is therefore grounded in physical technology and manufacturing capabilities—not simply an association with AI.

The competitive assets I would emphasize are specialized photonics expertise, manufacturing scale, and the ability to supply demanding applications. In a capital-intensive industry, those capabilities take time and investment to develop.

The supplied research does not establish dominant market share or quantify a durable pricing advantage, so I would not claim either. But the combination of strong revenue growth and improving gross margins demonstrates that COHR is currently expanding with better gross-profit economics.

The capacity-constraint and AI data-center headlines reinforce the market opportunity. They are supporting evidence, not substitutes for disclosed orders: we still need customer commitments, delivery schedules, and backlog-conversion details.

Nevertheless, if optical demand remains constrained by supply, existing technical capabilities and productive capacity can become valuable advantages. COHR has a credible platform to participate in that opportunity.

3. “But cash flow is terrible.” Agreed—and that is the central test¶

I will address the strongest bearish point directly:

FY2026 cash-flow measure	Amount
Operating cash flow	$80 million
Capital expenditure	$1.103 billion
Statement-derived free cash flow	−$1.023 billion

Those figures are poor. Capital spending does not explain the collapse in operating cash flow; they are separate issues. A credible bull cannot simply call everything “growth investment” and move on.

But the correct conclusion is that the cash-return thesis remains unproven—not that the revenue recovery is fictitious.

There are two questions:

Can operating cash flow recover? The supplied data do not explain whether working capital, noncash adjustments, or other factors drove the weakness.
Will elevated capital expenditure generate adequate returns? Rising revenue and gross margins are encouraging, but they do not yet demonstrate an acceptable cash payback.

COHR ended FY2026 with $1.162 billion in cash and a 2.43× current ratio. Those provide some liquidity support, but incomplete debt and preferred-capital disclosures prevent me from calling the balance sheet a fortress.

The bull case is not that cash flow does not matter. It is that improving operating scale can precede improving cash returns—and COHR has demonstrated the first part. Continued cash outflows without a convincing explanation or improving returns would materially weaken my position.

The earnings-data discrepancies also deserve reconciliation. However, the vendor’s FY2026 net-income change from $805 million to $787 million, with revenue and EPS unchanged, does not establish a company-announced restatement or operating downgrade.

4. The valuation offers potential—not a free pass¶

At $263.32, COHR trades at approximately:

63.9× trailing earnings
18.7× the provider’s forward EPS estimate

The trailing valuation is demanding. The forward valuation could be reasonable for a business sustaining strong growth and improving profitability.

But the $14.05 forward EPS estimate lacks a confirmed forecast period and accounting basis. It cannot responsibly be described as a verified, like-for-like 241% earnings-growth forecast.

Here is the valuation sensitivity if the provider’s full forward EPS is achieved:

Illustrative multiple	Implied COHR value	Change from $263.32
15×	Approximately $211	−20%
20×	Approximately $281	+7%
25×	Approximately $351	+33%

These are scenarios, not price targets or peer-derived fair values. If earnings disappoint and the multiple contracts simultaneously, downside could be substantially larger.

So my bullish argument is not “below 20× forward earnings must be cheap.” It is this: if forward earnings are validated and cash conversion improves, COHR has a credible path to a materially higher valuation. Earnings delivery—not imminent rate cuts—must carry that case.

5. Financing fears are a risk, not proof of canceled demand¶

Higher yields can hurt COHR in two ways: lower equity valuation multiples and more expensive customer financing. I would not dismiss either.

But the supplied headlines establish AI-financing anxiety and sector-wide selling, not confirmed COHR order cancellations, a guidance reduction, or a company-specific earnings shortfall.

That distinction cuts both ways:

Bulls cannot treat “sold-out capacity” headlines as guaranteed future cash flow.
Bears cannot treat financing concerns as proof that committed spending has disappeared.

The next earnings disclosure should help resolve the disagreement through funded demand, shipment timing, margins, capital-spending plans, and cash conversion.

I am underwriting continued operating execution, not a rescue from monetary easing.

6. A bullish investment view does not require pretending the chart is healthy¶

COHR has fallen approximately 22.2% since the October 6 close and sits below its verified 50-day and 200-day moving averages. Daily momentum is weak.

Still, the higher-timeframe picture has not fully reversed:

Weekly and monthly SuperTrend remain UP.
The daily Z-score of −2.05 indicates downside stretch.
The longer-window OBV comparison presents a potential positive divergence, although recent OBV has declined.

None of that confirms a bottom. It does, however, weaken the argument for aggressively chasing the selloff.

For staged accumulation, I would favor stabilization, a higher low, and improving participation. A reclaim of $285, followed by progress through the current $293.97 and $303.43 moving-average references, would strengthen the recovery case.

Conversely, a confirmed weekly loss of the then-current weekly SuperTrend boundary would weaken the technical setup. The present $255.29 reference is not a guaranteed floor or a maximum-loss estimate—particularly with daily ATR around 8.5% of the share price.

My opening conclusion¶

I favor selective, staged accumulation of COHR on confirmed stabilization—not an unconditional dip-buy.

The strongest bullish evidence is already tangible: two years of revenue growth above 20%, accelerating implied quarterly revenue, and gross profit growing faster than sales. The principal uncertainty is whether those improving economics will convert into durable cash generation.

To the bear, my opening challenge is this:

Weak cash conversion justifies caution. It does not, by itself, invalidate a business whose revenue and gross-profit performance are improving substantially.

If cash generation recovers while the operating trajectory holds, COHR could reward investors who establish exposure before every uncertainty is resolved. If cash outflows persist, margins reverse, or funded demand deteriorates, I would reassess. Today, the evidence supports a constructive, risk-controlled bull position—not a claim that the growth opportunity has broken. Bull Analyst: # COHR: Bull Counter-Rebuttal — The Cash-Flow Risk Is Real, but So Is the Earnings Opportunity

As of October 14, 2026 | Reference close: $263.32 Bull position: Selective, staged accumulation of COHR for a 12–24-month investment horizon—not an unconditional purchase into the selloff.

You are right about an important distinction: an improving business is not automatically an attractive stock. My opening argument did not fully answer that valuation challenge.

But your conclusion—avoid all new exposure until cash conversion is established—also carries an assumption: that waiting for confirmation offers a better investment trade-off than taking limited exposure before the recovery is fully reflected in cash flow.

That is where we disagree. COHR has demonstrated enough operating progress to justify a measured investment thesis, even though it has not earned a full-sized position or an unquestioned valuation premium.

1. You are understating the significance of the exit-rate improvement¶

You accept the revenue and gross-margin recovery, but treat them largely as background to the cash-flow problem. They are more important than that: they are the operating foundation from which future earnings and cash generation must come.

COHR delivered:

22.5% FY2026 revenue growth, following 23.4% growth in FY2025.
$626 million of additional annual gross profit, a 30.6% increase.
Approximately 233 basis points of gross-margin expansion, to 37.5%.

The implied June-quarter figures strengthen the case: $2.045 billion of revenue and $787 million of gross profit, with a 38.5% gross margin.

Annualizing that implied quarterly gross profit produces approximately $3.15 billion, roughly $480 million above FY2026’s annual gross profit.

That is not guidance. It assumes the quarter can be sustained, ignores seasonality, and does not account for operating expenses, financing, taxes, or common-shareholder allocations. But it illustrates why the latest operating trajectory matters.

The bull case does not require treating revenue as shareholder value. It requires recognizing that substantially greater gross-profit capacity creates an opportunity for greater shareholder value—if cash conversion and capital allocation improve.

You correctly demand the bridge from gross profit to cash. But the substantial increase in the starting point of that bridge should influence the investment assessment.

2. Cash flow requires two repairs—but there is evidence of past cash-generating capability¶

Your counterfactual is correct: holding capital expenditure at FY2025’s dollar level would not have rescued FY2026 free cash flow. Operating cash generation and capital intensity both need attention.

Where I push back is against letting one severely weak year become the default long-term characterization of COHR.

Across FY2022–FY2025, COHR generated:

$413 million–$634 million of annual operating cash flow.
Positive annual free cash flow of $99 million–$199 million.

Those historical results do not establish today’s normalized cash flow, particularly given changes in business scale. They do establish that COHR is not a business with an uninterrupted history of cash consumption.

Consider the mechanics at FY2026 revenue:

Restoring FY2025’s approximately 10.9% operating-cash-flow margin would produce about $777 million of operating cash flow.
Keeping FY2026 capital expenditure at $1.103 billion would still leave approximately $326 million of negative free cash flow.
If capital expenditure also returned to FY2025’s approximately 7.6% of revenue, spending would be about $540 million, leaving approximately $236 million of positive free cash flow.

These are illustrative calculations, not forecasts. And $236 million of free cash flow would not, by itself, justify COHR’s approximately $51.9 billion market capitalization.

The point is narrower: the route back to self-funding is identifiable, but requires both better operating cash conversion and more sustainable capital intensity. Longer-term valuation support requires considerably more.

My bullish interpretation is that expanding gross-profit capacity gives COHR a stronger platform from which to achieve that transition. Your bearish interpretation is that the transition remains too uncertain to own. Both recognize the same deficit; we differ over how much exposure the demonstrated operating progress warrants.

3. Your valuation scenarios establish downside—not a negative expected return¶

I agree that 18.7× forward earnings is not a reliable bargain signal until the $14.05 EPS estimate’s period and accounting basis are verified. That verification should happen before using it to justify meaningful capital deployment.

But two elements of your valuation argument deserve qualification.

First, the entry price has already changed materially¶

Using the same provider EPS estimate purely as a constant illustration:

The October 6 close of $338.36 corresponds to approximately 24.1× that estimate.
The current $263.32 corresponds to approximately 18.7×.

This is not a reconstruction of historical consensus multiples; we do not have estimate vintages. It shows that investors can now purchase the same hypothetical future earnings stream at a materially lower price.

That does not prove sufficient compensation for the risks. But it means financing and valuation concerns should be assessed against the current entry price—not the price before the 22.2% decline.

Second, substantial returns do not inherently require multiple expansion¶

Your approximately 7% upside at 20× assumes a fixed earnings figure. That is a useful sensitivity, but not a complete multi-year growth framework.

If, over an investment horizon, comparable per-share earnings were 20% above the provider’s figure and the multiple remained approximately 18.7×, the arithmetic would imply roughly $316, or approximately 20% upside, without a rerating.

That is a conditional illustration—not a forecast or price target. Its purpose is to distinguish earnings-led returns from multiple-led returns.

I would not make 25× earnings the foundation of the COHR thesis. The stronger argument is that continued operating growth, better cash conversion, and disciplined funding could support increasing per-share earnings at a stable multiple.

Your −36% stress case is legitimate. My upside illustrations are legitimate. Neither establishes expected returns without defensible earnings assumptions and probabilities. That uncertainty argues for position restraint, not necessarily zero exposure.

4. Manufacturing scale is not a proven moat—but neither is it merely a burden¶

You are right that the supplied research does not establish dominant market share or superior returns on invested capital. I am not claiming either.

The competitive case for COHR is more practical:

Established photonics capabilities across optical components, lasers, and engineered materials.
An existing manufacturing platform supporting more than $7 billion of annual revenue.
Demonstrated ability to expand revenue while improving gross-profit economics.

Those capabilities are relevant in a market where the supplied headlines describe optical-capacity constraints and growing data-center bandwidth requirements. They are harder to reproduce quickly than a bullish market narrative.

Your oversupply scenario is a valid risk. But it remains a scenario—not an observed deterioration in COHR’s current gross margins.

The appropriate test is whether capacity additions translate into funded shipments, sustained utilization, and adequate cash returns. Capacity is valuable only when its economics work; COHR’s improving gross margins are encouraging evidence, though not the final proof.

5. Financing conditions matter—but the thesis does not need a monetary rescue¶

I accept your point that projects can be delayed without orders being canceled. A delay can hurt cash receipts and returns even when long-term demand remains intact.

Accordingly, I would not dismiss higher yields or assume that strong optical demand immunizes COHR from financing conditions.

But the supplied evidence still distinguishes:

Demonstrated operating growth and margin improvement, from
Headline-based concerns about future financing and spending.

That does not make the latter unimportant. It means the next company disclosure should be judged on specific transmission channels: shipment timing, customer commitments, cash collection, capital expenditure, and funding requirements.

The bull thesis needs execution under prevailing financing conditions—not imminent rate cuts.

6. My recommendation is to separate verification from waiting for perfection¶

Some of your requested checks are basic due diligence and should not be postponed: reconcile the earnings definitions, inspect the cash-flow schedules, and establish the capital structure.

That is different from requiring several quarters of fully normalized free cash flow before taking any exposure.

For COHR, I favor this progression:

Verify the minimum financial foundations. Do not anchor valuation to an undefined forward EPS estimate.
Establish only a small position after price stabilization. A higher low and improving participation matter more than a statistically stretched reading alone.
Increase exposure when cash conversion improves, supported by durable margins and funded shipment visibility—not merely a rebound in the share price.
Reassess if cash outflows persist without a convincing explanation, financing needs recur without visible returns, or margins deteriorate.

Technically, a reclaim of $285, followed by progress through the current $293.97 and $303.43 moving-average references, would improve confidence. Weekly SuperTrend remains UP, but its $255.29 reference is vulnerable—not a guaranteed floor. With daily ATR of $22.50, position sizing must accommodate substantial volatility.

Bottom line¶

Your strongest argument is that COHR has not yet demonstrated attractive cash returns on its accelerating growth. I accept that.

My strongest counterargument is that the operating improvement is substantial, the entry price has fallen materially, and investors need not wait for every uncertainty to disappear before taking limited exposure.

COHR is not a demonstrated deep-value bargain. It is a growth-and-cash-conversion opportunity with meaningful downside if execution fails.

I remain bullish on selective accumulation of COHR: verify the financial foundations, wait for stabilization, start small, and let improving cash economics—not enthusiasm alone—earn a larger position. Bull Analyst: # COHR: Bull Rebuttal — The Cash-Flow Picture Is Weak, but Not Uniformly Worsening

As of October 14, 2026 | Reference close: $263.32 Bull position: Selective accumulation of COHR on stabilization, with larger commitments contingent on verified cash conversion and funding economics.

You are right: “start small” is position sizing, not a valuation argument. It limits the consequences of being wrong; it does not make an investment attractive.

But your latest rebuttal overlooks an important distinction in the June-quarter figures: free cash flow deteriorated while operating cash generation improved relative to the preceding nine months. That does not establish a completed turnaround. It does make the evidence more constructive than “stronger gross profit, but no observable cash improvement” suggests.

My bullish argument rests on that distinction, the quality of COHR’s incremental gross profit, and the opportunity to invest in improving earnings capacity before its cash returns are fully established.

1. Apply the operating-cash-flow versus capex distinction to the exit quarter, too¶

Earlier, you correctly insisted that capital expenditure does not explain weak operating cash flow. The same separation matters when interpreting the latest quarter.

Using the supplied annual and derived June-quarter figures:

COHR measure	First nine months of FY2026	Implied June quarter
Revenue	Approximately $5.073 billion	$2.045 billion
Operating cash flow	Approximately $10 million	$70 million
Operating-cash-flow margin	Approximately 0.2%	3.4%
Capital expenditure	Approximately $547 million	$556 million
Free cash flow	Approximately −$537 million	−$486 million

These are approximate calculations from the supplied statements, subject to consistent reporting scope—not separately verified new quarterly disclosures.

Two facts emerge:

The June quarter generated approximately 87.5% of FY2026 operating cash flow.
It also accounted for approximately 50.4% of annual capital expenditure.

So, yes, the June quarter had the largest quarterly free-cash-flow deficit. But that deficit coincided with both greater operating cash generation and exceptionally concentrated investment spending.

I am not claiming sequential operating-cash-flow improvement over every preceding quarter; the supplied figures do not establish that. Nor is a 3.4% operating-cash-flow margin satisfactory.

The narrower, defensible conclusion is that cash generated by operations improved against the first-nine-month pace, while capital spending accelerated even more sharply. That is different from a business showing no improvement anywhere in its cash economics.

It is an early positive signal—not proof of normalization, but not something the investment assessment should disregard.

2. The incremental gross-profit economics deserve more weight¶

You accept the revenue recovery. I think you still underweight its quality.

Between FY2025 and FY2026:

Revenue increased approximately $1.308 billion.
Gross profit increased approximately $626 million.

That means COHR generated approximately 48 cents of additional gross profit for each additional dollar of revenue across that annual comparison.

This is not an incremental operating margin, cash margin, or return on invested capital. Product mix, utilization, pricing, and costs could all contribute. Nevertheless, it shows that expansion was accompanied by improving gross-profit economics—not simply more sales at weaker margins.

Another way to express the improvement: applying FY2025’s gross margin to FY2026 revenue would produce approximately $166 million less gross profit than COHR actually delivered.

The quarterly progression reinforces the point:

36.6% → 37.0% → 37.7% → 38.5% implied gross margin.

That is a sustained operating trend, not merely one favorable headline.

Your concern is whether shareholders will capture the benefits of growth. My response is that COHR is creating a substantially larger pool of gross profit from which those benefits can emerge—and the latest quarter generated most of the year’s operating cash.

Neither fact guarantees attractive shareholder returns. Together, they provide a stronger foundation for a recovery investment than revenue growth alone.

3. I am not combining three favorable assumptions into a fair-value estimate¶

Your criticism of my earlier normalization illustration is fair. Restoring an old operating-cash-flow margin and an old capex ratio does not establish what COHR should be worth.

I would retire that calculation as a valuation argument. It illustrated a route back to self-funding, not adequate support for a $51.86 billion equity valuation. Your approximately 0.46% free-cash-flow yield observation makes that limitation clear.

But we should also avoid treating FY2026’s investment intensity as an established permanent requirement.

The supplied evidence does not identify:

Maintenance versus expansion expenditure.
How much spending completes existing projects.
When new assets become productive.
Whether subsequent capacity additions require comparable spending.

That uncertainty cuts both ways. Bulls cannot assume capex will promptly revert to 7.6% of revenue. Bears cannot establish that the latest investment burden must persist indefinitely.

My thesis does not require an immediate halving of capital expenditure. It requires investment to produce sufficient incremental earnings and cash, and eventually to grow more slowly than the benefits it creates.

The June-quarter concentration of spending is consistent with a lumpy investment program, although it does not prove that interpretation. The operating-cash-flow bridge and project-payback disclosures remain essential.

4. COHR’s competitive assets matter even without a proven moat¶

I agree that industry demand is not the same as a COHR-specific competitive advantage.

Still, COHR brings an established photonics platform spanning optical components, lasers, and engineered materials, supported by a manufacturing business generating more than $7 billion in annual revenue.

Those are relevant capabilities in a market where the supplied coverage describes optical-capacity constraints and increasing data-center bandwidth requirements.

The distinction is important:

A promotional AI narrative offers exposure to an attractive theme.
COHR offers an existing technical and manufacturing platform that is already producing accelerating revenue and better gross margins.

That does not establish dominant market share, durable pricing power, or superior incremental returns. But it gives COHR a credible route to serving demand without first having to build an operating business from scratch.

Your oversupply scenario remains legitimate. The current financial evidence, however, shows improving—not deteriorating—gross-margin performance. I would change my assessment if funded demand weakened, utilization deteriorated, or capacity expansion began eroding margins.

5. The valuation case must be prospective—but it cannot be casual¶

You are also right that the 22.2% decline establishes a lower price, not intrinsic undervaluation.

And I will not defend a precise COHR price target using $14.05 of undefined forward EPS. Its period, accounting basis, and common-share assumptions need verification.

But neither 63.9× trailing earnings nor 7.3× trailing sales settles the valuation question. A recovering business should be assessed against sustainable future shareholder economics—not exclusively against a trailing year, and certainly not against an unexplained forward number.

Here is the actual bullish underwriting proposition:

COHR sustains a meaningful portion of its demonstrated revenue and gross-margin improvement.
Operating cash generation builds on the modest late-year improvement.
Expansion spending produces returns rather than becoming a permanent funding treadmill.
Those returns accrue to common shareholders after financing costs and dilution.

If those conditions develop, the investment can work through improving per-share earnings and cash generation—not necessarily through a higher valuation multiple.

This is not a demonstrated deep-value purchase. It is a growth-recovery investment with a cash-conversion catalyst. That distinction warrants valuation discipline, but it does not automatically warrant zero exposure.

6. Your disclosure requirements are reasonable; our weighting of the evidence differs¶

I accept your requested operating-cash-flow bridge, investment plan, and defined earnings forecast. You are asking for minimum underwriting evidence, not perfection.

Where we differ is how we interpret the evidence already available:

Question	My bullish assessment
Is commercial execution improving?	Yes: two years of revenue growth above 20%, accelerating implied quarterly growth, and rising gross margins.
Is there any operating-cash improvement?	Yes, modestly: most annual operating cash flow was generated in the final quarter.
Are attractive cash returns established?	No: capex, funding needs, and cash conversion remain decisive uncertainties.
Is an unconditional purchase justified?	No: financial verification and price stabilization still matter.
Is COHR merely a watchlist candidate?	Not necessarily: the demonstrated operating progress can justify limited, conditional exposure for growth-oriented investors.

Technically, I would still favor a higher low and improving participation before accumulation. A recovery through $285, followed by the current $293.97 and $303.43 moving-average references, would strengthen the setup—not validate the fundamentals.

The weekly SuperTrend reference of $255.29 is not protection, particularly with $22.50 daily ATR.

Bottom line¶

You have established why COHR should not receive an unquestioned premium. You have not established that its improving operating capacity deserves no investment exposure until the cash-return path is fully documented.

The most important additional evidence is this:

COHR’s strongest implied revenue and gross-margin quarter also generated most of its annual operating cash flow. Its worsening free cash flow was accompanied by a heavily concentrated capex surge—not an absence of improvement in every cash measure.

That is not enough for a full-sized investment. It is enough to keep the bull thesis substantive.

My COHR recommendation remains selective accumulation after stabilization and basic financial verification, with larger allocations earned through better cash conversion and credible investment payback. Persistent weak operating cash flow, recurring funding without visible returns, or reversing margins would invalidate that approach. But the present combination of stronger incremental gross-profit economics and modest late-year operating-cash improvement supports a constructive position—not simply avoidance. Bull Analyst: # COHR: Bull Rebuttal — The Growth-to-Cash Opportunity Deserves More Than a Watchlist

As of October 14, 2026 | Reference close: $263.32 Bull position: Selective, verification-gated accumulation of COHR—not an unconditional purchase at the current quote.

You are right that $70 million of quarterly operating cash flow cannot justify a $51.86 billion equity valuation. And the fact that it represented 87.5% of annual operating cash flow is an improvement statistic, not a valuation argument.

But let’s separate two conclusions:

COHR has not yet demonstrated attractive, sustainable cash returns.
COHR therefore offers insufficient prospective investment opportunity to justify exposure.

The first is established. The second remains a judgment—and I believe it underweights the scale of the operating improvement and the potential for that improvement to become shareholder cash.

My response is not “cash flow will eventually recover.” It is to identify what the recovery would need to achieve, what could cause it, and which evidence would justify investing before the transition is complete.

1. Let’s quantify the future cash hurdle against a growing business¶

Your cash-yield table is useful. At the supplied market capitalization, a 2% free-cash-flow yield corresponds to approximately $1.04 billion annually, and 3% corresponds to $1.56 billion.

Those are substantial amounts. But comparing them exclusively with FY2026 revenue makes the required cash margins look more demanding than they would be if COHR sustains meaningful growth.

Consider these illustrative three-year operating scenarios, starting with FY2026 revenue. Neither is guidance or a forecast:

Illustrative COHR scenario	Revenue after three years	Gross profit at unchanged 37.5% margin	FCF margin needed for a 2% yield on today’s market cap
15% annual revenue growth	$10.83 billion	$4.06 billion	9.6%
20% annual revenue growth	$12.30 billion	$4.61 billion	8.4%

The gross-profit figures would be approximately $1.39 billion–$1.94 billion above FY2026, without assuming further gross-margin expansion.

Why consider those growth rates? Because COHR has already delivered 23.4% and 22.5% annual revenue growth, followed by an implied June-quarter growth rate of 33.7%. Sustaining 15%–20% growth for another three years is a meaningful assumption, but it is connected to demonstrated commercial momentum—not invented from an AI narrative.

Now, the difficult part: if capital expenditure remained at 10% of revenue, reaching the table’s 2% cash-yield benchmark would require operating-cash-flow margins of approximately 19.6% or 18.4%.

That is a major improvement from current performance. I am not claiming it is established. A 3% cash yield would require still more demanding economics.

But this framework locates the underwriting burden:

The bullish opportunity is substantial revenue growth combined with better cash conversion—not merely restoring yesterday’s modest free cash flow.

These are operating targets, not discounted fair values. Timing, financing costs, dilution, and continued growth beyond the modeled period still matter. Nevertheless, they show why COHR’s expanding gross-profit capacity is central to the investment case rather than background information.

2. There is a concrete cash-conversion hypothesis to investigate¶

You ask for a mechanism rather than a desirable outcome. That is fair.

The balance sheet provides a specific place to investigate:

Noncash current assets increased from $3.018 billion to $5.763 billion, a $2.745 billion increase.
Current liabilities increased by $1.059 billion.
Consequently, noncash current assets less current liabilities increased approximately $1.686 billion.

That last calculation is not a measure of operating working capital or a cash-flow reconciliation. The balances could include nonoperating items, changes in reporting scope, or financing-related classifications. We cannot identify receivables or inventory from the supplied data.

Still, the magnitude matters. It gives us a testable hypothesis:

Did COHR’s growth require a substantial build of operating assets that absorbed cash before collections and shipments caught up?

If the filings establish that a meaningful portion of the increase consists of collectible receivables or inventory tied to funded shipments, cash recovery would have an identifiable mechanism. If they instead reveal weak collections, inventory problems, or balances unrelated to operating conversion, that interpretation would fail.

And I would distinguish two benefits:

A working-capital release could help fund the transition.
Repeatable conversion of higher operating profits into cash would support valuation.

A one-time release is not recurring earnings power. But it could reduce financing pressure while the larger business develops that earnings power.

That is why I view the missing bridge as an important research opportunity—not automatically as evidence that the growth model is structurally unattractive.

3. COHR’s competitive case is economic execution, not an unproven moat¶

You correctly reject the idea that factories alone establish attractive returns. I agree.

But COHR’s competitive argument is stronger than “it owns manufacturing capacity.” It combines:

An established photonics platform across optical components, lasers, and engineered materials.
More than $7 billion of annual revenue.
Two consecutive years of growth above 20%.
Gross profit growing 30.6%, faster than sales.
A quarterly gross-margin progression of 36.6%, 37.0%, 37.7%, and an implied 38.5%.

That combination indicates an operating platform expanding with improving gross-profit economics. It does not establish dominant market share or superior incremental returns on capital, but it is positive evidence of execution.

The optical-demand and capacity-constraint headlines add industry context. They do not prove COHR-specific backlog quality, and I would not treat them as such.

Your oversupply scenario is legitimate. Yet the current company evidence shows rising margins, not the utilization and pricing deterioration that would support that scenario becoming the base case.

The competitive advantage worth underwriting is therefore specialized capability plus demonstrated commercial scaling. The next test is whether that advantage survives after accounting for the capital needed to sustain it.

4. Financing risk raises the hurdle; it does not erase the opportunity¶

Your strongest financing point is company-specific: COHR generated only $80 million of operating cash flow while receiving $1.477 billion of net financing inflows.

Agreed. That is an existing dependence on external capital during the year—not merely a hypothetical macro concern.

But the financing composition remains unknown. We should establish its cost and effect on common shareholders before interpreting it as either prudent expansion funding or an expensive funding treadmill.

The same discipline applies to customer financing:

Funded orders with reliable shipment and payment schedules would support the bull case.
Project delays could weaken returns without cancellations.
Repeated capital raising without visible cash payback would undermine the thesis.

Higher yields make execution more demanding. My COHR thesis does not require rate cuts, and it should not receive credit for an assumed monetary rescue.

The identifiable upcoming event is the FY2027 first-quarter earnings disclosure, whose exact date is absent from the supplied material. Improved cash conversion is a possible outcome—not itself a confirmed catalyst. The disclosure becomes a catalyst only if it supplies a credible mechanism and changes expectations.

5. Here is the investment decision I would actually make¶

You correctly observe that neither price stabilization nor the minimum financial verification has been established in the supplied record.

Therefore, I am not recommending an immediate market order for COHR based solely on these reports. That is an execution limitation, not a withdrawal of the bullish investment view.

My threshold for initiating exposure would be:

A credible operating-cash-flow bridge identifying the principal cash absorbers and evidence supporting their reversal or stabilization.
A funded investment plan connecting committed spending to capacity utilization, shipment schedules, and expected cash returns.
Reconciled common-share economics, including the accounting basis and period behind any forward EPS used in valuation.
Price stabilization with improving participation, rather than statistical stretch alone.

I would not require the entire cash-return opportunity to have already been realized. A sufficiently credible disclosure package could justify a starter investment while subsequent execution earns a larger allocation.

Technically, a higher low, rising OBV, and a reclaim of $285 would improve timing. Progress through the current $293.97 and $303.43 moving-average references would strengthen confirmation. None substitutes for fundamental verification.

The $255.29 weekly SuperTrend reference is not downside protection, especially with daily ATR of $22.50.

Bottom line¶

Your argument establishes why COHR should not receive an unquestioned premium. It does not eliminate the prospective value of a business generating substantially more revenue and gross profit while potentially moving through a cash-intensive expansion phase.

The strongest bull evidence remains tangible: sustained growth, accelerating implied quarterly revenue, and improving gross-profit economics. The cash-return mechanism remains the decisive uncertainty.

I remain bullish on selective COHR accumulation once the minimum financial bridge and price stabilization are established. Persistent weak conversion, expensive recurring funding, or deteriorating margins would invalidate that approach.

COHR is not a proven bargain at $263.32. But it is a substantive growth-to-cash investment opportunity—not merely a weak-cash-flow company carrying an attractive industry narrative. Bull Analyst: # COHR: Bull Counter-Rebuttal — Growth Can Improve Capital Efficiency Without a Cash Windfall

As of October 14, 2026 | Reference close: $263.32 Bull position: Conditional accumulation of COHR for a two-to-three-year horizon—not an unconditional purchase into the current selloff.

Your strongest point is that growth consumes capital, and an attractive industry opportunity does not automatically produce attractive shareholder returns. I accept that.

But the bullish case need not depend on liquidating working capital, sharply cutting investment, or treating the undefined $14.05 forward EPS estimate as reliable.

A more defensible thesis is this:

COHR’s expanding gross-profit base can outgrow its funding requirements if existing investment produces additional output and operating capital turns efficiently.

That mechanism remains unproven. Nevertheless, the substantial improvement in COHR’s commercial execution gives it more credibility than a growth narrative unsupported by financial results.

1. Lower capital intensity does not necessarily mean cutting investment¶

You correctly highlight the sensitivity of future free cash flow to capital expenditure. But there is an important distinction between reducing investment dollars and reducing investment as a percentage of revenue.

Consider the previously discussed growth scenarios while keeping annual capital expenditure at FY2026’s elevated $1.103 billion:

Illustrative COHR scenario	Revenue after three years	Annual capex	Capex/revenue
FY2026 starting point	$7.118 billion	$1.103 billion	15.5%
15% annual revenue growth	$10.83 billion	$1.103 billion	10.2%
20% annual revenue growth	$12.30 billion	$1.103 billion	9.0%

These are conditional calculations, not forecasts. They assume the same annual investment budget can support the larger business.

The significance is straightforward: capital intensity can decline substantially without withdrawing the investment budget. That could happen if recently installed capacity ramps production, utilization improves, or subsequent expansion requires less expenditure per additional revenue dollar.

We do not yet know whether COHR’s projects permit that outcome. But the relevant disclosure is therefore capacity supported by committed investment, not simply a promise to cut spending.

This does not eliminate your cash-conversion hurdle. Under the 20% growth scenario and unchanged capex dollars, the illustrative 2% FCF-yield benchmark would still require approximately $2.14 billion of operating cash flow, or a 17.4% margin. That remains demanding.

My point is narrower: the bull case can accommodate continued heavy investment. It does not necessarily require management to choose between growth and a dramatically smaller capital budget.

2. Working capital can increase while cash generation improves¶

Your receivables-and-inventory argument is correct: collections do not automatically release the aggregate investment when new business continually replaces those balances.

I would therefore remove an absolute working-capital release from the core bull thesis. It would be helpful, but it should not be necessary.

If operating working capital remains a stable proportion of sales:

Additional working-capital investment = working-capital/sales ratio × additional sales

For illustration, 20% growth from FY2026 revenue would add approximately $1.424 billion of sales:

Every 10 percentage points of sales required in operating working capital would absorb approximately $142 million.
A hypothetical 20% working-capital requirement would absorb approximately $285 million.
At an unchanged 37.5% gross margin, the additional revenue would generate approximately $534 million of additional gross profit.

The working-capital ratio is an assumption—not an estimate of COHR’s actual requirement. Operating expenses, interest, taxes, and capital expenditure still have to be funded.

Nevertheless, this illustrates the distinction:

Growing working-capital balances do not necessarily prevent improving cash generation. The question is whether incremental cash earnings exceed the incremental funding requirement.

Conversely, at a hypothetical 40% working-capital requirement, the same growth would absorb approximately $569 million—more than the additional gross profit before other expenses. Capital turnover is therefore a decisive underwriting variable.

There is also a reason to investigate FY2026 rather than simply regard its cash absorption as ordinary growth funding. Noncash current assets increased approximately 91%, while revenue increased 22.5%. Those assets are not necessarily operating working capital; reporting-scope changes and nonoperating classifications could matter.

That is not evidence of an impending release. It is evidence that the cash-flow bridge must explain a balance-sheet expansion much larger than revenue growth alone.

3. The strongest bullish evidence is improving economics—not the AI label¶

Let’s return to what is demonstrated:

FY2026 revenue increased 22.5%, following 23.4% growth in FY2025.
Gross profit increased approximately $626 million, or 30.6%.
Gross margin improved approximately 233 basis points.
Quarterly gross margins progressed from 36.6% to 37.0% to 37.7%, then an implied 38.5%.

Across the annual comparison, COHR generated approximately 48 cents of additional gross profit per additional revenue dollar.

You correctly note that this is not a return on incremental capital. It includes margin improvement across the existing business, and it cannot be extrapolated indefinitely.

But it is still economically important. COHR is expanding while improving the gross-profit contribution of its revenue base. That is a stronger foundation for future cash generation than growth accompanied by margin dilution.

Its competitive assets also matter: established photonics capabilities across optical components, lasers, and engineered materials, supported by a manufacturing platform generating more than $7 billion annually.

I am not claiming dominant market share or a proven moat. The advantage is an existing technical and manufacturing platform already demonstrating commercial scaling. Optical-capacity and data-center bandwidth headlines support the opportunity, but the financial results—not those headlines—carry the argument.

4. Your valuation objection is valid—but the cash-yield benchmark is not the whole valuation¶

You are right: $1.04 billion of FCF achieved three years from now does not, by itself, establish that today’s $51.86 billion market capitalization is attractive.

A valuation must incorporate intervening cash deficits, financing costs, dilution, and economics beyond year three. I would not present the growth scenarios as a margin-of-safety calculation.

But neither should a future cash-yield benchmark become a complete investment test. During expansion, expenditure on productive assets can suppress current distributable cash while creating future earning capacity.

The crucial distinction is:

Value-creating reinvestment: cash is retained today to generate adequate future returns.
A funding treadmill: cash is repeatedly consumed without sufficient per-share benefits.

I would not add back unidentified “growth capex” and declare COHR cheap. The maintenance-versus-expansion split and project returns must be established.

Likewise, the provider’s 18.7× forward P/E remains conditional information, not verified valuation support.

Where I remain bullish is the prospective operating direction: COHR has demonstrated the larger gross-profit engine that a successful transition requires. What is missing is evidence that common shareholders will capture enough of its output.

5. The next disclosure can establish the mechanism before the recovery is complete¶

We agree that investors do not need to wait years for perfect results. The initiation decision should turn on whether disclosures establish:

Repeatable cash conversion: an explanation of the $80 million annual operating cash flow, with evidence distinguishing temporary absorption from continuing requirements.
Capacity productivity and funding: remaining commitments, ramp schedules, and funding costs—not merely “sold-out capacity.”
Per-share economics: reconciled earnings definitions, capital structure, and a valuation using the then-current price.

The $1.162 billion cash balance and 2.43× current ratio provide breathing room, but not funding independence. The $1.477 billion financing inflow must be understood before assigning its costs to common shareholders.

Higher yields raise the hurdle. My bullish thesis requires execution under those conditions—not a monetary rescue.

Bottom line¶

On immediate execution, our disagreement is narrower than our labels suggest: the supplied record does not justify a blind market order. Price stabilization and financial verification remain unfulfilled.

But COHR deserves a bullish investment bias, not merely recognition that its revenue is recovering. Two years of strong growth, faster gross-profit growth, and steadily improving margins provide tangible evidence of an increasingly capable operating business.

Technically, a higher low and improving OBV would support entry timing; recovery through $285 and the current $293.97/$303.43 moving-average references would strengthen confirmation. The $255.29 weekly SuperTrend reference is not protection, particularly with $22.50 daily ATR.

My COHR recommendation remains conditional accumulation once the funding and per-share return path becomes credible at an attractive then-current valuation. I would not require a working-capital windfall or completed cash normalization.

Your bear case explains how a growing business can disappoint shareholders. The bull case explains why this particular business has a substantive opportunity to do better: its revenue is expanding with improving gross-profit economics, and greater capital efficiency can emerge without dismantling its growth investment. That is a credible opportunity to own when the financial bridge is established—not simply an attractive industry story.

Bear Researcher¶

Bear Analyst: # COHR: Bear Rebuttal — Improving Sales Are Not Yet Improving Shareholder Economics

As of October 14, 2026 | Supplied closing price: $263.32 Bear position: Avoid initiating or adding COHR until cash conversion and the forward-earnings basis are better established.

You have made a credible case that COHR’s business is recovering. But that is not the same as demonstrating that COHR is an attractive investment at $263.32.

I accept the revenue growth and gross-margin improvement. My argument does not require collapsing sales, fictitious profits, or confirmed order cancellations.

The bearish case is more straightforward: COHR’s growth has become materially less self-financing, its apparently reasonable valuation depends on an inadequately defined earnings forecast, and its capital-intensive expansion is occurring against a less supportive financing backdrop.

Your challenge asks me to explain why accelerating revenue should be treated as business deterioration. I would turn that around:

Why should investors pay a demanding valuation for accelerating revenue before they understand why so little of the resulting profit is becoming cash?

1. The cash-flow problem is an existing negative—not merely an unanswered question¶

You correctly distinguish operating cash flow from capital expenditure. That distinction strengthens the bear case.

According to the supplied annual statements:

Cash-flow measure	FY2025	FY2026
Operating cash flow	$634 million	$80 million
Capital expenditure	$441 million	$1.103 billion
Statement-derived free cash flow	$193 million	−$1.023 billion
Capital expenditure/revenue	7.6%	15.5%

Revenue rose 22.5%, yet operating cash flow fell 87.4%. FY2026 operating cash flow represented only approximately 10% of the latest reported net-income figure.

That is not simply “investment spending temporarily reducing free cash flow.” The weakness begins before capital spending.

For perspective, even if FY2026 capital expenditure had remained at FY2025’s $441 million, the reported $80 million of operating cash flow would still have produced negative $361 million of free cash flow. That is a counterfactual illustration—not an estimate of normalized cash flow—but it shows why reducing growth investment alone would not resolve the problem.

Nor did the cash outflow improve toward year-end. The supplied quarterly calculations show free cash flow of:

−$383 million in the March quarter.
−$486 million in the June quarter.

You say operating scale can precede cash returns. Certainly. But investors need evidence that COHR is approaching that transition, not simply evidence that the factories are producing more revenue.

The recovery in gross-profit economics is demonstrated. The recovery in cash economics is not.

2. Liquidity provides breathing room, not proof that the expansion is sustainable¶

I agree that $1.162 billion of cash and a 2.43× current ratio do not suggest an immediate liquidity crisis. I am not making a bankruptcy argument.

But the direction of the latest balance-sheet movements matters:

Cash declined from $1.593 billion in March to $1.162 billion in June, down 27.1%.
Current liabilities increased 35.1% over the same period.
The current ratio fell from approximately 3.05× to 2.43×.

Moreover, most of the annual increase in current assets was noncash. Without their composition, a higher current ratio cannot be treated as equivalent to readily available funding.

FY2026 also included $1.477 billion of net financing inflows. The supplied data do not establish whether those inflows principally represented borrowing, equity-related transactions, or other financing, so I will not label them all new debt. Nevertheless, financing was an important support while internally generated cash was weak.

That creates a relevant investment risk: if cash conversion does not recover, COHR may need further funding, investment restraint, or both. The cost to shareholders would depend on the funding mechanism.

Your liquidity argument buys COHR time. It does not establish the return investors will earn on that time.

3. The forward P/E is the weakest foundation for calling COHR attractive¶

At the supplied price, COHR trades at approximately 63.9× trailing earnings and 7.3× trailing sales. Those figures do not establish overvaluation by themselves, but they hardly suggest a stock priced for negligible expectations.

The more appealing 18.7× forward P/E rests on $14.05 of provider-reported forward EPS. Yet its forecast period, accounting basis, and estimate provenance are missing.

You acknowledge that limitation, but then make validated forward earnings a central route to upside. That is precisely the issue: the most valuation-friendly part of the thesis is also one of its least verified inputs.

The $14.05 estimate is approximately 3.4 times trailing EPS. That is not a confirmed like-for-like growth forecast. It does mean we cannot confidently interpret the apparent drop from 63.9× trailing to 18.7× forward as genuine cheapness without reconciling the earnings definitions.

Using the provider’s unrounded forward estimate, consider these arithmetic scenarios:

Illustrative assumption	Implied COHR value	Change from $263.32
Full forward EPS, 20× P/E	$281.07	+6.7%
Full forward EPS, 25× P/E	$351.34	+33.4%
Full forward EPS, 15× P/E	$210.80	−19.9%
Forward EPS 20% lower, 15× P/E	$168.64	−36.0%

These are sensitivities, not price targets, justified fair-value multiples, or probability-weighted forecasts.

But they expose the weakness in your valuation argument:

Your substantial upside case needs the full earnings estimate and multiple expansion.
A 20× multiple on the full estimate offers only approximately 7% upside.
Multiple compression alone produces meaningful downside.
An earnings miss combined with compression produces much greater damage.

Annualizing the implied June-quarter revenue to $8.18 billion does not resolve this. A sales run rate cannot validate common-share EPS without an operating-expense, financing, tax, and ownership-attribution bridge.

The issue is not whether COHR can grow. It is how much growth, cash recovery, and favorable valuation treatment the current price already requires.

4. Manufacturing scale can be an advantage—and a financial burden¶

Your argument about photonics expertise and manufacturing capabilities is reasonable. However, the supplied research does not establish superior market share, durable pricing power, or better investment returns than competitors.

The Lumentum demand headlines support a strong industry opportunity. They do not prove a COHR-specific competitive advantage.

COHR’s demonstrated vulnerability is capital intensity: capital expenditure increased from 7.6% to 15.5% of revenue. Manufacturing capacity can create a barrier to entry, but existing shareholders still have to fund it and earn an adequate return.

The competitive risk is conditional but important:

If COHR and its competitors expand capacity while customer projects slow or shift timing, today’s supply constraints could become tomorrow’s utilization and pricing pressure.

That is not a claim that oversupply or competitive share losses have already occurred. It is the risk investors assume when they capitalize a capacity-constrained demand narrative before its cash returns are visible.

“Sold-out capacity” is encouraging. Without delivery schedules, cancellation provisions, customer funding commitments, and conversion economics, it is not equivalent to shareholder cash flow.

5. COHR does not need canceled orders to suffer further downside¶

You emphasize that financing fears have not established COHR order cancellations. Agreed—but cancellations are not necessary for the bear thesis.

Two separate channels matter:

Valuation compression: Higher discount rates can reduce COHR’s share price even if earnings meet expectations.
Investment timing: More expensive customer financing can delay projects and cash receipts without eliminating long-term optical demand.

The supplied macro coverage points toward inflation and yield pressure, although official macro series were unavailable and the news evidence is headline-based. Reported prediction-market pricing put an October 25-basis-point Fed hike at 28%, up 13 percentage points over the week. Those are contract prices, not official forecasts, but they illustrate the tightening concern.

You are not relying on imminent easing. Fair enough. COHR remains exposed to financing conditions regardless of whether easing is part of your thesis.

Strong long-term demand and disappointing near-term shareholder returns can coexist.

6. An oversold bounce would not settle the investment debate¶

I also agree that aggressively shorting COHR after a 22.2% decline is unattractive. Daily statistical stretch and the potential longer-window OBV divergence create rebound risk.

But avoiding a poorly timed short does not make accumulation compelling.

The supplied technical evidence remains weak:

Price is below the $293.97 200-day SMA and $303.43 50-day SMA.
RSI is 39.30—bearish, but not conventionally oversold.
Recent OBV declined.
None of the TD-9 setups is complete.

Weekly and monthly SuperTrend remain UP, and there is no current death cross. Those qualifications matter. Nevertheless, the weekly trailing-stop reference at $255.29 is only $8.03, or approximately 3.1%, below the latest close—just 0.36 daily ATR away.

That does not predict a breach, and any weekly reversal requires confirmation against the recalculated boundary. It does show how little separation exists between the current price and a potentially important regime change.

A higher low and recovery through moving averages would improve trading conditions. They would not explain the operating-cash-flow collapse or validate $14.05 of forward EPS.

My conclusion: COHR has not earned the benefit of the doubt at this price¶

Your closing statement is that weak cash conversion does not invalidate an improving business.

I agree. But an improving business is not automatically an attractive stock.

For COHR, I would want a minimum evidentiary foundation before adding exposure:

A reconciled, period-specific forward EPS estimate.
A clear explanation of weak operating cash flow and evidence of recovery.
Credible capacity-investment payback and funding plans.
Funded demand and backlog-conversion details.

The vendor’s earnings discrepancies are reasons to verify those foundations—not evidence of a company-announced restatement. Likewise, the cash-flow source discrepancy needs reconciliation, although both reported definitions show negative free cash flow.

My bear recommendation for COHR is to avoid new long exposure for now. Tactically, a confirmed failed recovery would offer a more defensible bearish setup than chasing the latest low.

You are asking investors to enter before cash returns are proven. I am asking whether the current valuation adequately compensates them for assuming those returns will arrive. On the supplied evidence, it does not yet offer a convincing margin of safety. Bear Analyst: # COHR: Bear Counter-Rebuttal — “Start Small” Is Position Sizing, Not a Valuation Case

As of October 14, 2026 | Reference close: $263.32 Bear position: Avoid new COHR long exposure until the cash-flow bridge, investment requirements, and forward-earnings basis are sufficiently established. Do not chase the selloff with an indiscriminate short.

You have narrowed the disagreement constructively. COHR’s revenue recovery is real, its gross-margin improvement matters, and earnings-led share-price appreciation does not inherently require multiple expansion. My earlier suggestion that substantial upside necessarily required a rerating was too broad.

But your revised argument still combines the latest quarter’s stronger gross profit, an earlier period’s lower investment intensity, and an undefined forward EPS estimate.

Those assumptions might ultimately fit together. The supplied evidence does not yet establish that they do—or that $263.32 adequately compensates investors for the possibility that they do not.

1. If the exit rate matters, the cash-flow exit rate matters too¶

You emphasize approximately $3.15 billion of annualized gross profit based on the implied June quarter. Fair enough—but consider the complete picture from that same quarter:

COHR implied/derived June-quarter measure	Amount
Revenue	$2.045 billion
Gross profit	$787 million
Gross margin	38.5%
Operating cash flow	Approximately $70 million
Capital expenditure	Approximately $556 million
Statement-derived free cash flow	Approximately −$486 million

Revenue and gross profit are derived from annual totals less the first three quarters; cash-flow figures are derived from the cumulative statements.

Capital expenditure therefore represented approximately 27.2% of quarterly revenue, while the free-cash-flow margin was approximately negative 23.8%.

I would not annualize that cash outflow into a forecast. Equally, I would not treat annualized gross profit as evidence that the cash turnaround is approaching.

COHR’s strongest implied revenue and gross-margin quarter coincided with its largest quarterly cash deficit of FY2026. That does not prove permanent deterioration. It does show that improving gross-profit economics have not yet produced an observable cash-flow turning point.

Your higher gross-profit starting point is valuable. But the latest evidence still leaves unanswered how much additional investment is necessary to sustain it.

2. Your normalization scenario reveals how much recovery the valuation still needs¶

Your historical argument is valid: COHR has generated positive free cash flow before.

But the amounts matter. Statement-derived free cash flow totaled approximately $689 million across FY2022–FY2025. The FY2026 outflow alone was $1.023 billion.

Changes in business scope prevent treating those periods as perfectly comparable. Nevertheless, that history provides much less reassurance than “four years of positive free cash flow” might initially suggest.

Now consider your illustrative recovery:

Operating-cash-flow margin returns to approximately 10.9%.
Capital expenditure falls to approximately 7.6% of revenue.
Annual free cash flow reaches approximately $236 million.

Against the supplied $51.86 billion market capitalization, that represents a free-cash-flow yield of approximately 0.46%.

You acknowledge that $236 million would not independently justify the valuation. I agree—and that concession is central:

Even after both proposed repairs, COHR would still need substantial additional cash-generation growth to provide compelling valuation support.

There is another unresolved dependency. Can COHR preserve its stronger revenue and gross-profit trajectory while cutting capital expenditure from 15.5% to 7.6% of revenue?

Possibly. Some investment may be front-loaded. But we lack the maintenance-versus-growth spending split, committed expansion budget, and investment-payback schedule needed to establish that compatibility.

The bull case therefore needs more than “cash flow normalizes.” It needs cash flow to improve substantially while investment intensity falls and operating momentum remains strong.

3. Earnings growth can deliver returns—but modest compression can absorb them¶

You correctly distinguish earnings-led returns from multiple-led returns. But increasing the provider’s undefined EPS estimate by another 20% does not resolve the original verification problem.

It creates an additional assumption.

Using the supplied forward EPS solely for illustration:

Conditional COHR scenario	Implied value	Change from $263.32
EPS 20% above the provider estimate; unchanged provider multiple	Approximately $316	+20%
EPS 20% above the provider estimate; 15× P/E	Approximately $253	−4%
EPS 20% below the provider estimate; 15× P/E	Approximately $169	−36%

These are sensitivities, not price targets, justified fair-value multiples, or probability-weighted forecasts.

The important point is that COHR could achieve your illustrative 20% earnings improvement and still deliver a slightly negative share-price return if the multiple fell to 15×.

That does not establish that 15× is the correct valuation. It establishes that operating success and investment success remain different questions.

You are also correct that my downside scenarios do not prove a negative expected return. But your upside scenarios do not establish an attractive expected return either. Neither side has a sufficiently defined earnings base or defensible probabilities.

The difference is that the current price still represents approximately 63.9× trailing earnings and 7.3× trailing sales. This is not an obviously low-expectation valuation that makes the missing evidence easy to overlook.

And the 22.2% decline does not settle that issue. It establishes a discount to the October 6 price—not necessarily a discount to intrinsic value. Without historical estimate vintages, we cannot establish whether price has fallen faster than the relevant earnings outlook.

4. The financing problem already exists inside COHR¶

You contrast demonstrated operating progress with headline-based concerns about future financing conditions. That framing leaves out a demonstrated company-level weakness.

FY2026 included:

$80 million of operating cash flow
$1.414 billion of net investing outflows
$1.477 billion of net financing inflows

The financing inflows cannot responsibly be labeled entirely new debt. Their composition is unavailable. But they show that external financing was an important support while internal cash generation was weak.

That matters even if every major customer remains committed to optical investment.

If weak cash conversion persists, COHR may need further funding, slower investment, or both. Depending on the funding mechanism, shareholders could face higher financing costs, dilution, or reduced growth capacity. These are conditional risks—not claims that any particular financing transaction has occurred.

The $1.162 billion cash balance and 2.43× current ratio provide breathing room. They do not establish funding independence, particularly after cash fell 27.1% sequentially in the June quarter.

So no, my thesis does not require confirmed customer cancellations or a monetary-policy shock. COHR’s existing gap between growth and internal funding is already sufficient to demand a valuation discount.

5. Manufacturing capability does not establish attractive incremental returns¶

I accept that COHR’s technical capabilities and manufacturing platform are meaningful assets. But their economic value depends on what shareholders must keep investing to remain competitive.

The supplied research does not establish:

Durable COHR-specific pricing power.
Superior returns on incremental capital.
A quantified competitive advantage in backlog quality.
How much capacity spending is required merely to keep pace.

Industry capacity constraints support demand. They do not automatically establish a durable moat for COHR.

If competitors expand while customer projects shift timing, utilization and pricing could weaken before long-term bandwidth demand disappears. That is a risk scenario, not an observed deterioration. But it is precisely why current gross-margin improvement cannot, by itself, validate the return on today’s expansion spending.

An attractive market can still require its suppliers to reinvest heavily without producing attractive shareholder cash returns.

6. I am asking for minimum underwriting evidence—not perfection¶

You suggest that waiting means requiring several quarters of fully normalized cash flow. That is not my standard.

A credible disclosure package could materially change my assessment:

An operating-cash-flow bridge: What caused the fall to $80 million, which items are temporary, and what supports their reversal?
An investment and funding plan: What spending is committed, what can decline, and how will capacity additions generate cash returns?
A defined common-share earnings forecast: What period and accounting basis underlie $14.05, with what dilution and capital-structure assumptions?

I do not need every uncertainty eliminated. I need enough evidence to distinguish a temporary investment cycle from a persistently expensive growth model.

Nor does technical stabilization substitute for those answers. Weekly and monthly SuperTrend remain UP, so a full higher-timeframe bearish reversal is not confirmed. But COHR remains below its verified moving averages, with RSI at 39.30 and declining recent OBV.

The $255.29 weekly SuperTrend reference is only $8.03 below the close, versus daily ATR of $22.50. It is a regime-monitoring reference—not protection for a starter position.

Starting small reduces dollar exposure. It does not improve the valuation or expected return per dollar invested.

Bottom line¶

Waiting could mean paying more after favorable evidence arrives. I accept that opportunity cost; I am not claiming confirmation guarantees a cheaper entry.

But COHR’s current evidence establishes stronger gross-profit generation alongside exceptionally weak cash generation, not a demonstrated transition toward attractive cash returns.

Your argument earns COHR a place on a watchlist. It has not yet established why committing capital at $263.32 offers adequate compensation for the remaining funding, reinvestment, and earnings risks.

My recommendation remains to avoid new COHR long exposure for now. Reconsider when credible disclosures make the cash-return path underwritable—not merely when the share price stabilizes. Bear Analyst: # COHR: Bear Rebuttal — A Modest Cash Improvement Does Not Yet Establish an Attractive Investment

As of October 14, 2026 | Supplied close: $263.32 Bear position: Avoid new COHR long exposure until the cash-conversion mechanism, investment requirements, and sustainable common-share earnings are sufficiently established.

Fair correction: COHR’s implied June-quarter operating cash flow improved relative to the preceding nine-month pace. My earlier wording should not suggest that every cash measure was deteriorating.

But that correction changes the description more than the investment conclusion.

You have identified a modest positive signal within a severely cash-constrained recovery. What remains missing is evidence that this improvement can become large enough—and durable enough—to support the valuation.

“Not uniformly worsening” is a lower hurdle than “attractive at $263.32.”

1. Generating 87.5% of annual operating cash flow sounds stronger than the underlying dollars¶

The June quarter generated approximately $70 million of operating cash flow, compared with approximately $10 million across the preceding nine months. That improvement deserves recognition.

However, the 87.5% statistic uses an exceptionally weak $80 million annual denominator. The more economically useful measurements are:

Operating-cash-flow margin: approximately 3.4%.
Operating cash flow as a proportion of quarterly capital expenditure: approximately 12.6%.
Quarterly free cash flow: approximately negative $486 million.

These figures are derived from the supplied cumulative statements, subject to consistent reporting scope.

Without a working-capital bridge and comparable prior-year quarterly cash-flow figures, we cannot determine how much of the improvement reflects durable conversion gains rather than collection timing or seasonality. That is not a claim that timing caused the improvement; it is a limitation on interpreting it.

Your capex-concentration argument is also reasonable—but insufficient.

For illustration, suppose June-quarter capital expenditure had matched the approximately 10.8% of revenue spent during the first nine months, rather than the actual 27.2%. Holding June operating cash flow unchanged:

Capital expenditure would have been approximately $221 million.
Free cash flow would still have been approximately negative $151 million.

That is a counterfactual, not a normalized-cash-flow forecast. It shows that removing much of the spending spike would not, by itself, have produced self-funding growth.

You are not claiming otherwise. But it explains why I give the late-year operating-cash improvement limited weight: both cash conversion and investment intensity still require substantial repair.

2. Better gross-profit economics are real—but they do not establish capital productivity¶

Your approximately 48 cents of additional gross profit per additional revenue dollar is a valid calculation. So is the approximately $166 million benefit from achieving a higher gross margin on FY2026 revenue.

I count the gross-profit improvement as strong positive evidence. I do not count it as evidence that the expansion is earning an attractive return on capital.

The distinction matters because that incremental gross-profit ratio combines:

Revenue growth.
Margin changes across the existing revenue base.
Potential changes in utilization, pricing, mix, and manufacturing costs.

It does not isolate the return on the additional factories, equipment, working capital, or financing needed to support growth.

Gross margin also does not deduct current capital spending as a cash outflow; the associated accounting expense follows a different timetable. Consequently, better reported gross margins can coexist with an expansion that remains expensive for shareholders to fund.

And the annual comparison remains striking:

Gross profit increased approximately $626 million, while operating cash flow declined approximately $554 million.

That does not establish a causal relationship or invalidate the margin recovery. It establishes that improved gross-profit economics have not yet translated into comparable cash benefits.

On competitive positioning, I accept that COHR has valuable technical capabilities and an established manufacturing platform. But the relevant comparison is not COHR versus an aspiring supplier with no factories. It is COHR versus alternative investments offering different combinations of growth, capital requirements, and shareholder returns.

Until we understand how much investment is discretionary expansion versus spending necessary to remain competitive, manufacturing scale remains both an asset and an obligation.

3. Retiring the normalization valuation leaves a significant valuation gap¶

You appropriately withdrew the earlier cash-flow normalization calculation as valuation support. But what replaces it?

The current proposition is essentially:

Revenue and gross margins remain strong; operating cash flow improves; investment produces adequate returns; and those returns accrue to common shareholders.

That is a plausible business scenario. It is not yet a valuation framework because the size, timing, and funding cost of those returns remain unspecified.

Set aside the undefined $14.05 forward EPS estimate for a moment. At the supplied $51.86 billion market capitalization, consider the scale of sustainable free cash flow associated with two illustrative equity cash yields:

Illustrative FCF yield	Annual FCF	Equivalent percentage of FY2026 revenue
2%	$1.04 billion	14.6%
3%	$1.56 billion	21.9%

These are not required fair-value yields, forecasts, or price targets. They simply translate the equity valuation into cash-generation amounts.

Future revenue growth could reduce the margins needed to reach those amounts. Nevertheless, the table illustrates how much further the cash-return thesis must travel beyond generating $70 million of quarterly operating cash flow before capital expenditure.

I am not valuing COHR solely on depressed current cash flow. I am asking for a credible bridge to sustainable future cash flow.

Likewise, neither 63.9× trailing earnings nor 7.3× trailing sales proves overvaluation. But those figures make it difficult to argue that investors are paying so little that the missing bridge is unimportant.

A prospective valuation still needs quantified prospective economics. Calling the opportunity a “growth recovery” does not remove that requirement.

4. The time between investment and cash returns is not free¶

You argue that capex could be lumpy rather than permanently elevated. Agreed. My bear case does not require FY2026 spending intensity to persist indefinitely.

But even productive, temporary investment can disappoint shareholders if:

Assets take longer than expected to become productive.
Customers shift shipment or payment timing.
Additional capital is required before the first projects generate cash.
Financing costs or dilution absorb more of the operating improvement.

COHR’s FY2026 financial statements already show why that timing matters:

$80 million of operating cash flow.
$1.103 billion of capital expenditure.
$1.477 billion of net financing inflows.

The financing composition is unavailable, so those inflows should not be labeled entirely new debt or assumed to represent forced financing. Nevertheless, external capital was an important support during a period of weak internal cash generation.

The $1.162 billion cash balance and 2.43× current ratio provide breathing room—not evidence of funding independence. June-quarter cash also declined 27.1% sequentially.

Headline-based concerns about inflation and rising yields add to this risk, although official macro observations were unavailable in the supplied research. Higher financing costs need not destroy optical demand to reduce shareholder returns.

Orders can remain intact while the cash arrives later, investment payback lengthens, and the equity becomes worth less.

That is why the absence of confirmed cancellations does not neutralize the bear case.

5. A cash-conversion catalyst needs a mechanism—not just a desirable outcome¶

You describe improving cash conversion as a catalyst. I would distinguish between a potential outcome and an identifiable catalyst with a supported mechanism.

The next COHR earnings disclosure could provide that mechanism. But the supplied material does not yet establish:

What caused the operating-cash-flow collapse, which items should reverse, and when.
How much spending remains committed, when capacity becomes productive, and what cash returns management expects.
What earnings accrue to common shareholders, using a defined forecast period, accounting basis, and capital-structure assumptions.

One credible disclosure package could materially change my assessment. I am not demanding years of perfect execution.

Your accumulation recommendation is itself conditional on stabilization and basic financial verification. Neither condition has been established in the supplied record. That makes accumulation a possible future decision—not a demonstrated current opportunity.

Technically, weekly and monthly SuperTrend remain UP, so I would not claim a confirmed higher-timeframe bearish reversal. But COHR remains below its verified moving averages, with RSI at 39.30 and declining recent OBV. The nearby $255.29 weekly reference is not downside protection, especially against $22.50 daily ATR.

A rebound could improve the chart without resolving the investment case. Equally, the statistical downside stretch makes chasing a fresh short unattractive.

Bottom line¶

Your latest argument establishes something useful: COHR’s cash picture is not uniformly worsening, and the operating recovery has substance.

It does not establish that the current price adequately compensates investors for the remaining cash-conversion, reinvestment, financing, and common-share earnings risks.

My bearish conclusion does not require COHR’s growth opportunity to break. It requires only that cash returns arrive later, cost more to achieve, or accrue less favorably to common shareholders than the bullish narrative assumes.

My recommendation remains to avoid new COHR long exposure for now. Reconsider when disclosures make the magnitude and funding of future shareholder returns underwritable—not merely when operating cash flow improves from near zero or the share price stabilizes. Bear Analyst: # COHR: Bear Rebuttal — A Growth Scenario Is Not Yet a Funded Investment Case

As of October 14, 2026 | Reference close: $263.32 Bear recommendation: Avoid initiating or adding COHR until disclosures support a credible, adequately funded path to attractive common-shareholder returns.

Your latest framework improves the debate because it quantifies what COHR must achieve. But it also exposes the central weakness: the investment case requires a transformation in cash conversion—not simply continued revenue growth.

I accept that COHR has a substantive operating recovery. I also accept that a credible disclosure package could justify investing before the cash recovery is complete.

What I do not accept is that a plausible growth scenario, combined with a possible working-capital explanation, establishes adequate compensation for the risks at $263.32.

The question is not whether COHR has prospective value. It is whether investors are paying an attractive price for that value after accounting for the capital required to realize it.

1. Your three-year scenarios require a new cash-generation regime¶

Let’s extend your calculations. At today’s approximately $51.86 billion market capitalization, the illustrative 2% FCF-yield benchmark requires $1.037 billion of annual free cash flow.

With capital expenditure at your assumed 10% of revenue:

Illustrative COHR scenario	Year-three revenue	Annual capex at 10%	Operating cash flow needed	Required OCF margin
15% annual revenue growth	$10.83bn	$1.08bn	$2.12bn	19.6%
20% annual revenue growth	$12.30bn	$1.23bn	$2.27bn	18.4%

These are conditional operating calculations—not forecasts, required fair-value yields, or price targets.

That means COHR would need to generate more than three times FY2025’s $634 million operating cash flow, and dramatically more than FY2026’s $80 million.

The required margins also substantially exceed:

FY2025’s approximately 10.9% operating-cash-flow margin.
FY2026’s approximately 1.1%.
The implied June quarter’s approximately 3.4%.

You acknowledge the challenge. But it deserves more emphasis: even returning to the earlier cash-conversion margin would not come close to satisfying your illustrative benchmark.

At approximately 10.9% operating-cash-flow margin and 10% capex intensity, your larger future business would produce only roughly $100–110 million of annual FCF.

So the bullish proposition is not merely:

“Maintain growth and repair an unusually weak cash year.”

It is:

“Maintain strong growth, achieve substantially better cash conversion than FY2025, and support that growth with lower capital intensity than FY2026.”

That combination is possible. The supplied evidence does not yet make it underwritable.

2. Working capital may be a continuing requirement—not a reservoir waiting to be released¶

Your $1.686 billion increase in noncash current assets less current liabilities is a useful research lead. You correctly acknowledge that it is not an operating-working-capital reconciliation.

But even if filings validate your preferred explanation, there is a further hurdle:

Collectible operating assets do not automatically represent releasable cash in a rapidly growing business.

If receivables are collected, new sales can create new receivables. If inventory ships, growing production can require replacement inventory. The individual assets convert into cash, while the aggregate investment remains—or increases.

That matters because your revenue scenarios require approximately 52%–73% cumulative growth over three years.

To combine that expansion with a meaningful working-capital release, COHR would need something beyond ordinary collections:

Faster receivables turnover.
Better inventory efficiency.
More favorable supplier terms.
Customer deposits or other funding support.
Evidence that the initial asset build exceeded ongoing operating requirements.

None is established in the supplied record.

You already distinguish a one-time release from recurring cash generation. My additional point is that the ongoing growth assumption can itself compete with the release assumption.

If the balances are healthy operating assets, they may still reveal a business whose growth consumes substantial funding. If they include nonoperating balances, scope changes, or financing classifications, they may not explain the operating-cash-flow weakness at all.

The hypothesis deserves investigation. Its existence is not yet positive evidence of an impending cash release.

3. Strong current margins do not remove the reinvestment risk¶

I agree that rising gross margins demonstrate improving execution. I am not making oversupply or competitive share losses my established base case.

But your projection holds gross margin at 37.5% while revenue compounds and capex intensity falls to 10%. That assumes COHR can preserve favorable manufacturing economics while making its investment program more efficient relative to sales.

We still lack the evidence needed to assess that combination:

Maintenance versus expansion spending.
Remaining project commitments.
Capacity utilization and ramp schedules.
Contractual customer commitments.
Returns on incremental capital.

Consider a modest sensitivity within your own framework. If future capex were 12% of revenue rather than 10%, additional annual spending would be approximately $217–246 million.

Holding operating cash flow unchanged, that would consume approximately 21%–24% of the $1.037 billion FCF benchmark.

This does not assume FY2026’s 15.5% spending intensity persists indefinitely. It shows that a relatively small miss on reinvestment efficiency materially changes the cash outcome.

Competitive conditions create another vulnerability. Industry capacity constraints can support current economics while encouraging suppliers to expand. If customer projects shift timing as that capacity arrives, utilization and pricing can weaken without long-term optical demand disappearing.

COHR’s specialized capabilities are valuable. What remains unproven is whether those capabilities allow shareholders to earn attractive returns after paying to maintain and expand them.

4. A future 2% cash yield still does not establish today’s margin of safety¶

You properly label the three-year figures as operating targets rather than discounted fair values. That distinction is decisive.

A 2% FCF yield on today’s market capitalization, achieved three years from now, corresponds to approximately 50 times that future annual FCF on the original equity valuation.

That could be supportable with sufficiently durable subsequent growth. But it is not inherently inexpensive, and the cash yield is not the investor’s total return.

A valuation still needs:

The intervening cash-flow path.
The peak funding requirement.
Financing costs and potential dilution.
Sustainable growth and reinvestment assumptions beyond year three.
The portion of future economics attributable to common shareholders.

The existing statements show why those intervening years matter:

FY2026 operating cash flow: $80 million.
Capital expenditure: $1.103 billion.
Statement-derived FCF: negative $1.023 billion.
Net financing inflows: $1.477 billion.

Those financing inflows cannot responsibly be classified entirely as debt or equity issuance. But their unknown composition is not economically irrelevant. How COHR finances the transition affects how much of the eventual improvement belongs to each common share.

The $1.162 billion cash balance and 2.43× current ratio provide breathing room; this is not an immediate insolvency thesis. Nevertheless, headline-reported yield pressure makes a funding-dependent transition less forgiving.

And the alternative valuation shortcut remains unavailable: the provider’s $14.05 forward EPS still lacks a defined period and accounting basis.

The result is not proof that COHR is overvalued. It is that neither the forward-earnings framework nor the cash-flow framework currently demonstrates an adequate margin of safety.

5. Your initiation conditions support patience today¶

Your actual recommendation requires:

A credible operating-cash-flow bridge.
A funded investment plan.
Reconciled common-share economics.
Price stabilization.

Those are sensible conditions. They also remain unfulfilled in the supplied record.

That substantially narrows our practical disagreement. I am not demanding several years of completed cash recovery. A sufficiently credible, quantified disclosure package could change my assessment before normalized FCF appears.

But the package must support valuation—not merely explain historical weakness. It should show how much cash COHR can sustainably generate, what investment remains necessary, and what common shareholders retain after funding the transition.

Any purchase would then need to be assessed at the then-current price, rather than assuming today’s $263.32 entry remains available.

Technically, COHR remains below the verified $293.97 and $303.43 moving-average references. Weekly SuperTrend remains UP, and daily statistical stretch creates rebound risk. Accordingly, my bearish investment view does not translate into chasing an indiscriminate short after the selloff.

Bottom line¶

You have described a credible opportunity to investigate. You have not yet demonstrated an attractive opportunity to fund at the current valuation.

The important tension is this:

Your growth assumptions can enlarge future gross profit, but they can also enlarge the working-capital and capacity requirements standing between gross profit and shareholder cash.

COHR does not need collapsing demand or canceled orders to disappoint. Cash conversion can recover more slowly, investment can remain somewhat heavier, or financing can absorb more of the benefit than expected.

My recommendation remains to avoid new COHR long exposure for now. Reconsider when disclosures connect the growth opportunity to quantified, funded, per-share cash returns at an attractive valuation—not simply when they make the recovery narrative more plausible. Bear Analyst: # COHR: Bear Rebuttal — Lower Capital Intensity Is Not Yet Higher Shareholder Returns

As of October 14, 2026 | Reference close: $263.32 Bear recommendation: Avoid new COHR long exposure until the cash-return and funding assumptions support the valuation. Do not chase the selloff with an indiscriminate short.

Your latest refinements are reasonable: capital intensity can decline without cutting investment dollars, and working capital can grow while cash generation improves.

But those relationships establish how a recovery could work, not whether COHR is likely to deliver sufficient returns at $263.32.

The remaining disagreement is not whether COHR has a credible operating business. It does. It is whether investors should assign a bullish investment bias before understanding the economics of financing that business’s expansion.

COHR has demonstrated that it can generate more gross profit. It has not yet demonstrated how much additional capital shareholders must supply to capture that improvement.

1. Fixed capital spending helps the arithmetic—but leaves a substantial cash-conversion hurdle¶

You are correct that holding annual capital expenditure at $1.103 billion would reduce capex/revenue as sales expand.

However, the critical assumption is not the falling ratio. It is that the same spending budget can support a business with 52%–73% more revenue, while preserving product competitiveness, manufacturing economics, and delivery performance.

That requires evidence about capacity, utilization, project completion, and future investment commitments. The supplied research does not provide it.

More importantly, let’s combine your fixed-dollar capex assumption with a meaningful operating recovery: restoring FY2025’s approximately 10.9% operating-cash-flow margin.

Illustrative COHR scenario	Year-three revenue	OCF at FY2025’s margin	FCF after $1.103bn capex	FCF yield on today’s $51.86bn market cap
15% annual revenue growth	$10.83bn	$1.18bn	$78m	0.15%
20% annual revenue growth	$12.30bn	$1.34bn	$239m	0.46%

Conditional calculations, not forecasts or fair-value estimates. They use FY2025’s unrounded OCF margin and do not model financing or share-count changes.

This is a favorable combination: strong growth, substantially repaired cash conversion, and no increase in annual investment dollars. Yet the resulting free cash flow provides limited support for the current equity valuation.

You acknowledge that the 20% growth scenario would need approximately 17.4% operating-cash-flow margin to produce the previously discussed illustrative 2% FCF yield.

That acknowledgment is decisive. The bull case requires more than restoring earlier cash economics; it requires materially better cash economics on a much larger revenue base.

And “unchanged annual capex” still means another $3.309 billion of capital spending over three years. Lower spending intensity does not make the intervening funding requirement disappear.

2. Your working-capital illustration starts above the relevant cash-profit line¶

Your example pairs approximately $534 million of additional gross profit with a hypothetical $285 million working-capital requirement.

The calculation is useful, but the comparison cannot establish incremental cash generation.

Gross profit is not incremental cash earnings. It precedes operating expenses, interest, taxes, and other adjustments; it also includes accounting costs whose cash timing differs. The relevant question is:

How much incremental cash profit remains after those obligations, and does it exceed the additional working-capital and capacity requirements?

The missing bridge matters because the actual annual evidence points in opposite directions:

Gross profit increased approximately $626 million.
Operating cash flow declined approximately $554 million.

That does not prove growth caused the cash deterioration. It does show why an assumed working-capital ratio cannot establish that future expansion will become adequately self-financing.

I also agree that the approximately 91% increase in noncash current assets, against 22.5% revenue growth, demands investigation. But its direction is not inherently bullish.

Depending on the underlying composition, it could reflect temporary operating investment, slower asset turnover, nonoperating balances, or reporting-scope changes. Until reconciled, that disproportionate expansion is a risk to explain—not a source of cash recovery to credit.

3. Rising gross margins are positive evidence—not protection against a three-year investment cycle¶

I accept the strength of COHR’s gross-margin progression. It is the most persuasive part of your argument.

But your investment horizon extends well beyond the period in which those improvements occurred. Maintaining favorable economics while competitors add capacity and customers adjust spending schedules is a separate challenge.

Consider a modest sensitivity within your $12.30 billion future revenue scenario:

A gross margin of 37.5% produces approximately $4.61 billion of gross profit.
A margin of 35.5% produces approximately $246 million less gross profit.

That lower margin would remain slightly above FY2025’s approximately 35.2%. It does not require an industry collapse or catastrophic competitive failure.

The $246 million reduction is not automatically an equivalent FCF reduction; taxes, noncash costs, and operating adjustments matter. Nevertheless, its scale is comparable to the $239 million FCF in the restored-cash-margin scenario above.

That is the vulnerability: a modest change in operating economics can absorb much of the cash benefit generated by several years of strong growth.

COHR’s specialized capabilities and manufacturing platform are valuable. But the supplied evidence does not establish pricing power or superior incremental capital returns. In technical manufacturing, capacity must also be qualified, appropriately configured, and economically productive for the products customers actually purchase.

Industry capacity constraints therefore cut both ways: they support demand today while encouraging investment that could become less attractive if customer projects shift timing.

4. Productive investment can still disappoint common shareholders¶

You correctly distinguish value-creating reinvestment from a funding treadmill. But that distinction depends on returns relative to the cost and timing of capital, not simply whether new equipment eventually produces revenue.

A project can be operationally successful and still disappoint shareholders if:

The ramp takes longer than expected.
Additional investment is required before cash returns arrive.
Customer payments lag.
Financing costs or dilution absorb more of the benefit.

COHR’s existing financial position makes those possibilities relevant:

FY2026 operating cash flow was $80 million.
Statement-derived FCF was negative $1.023 billion.
Net financing inflows were $1.477 billion.
Cash declined 27.1% sequentially in the June quarter.

The financing composition is unknown, so I will not label those inflows entirely new debt or assume they were forced. Likewise, $1.162 billion of cash and a 2.43× current ratio do not establish an immediate liquidity crisis.

But they do not eliminate the economic cost of bridging the expansion.

Headline-reported inflation and yield pressure make that bridge potentially less forgiving, although the supplied research lacks official macro observations needed to quantify the impact. COHR does not need canceled orders to suffer: later cash receipts and more expensive funding can reduce equity value while long-term demand remains intact.

5. Removing unreliable valuation shortcuts does not establish an attractive price¶

You have appropriately stopped relying on an undefined $14.05 forward EPS estimate. You have also declined to present the growth scenarios as discounted valuations.

That is sound discipline. But it leaves the central investment question unanswered:

What sustainable, funded, per-share economics make $263.32 attractive?

Neither 63.9× trailing earnings nor approximately 7.3× trailing sales proves overvaluation. But these are not obviously distressed valuation measures that make the missing cash-return analysis inconsequential.

And I agree that a future cash-yield benchmark is not a complete valuation. My objection is not that every growth company must immediately meet a particular yield. It is that COHR’s bullish case still lacks a quantified alternative connecting investment, funding, and future shareholder returns to today’s price.

“Conditional accumulation once the return path is credible at an attractive valuation” is a reasonable future decision rule. It is also compatible with avoiding COHR today.

Bottom line¶

Our immediate execution views have converged: neither financial verification nor price stabilization has been established in the supplied record.

The chart reinforces patience rather than resolving the fundamental disagreement. COHR remains below its verified $293.97 and $303.43 moving averages. Weekly SuperTrend remains UP, but its $255.29 reference is not downside protection against $22.50 daily ATR. Statistical downside stretch also makes an aggressive fresh short unattractive.

My recommendation remains to avoid new COHR long exposure for now. A credible disclosure package could change that assessment before cash flow fully normalizes—but it must establish capacity productivity, repeatable cash conversion, funding costs, and common-share returns at the then-current price.

Your argument explains why capital efficiency could improve. The bear case is that the current valuation still requires substantial improvement without establishing its probability, timing, or cost.

COHR’s operating recovery deserves credit. Its shareholders should not have to assume that the recovery will become adequately profitable for them.

Research Manager¶

Recommendation: Underweight

Rationale: For COHR, the bear wins on present shareholder economics, not on a claim that demand is collapsing. Using only the supplied October 14, 2026 snapshot at $263.32, the bull deserves credit for FY2026 revenue growth of 22.5%, gross-profit growth of 30.6%, and gross margin expanding to 37.5%. The derived June quarter also generated approximately $70 million of operating cash flow versus $10 million across the preceding nine months. That is a modest improvement, but its durability is unknown. Against those positives, annual operating cash flow fell from $634 million to $80 million, before $1.103 billion of capital expenditure produced statement-derived free cash flow of negative $1.023 billion. Capital spending does not explain the operating-cash-flow collapse. Net financing inflows of $1.477 billion provided material support, although their composition and common-shareholder cost are missing. The apparently attractive 18.7x forward P/E cannot anchor valuation because the $14.05 EPS estimate lacks a defined period and accounting basis; 63.9x trailing earnings does not establish a margin of safety either. The bull's growth and capital-efficiency scenarios describe possible mechanisms, not a quantified, funded valuation case at the supplied price. Cash of $1.162 billion, a 2.43x current ratio, genuine operating momentum, and intact higher-timeframe uptrends argue against a blanket exit or chasing a short. An underweight position therefore fits the evidence better than either accumulation or a neutral stance: the demonstrated cash shortfall and unresolved funding economics outweigh the prospective operating upside for now.

Strategic Actions: COHR positioning: cap an existing long at 0.5x the portfolio's standard COHR allocation, or lower if required by its volatility/risk limits. This is a ceiling, not an instruction to buy up to it; if unowned, do not initiate, and do not top up a smaller position. The trader and portfolio manager must apply actual holdings, which are not supplied. If above the ceiling, reduce half of the excess in the next liquid session and the remainder over the following 1-3 liquid sessions using limit orders and normal liquidity controls. Strength toward the supplied $285 reference can improve execution, but do not make trimming contingent on a rebound. All prices and technical levels are dated October 14, 2026 references and must be refreshed at execution. Do not initiate a fresh short after the approximately 22.2% decline. The supplied $22.50 daily ATR is about 8.5% of price: respect the portfolio's risk budget, allow for gaps, and do not treat the $255.29 weekly SuperTrend reference as a guaranteed floor or a tight protective stop. Reassess at the next FY2027 first-quarter disclosure; its date is not provided. Before increasing exposure, require reconciliation of cash-flow sources and the operating-cash-flow bridge; evidence that conversion gains are repeatable rather than just a one-time working-capital release; maintenance/growth capex, capacity-ramp and funding commitments; debt, preferred-capital and dilution economics; and period-specific common-share EPS. Re-underwrite valuation at the then-current price, supported by funded shipments and durable margins. Only then consider rebuilding in 0.25x-standard-allocation increments toward 1.0x, with improving price participation as execution confirmation rather than a substitute for valuation. If the next disclosure shows continuing severe cash burn without a credible funded improvement path, reduce the residual ceiling to 0.25x; material funding stress or sustained demand/margin deterioration would warrant eliminating the residual. A confirmed weekly trend reversal against the recalculated boundary is an additional risk-review trigger, not an automatic assumption that the old $255.29 level remains valid.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: Sell COHR down to an underweight because FY2026 operating cash flow fell from $634 million to $80 million and statement-derived free cash flow was negative $1.023 billion, while funding economics and forward-EPS definitions remain unresolved despite revenue and margin growth. At the supplied October 14, 2026 close of $263.32, COHR is below its $293.97 200-day and $303.43 50-day averages, with RSI 39.30 and declining recent OBV confirming daily weakness. Weekly and monthly SuperTrend remain UP, daily Z-score is -2.05, and ATR is $22.50, favoring phased long-exposure reduction rather than a blanket exit or a fresh short after the approximately 22.2% decline. Trim excess exposure without requiring a rebound to $285.00, refresh execution levels, and use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger rather than treating the dated $255.29 reference as a fixed protective stop.

Entry Price: 263.32

Stop Loss: not provided

Position Sizing: Cap an existing COHR long at 0.5x the portfolio's standard COHR allocation, or lower if required by volatility and risk limits; this is a ceiling, not a target to buy toward. If above the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following 1-3 liquid sessions using refreshed, executable limit orders without making trimming contingent on a rebound. If already at or below the ceiling, do not add; if unowned, do not initiate. Do not open a fresh short. Actual holdings, standard allocation, portfolio value, and risk budget are missing, so an exact share count or dollar amount cannot be specified. The $263.32 entry is the supplied dated sell-execution reference, not a live quote, guaranteed fill, or minimum sale condition.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: I support selling COHR down to an underweight. The aggressive move here is to challenge a compelling growth narrative before the market has fully resolved its cash economics—not to assume that buying every AI-related selloff is the only route to high returns. We are deliberately accepting the risk of missing part of a rebound rather than accepting full exposure to uncertain cash conversion, financing requirements, and earnings expectations. Since neither opposing analyst has spoken, these are the arguments I would put to them, not views I am attributing to them.

Start with the strongest objection: COHR’s operating recovery is real. Revenue grew 22.5% to $7.118 billion, calculated gross profit rose 30.6%, and annual gross margin reached 37.5%. The implied June-quarter margin of 38.5% strengthens the possibility that expanding optical capacity could produce meaningful operating leverage. Those are reasons to preserve some participation. They are not reasons to maintain a full allocation regardless of the cash required to deliver that growth.

The decisive distinction is that capital expenditure alone does not explain the cash weakness. Operating cash flow fell from $634 million to $80 million before subtracting $1.103 billion of capital expenditure. Anyone arguing that negative free cash flow simply reflects attractive growth investment still needs to explain that operating-cash-flow collapse. Temporary working-capital absorption could be the answer, but the supplied schedules do not establish it. Selling excess exposure does not require concluding that the investment will fail; it requires recognizing that its shareholder returns remain unproven.

I would also reject the argument that we must wait for every accounting and financing question to be resolved before reducing COHR. Uncertainty is itself relevant to position size. Statement-derived free cash flow was negative $1.023 billion; even the inconsistent provider snapshot showed approximately negative $650 million. The discrepancy matters, but neither figure supports a self-funding growth thesis. Meanwhile, $1.477 billion of net financing inflows accompanied the investment cycle. That is not proof of distress, and it must not be described as entirely new debt. It does mean that funding terms and capital allocation deserve more scrutiny than the growth headlines provide.

The apparently inexpensive forward valuation is another weak defense of full exposure. COHR’s reported 18.7× forward P/E depends on approximately $14.05 of EPS, versus $4.12 trailing EPS, without a supplied forecast period or consistent GAAP-versus-adjusted definition. I acknowledge the upside: achieving the provider’s full forward EPS at 25× would imply approximately $351.34, or 33.4% above the supplied $263.32 reference. But a 20% EPS reduction at the same reported forward multiple implies approximately $210.66, about 20% lower. These are arithmetic scenarios, not targets or probability estimates. Their lesson is that an undefined earnings denominator is not a reliable margin of safety.

If a neutral analyst argues that the intact weekly uptrend requires waiting, my answer is that a regime indicator is not a full-allocation instruction. COHR is below its supplied 200-day average of $293.97 and 50-day average of $303.43, RSI is 39.30, and recent OBV declined with price. Weekly SuperTrend remains UP, but the dated $255.29 boundary was only $8.03 below the supplied close, compared with daily ATR of $22.50. That does not predict a breach. It shows why waiting for weekly confirmation can still expose a full-sized position to substantial movement.

Conversely, if a conservative analyst argues for eliminating COHR entirely, I would push back. The weekly and monthly trends remain UP, daily Z-score is −2.05, and the longer-window OBV comparison offers a potential positive divergence. Combined with the revenue and margin recovery, those observations leave meaningful rebound and longer-term growth potential. The sensible expression is a smaller existing long, not a blanket exit. The 0.5× standard-allocation ceiling preserves participation without pretending that upside potential has already resolved the funding questions.

The rebound argument also does not justify making sales contingent on $285.00. That would require approximately an 8.2% recovery from the supplied close before acting. A rebound is plausible, but RSI is not conventionally oversold and none of the supplied TD-9 setups is complete. Why make necessary portfolio resizing depend on receiving a favorable bounce? At the same time, the statistical stretch is a strong reason not to chase a fresh short after the approximately 22.2% decline. Selling excess long exposure and initiating a short are fundamentally different decisions.

Sentiment does not rescue the hold case. The 60/40 bullish split comes from only ten labeled messages within a 30-message sample, with repeated contributors and no Reddit coverage. That is neither strong bullish confirmation nor convincing capitulation. The broader assessment is mixed with a bearish near-term tilt and low confidence. Likewise, funding fears do not establish COHR order cancellations. But we do not need confirmed cancellations to recognize that financing-sensitive growth expectations can lose valuation support. The supplied prediction-market snapshot priced a 28% chance of a 25-basis-point October hike, up 13 percentage points over the week. Those are contract prices, not official forecasts, but they offer little support for relying on imminent easing.

Implementation should follow the trader’s distinction between a ceiling and a target. Refresh COHR quotes, spreads, and execution levels first; $263.32 is the dated October 14, 2026 reference, not a live quote or minimum acceptable sale price. If an existing position exceeds the applicable ceiling—0.5× the portfolio’s standard COHR allocation, or lower under volatility and risk limits—sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Do not automatically sell half the entire holding. If already at or below the ceiling, do not add; if unowned, do not initiate.

For the residual position, use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger, not the stale $255.29 figure as a fixed protective stop. Weekly confirmation does not cap losses or eliminate gap risk. Without holdings, portfolio value, and risk-budget information, an exact share count or defensible protective-stop level cannot be specified.

My recommendation remains SELL COHR to an underweight. This is not a claim that de-risking automatically creates superior returns. It is a conviction that meaningful risk should be concentrated where the evidence supports the prospective reward. COHR’s innovation and growth opportunity remain credible; its conversion of that opportunity into shareholder cash remains unresolved. Preserve limited participation, release excess risk capacity, and require stronger evidence before restoring conviction. Aggressive Analyst: I remain firmly in favor of SELL COHR to a risk-budgeted underweight. Both of you have improved the safeguards, but those safeguards should sharpen the decision, not drain it of conviction. We can be decisive about reducing exposure without pretending to know tomorrow’s price. The deliberate risk is accepting potential underperformance if COHR rebounds sharply, rather than carrying full exposure to a growth story whose cash returns remain unresolved.

Neutral Analyst, your challenge to my earlier suggestion of an informational advantage is fair. We cannot establish that the market has failed to recognize COHR’s cash-flow problem, and I withdraw that implication. After a 22.2% decline, some uncertainty may already be reflected in the price. But we cannot establish how much, and a large decline does not independently establish attractive valuation. The advantage available here is disciplined capital allocation—not proprietary information or a demonstrated ability to forecast the next move. That is enough to support selling excess exposure now.

On cash flow, your June-quarter observation deserves attention, but it does not materially weaken the immediate sell case. Approximately $70 million of operating cash flow against approximately $556 million of capital expenditure means internally generated operating cash covered only about 12.6% of that quarter’s investment. That could precede a productive investment payoff, but it does not demonstrate one. Here is another useful sensitivity: even restoring annual operating cash flow to FY2025’s $634 million would leave approximately negative $469 million of free cash flow if capital spending stayed at FY2026’s $1.103 billion. That is not a forecast. It shows why explaining working capital alone may be insufficient; the investment trajectory and its returns also matter.

Conservative Analyst, you are right that preserving a residual position is optional and portfolio limits are mandatory. My earlier wording was too categorical. If actual constraints require zero COHR exposure, zero is appropriate. But opportunity cost should remain part of the decision, not an afterthought once downside controls are satisfied. Revenue grew 22.5%, calculated gross profit grew 30.6%, and the implied June quarter combined 33.7% year-over-year revenue growth with a 38.5% gross margin. Those are meaningful signs that COHR’s photonics manufacturing platform could benefit from expanding optical demand and operating leverage. They do not prove durable competitive advantage or future cash returns, but they make automatic abandonment an economically consequential choice.

That is where I am willing to take risk: retain limited participation in that growth opportunity when the portfolio can support it, while selling the excess. I am not calling the residual safe. I am distinguishing a deliberately sized growth exposure from a full-sized wager on unresolved earnings and funding assumptions.

Your liquidity concerns strengthen the sizing argument, Conservative Analyst, but they should not become an unstated distress thesis. The 27.1% sequential cash decline and 35.1% increase in current liabilities warrant scrutiny. Equally, $1.162 billion of cash and a 2.43× current ratio are relevant counterweights. Neither set establishes the financing terms COHR will face. The $1.477 billion of net financing inflows requires a breakdown; it is not all demonstrably new debt, nor can we assume unavoidable dilution. We should reduce exposure because funding economics are insufficiently understood, not because adverse terms have been proven. Likewise, the vendor inconsistencies require reconciliation, not allegations of misconduct or an asserted restatement.

On valuation, I accept your combined stress of approximately $168.64 from a 20% forward-EPS haircut and a 15× multiple. It captures a vulnerability that an earnings-only stress misses. But Neutral Analyst is right about its proper use: it belongs in assessing survivability, not in setting a central forecast. The approximately $351.34 upside illustration at the supplied forward EPS and 25× deserves the same discipline. Neither scenario has an established probability, both depend on an unreconciled earnings definition, and neither establishes expected return. The downside scenario tests how much COHR the portfolio can afford; the upside scenario makes the cost of complete liquidation visible. We should neither average them into a target nor treat the roughly 36% downside stress as a maximum possible loss.

The technical evidence supports acting without supporting an indiscriminate bearish bet. COHR is below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined with price. The October 14 close was only $1.42 above the session low. That is weak daily price action, not a reason to postpone necessary resizing. But weekly and monthly SuperTrend remain UP, the daily Z-score is −2.05, and the longer-window OBV comparison offers potential positive divergence. Conservative Analyst, those signals do not establish a floor; Neutral Analyst, they also do not cancel the daily deterioration. Together, they support selling excess long exposure while avoiding a fresh short.

We also agree that the weekly indicator is not capital protection. The dated $255.29 reference was only $8.03 below the supplied close, versus $22.50 of daily ATR. Neither figure defines maximum loss. Use a confirmed weekly break of the recalculated boundary as a risk-review trigger, while addressing portfolio-loss, liquidity, or concentration breaches independently—even before the weekly close if necessary. An intraday breach of an old reference should not automatically determine the residual position, and weekly confirmation should not become permission to ignore an existing portfolio breach.

On macro and sentiment, I accept the demand for restraint, but supporting evidence can still matter without being decisive. The supplied prediction-market snapshot priced an October hold at 70% and a 25-basis-point hike at 28%. That does not establish tightening will occur. However, a hold is not a cut, and it does not itself guarantee cheaper funding or renewed valuation expansion. Official macro observations were unavailable, so the headline-based yield narrative remains qualified. Likewise, six bullish versus four bearish labels among ten labeled messages cannot establish broad conviction. Overlapping selloff headlines, repeated social commentary, and falling prices should not be counted as independent confirmations of financing failure. My sell recommendation rests principally on cash conversion, uncertain forward valuation, and position risk—not a manufactured bearish consensus.

For sizing, I accept the lowest applicable ceiling: half the caller’s standard COHR allocation, the weight permitted by the downside-stress budget, and applicable concentration and liquidity limits. Half the standard allocation is neither 0.5% of the portfolio nor an instruction to sell half the entire holding. Aggregate optical and AI-infrastructure exposure must also be assessed; several modest holdings can share one large financing-sensitive risk. Without holdings, portfolio value, and risk-budget information, we cannot responsibly specify shares, dollars, or a protective-stop level.

For execution, refresh COHR’s quote, spread, depth, and earnings calendar first. If above the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Monitor fills and reassess the pace if actual portfolio limits require faster action. Do not make trimming contingent on $285.00: that would require approximately an 8.2% recovery from the supplied reference before reducing risk we have already decided is excessive. The $263.32 October 14, 2026 close is dated—not a live quote, guaranteed fill, or minimum sale condition.

Finally, Neutral Analyst, I strongly agree that future reassessment must not become an indefinite demand for perfect evidence. Requiring every historical ratio to look healthy could mean recognizing the investment payoff only after substantial appreciation. A later decision could become more constructive before annual free cash flow turns positive if credible disclosures explain working-capital absorption, clarify peak investment and funding, establish the forward-EPS basis, and demonstrate funded demand alongside improving market participation. That would be a new decision—not permission to add today. Confirm the FY2027 first-quarter earnings timing through investor relations before deciding how much event risk to retain.

My recommendation remains SELL COHR where the existing position exceeds the applicable ceiling. If already within it, do not add; if unowned, do not initiate; do not open a fresh short. Released risk capacity need not be immediately redeployed, particularly into another holding exposed to the same financing shock.

The return-focused choice is not maximum exposure to every credible innovation story. It is choosing which uncertainties deserve meaningful capital. COHR’s growth opportunity warrants respect and, where permitted, limited participation. Its unresolved cash economics do not currently warrant a full allocation. I am prepared to accept the rebound opportunity cost to make that distinction now. Aggressive Analyst: I support SELL COHR down to the applicable risk-budgeted underweight. We agree on the transaction, so I will not manufacture disagreement about it. The real debate is whether uncertainty should eliminate participation in a credible growth opportunity, and how much evidence we need before reconsidering exposure. My aggressive position is to sell excess exposure decisively now while remaining willing to take a limited, explicitly monitored investment risk where the caller’s objectives and loss capacity permit it.

Conservative Analyst, you are right that passing a risk limit is not an investment thesis. But your closing distinction—that credible growth makes COHR worth monitoring while demonstrated funding capacity determines its allocation—risks discounting substantive operating evidence too heavily. Revenue increased 22.5%, calculated gross profit increased 30.6%, and annual gross margin improved to 37.5%. The implied June quarter showed 33.7% year-over-year revenue growth and a 38.5% gross margin. Those figures do not demonstrate satisfactory investment returns, but they are more than a speculative rebound narrative.

The conditional residual thesis is that COHR’s expanding revenue and improving manufacturing economics could translate into stronger cash generation as capacity investment produces shipments and working-capital demands stabilize. Those last steps remain hypotheses, not established facts. Nevertheless, investing in that transition before its payoff is complete can be a legitimate source of returns. A small existing position can express that thesis without granting it the capital commitment of a fully verified investment. That is not an argument to buy toward the ceiling, and ownership alone does not earn the right to retain it.

Your capital-preservation argument also needs its stated condition preserved. Under such a mandate, missed appreciation and capital loss have different standing. But no actual mandate has been supplied. We cannot universally subordinate opportunity cost to capital preservation, just as I cannot assume the caller wants maximum growth. The appropriate response is to respect the caller’s constraints, not import either of our preferences into them. If those constraints require zero COHR exposure, exit. If they permit a limited growth exposure, the operating evidence deserves consideration alongside the cash weaknesses.

Neutral Analyst, I agree that conviction should attach to correcting exposure, not predicting another decline. That distinction does not weaken the sell decision. We do not need to establish that COHR is mispriced, that the market has overlooked something, or that tomorrow’s close will be lower. We need to determine whether the supplied evidence justifies maintaining the current allocation. Where that allocation exceeds the trader’s applicable ceiling, the combination of weak cash conversion and unresolved valuation assumptions supports acting now.

On cash flow, both of you correctly distinguish increasing cash consumption from demonstrated deterioration in investment returns. But that distinction does not remove the funding burden. Operating cash flow fell 87.4%, from $634 million to $80 million, before capital expenditure. The implied June quarter’s approximately $70 million of operating cash flow covered only about 12.6% of approximately $556 million of capital spending. Its approximately negative $486 million of free cash flow is not proof that expansion will fail; it is evidence that expansion was not being financed predominantly by internally generated operating cash.

Neutral Analyst, your criticism of my negative $469 million sensitivity is fair: it is a static funding stress, not normalized cash flow. Here is why it remains decision-relevant. At unchanged FY2026 capital expenditure, free-cash-flow breakeven would require $1.103 billion of annual operating cash flow—approximately 74% above FY2025’s $634 million. Alternatively, if operating cash flow recovered only to that prior-year level, capital expenditure would need to fall approximately 42.5% to reach breakeven. Neither calculation is a forecast. They identify the scale of improvement that a convincing funding explanation must address.

Conservative Analyst, that supports your demand to distinguish maintenance spending, discretionary expansion, and remaining commitments. But we should use those questions to test the transition, not assume that spending either persists indefinitely or can be cut without consequences. The aggressive opportunity is precisely that heavy investment could precede substantially greater productive capacity and earnings. The sell case is that the current evidence does not yet justify financing that possibility with a full allocation. Those propositions can coexist.

On liquidity, I accept your warning about the quality of noncash current assets. A 2.43× current ratio cannot tell us how readily those assets become spendable cash. The 27.1% sequential cash decline and 35.1% increase in current liabilities warrant scrutiny. Equally, $1.162 billion of cash matters, and the available figures do not establish distress. The $1.477 billion of net financing inflows requires a breakdown; we cannot assume it was entirely debt, punitive funding, or unavoidable dilution. Neutral Analyst, your warning against repeatedly counting information gaps as separate adverse events is important. My case rests on the observed cash deficit and incomplete funding economics—not several invented versions of a financing crisis.

Conservative Analyst, I also agree that a downside stress does not need to be the central forecast to constrain exposure. The approximately $168.64 illustration, using a 20% forward-EPS haircut and a 15× multiple, can reveal an unacceptable portfolio loss even without an assigned probability. But the approximately $351.34 illustration at the supplied forward EPS and 25× remains relevant to the cost of complete liquidation. Upside cannot excuse breaching a mandate; it can help distinguish between eliminating exposure and retaining an affordable, thesis-supported position. Neither scenario establishes expected return, and neither bounds where COHR can trade.

Your proposal to include direct drawdown and event-gap stresses is stronger than relying exclusively on those valuation calculations. The reported 18.7× forward P/E depends on approximately $14.05 of EPS whose forecast period and accounting basis remain unresolved. A risk assessment should not inherit that same uncertainty unnecessarily. Use transparent, caller-approved stresses, including losses beyond the roughly 36% valuation illustration where appropriate. Do not treat any selected stress as a maximum possible loss.

For sizing, the assigned COHR loss budget must account for concurrent losses elsewhere. Giving every optical or AI-infrastructure holding the entire portfolio’s permissible loss budget would be false diversification. The applicable ceiling remains the lowest of 0.5× the caller’s standard COHR allocation, the exposure permitted by COHR’s assigned stress budget, and applicable concentration, liquidity, and volatility constraints. Half a standard allocation established under quieter conditions may still be excessive today. This is a ceiling, not an optimal weight, a minimum holding, or an instruction to buy.

On technicals, Conservative Analyst, you correctly say that an intact weekly trend does not validate funding economics. But technical evidence has a different job: it helps distinguish appropriate execution from an indiscriminate bearish wager. COHR is below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined with price. The October 14 close was only $1.42 above the session low. That is sufficient daily weakness to reject making necessary trimming conditional on a recovery.

At the same time, weekly and monthly SuperTrend remain UP, daily Z-score is −2.05, and the longer-window OBV comparison offers potential positive divergence. These do not establish a floor or independently justify a long investment. They do make immediate full liquidation and a fresh short materially different decisions from reducing excess exposure. Neutral Analyst, your measured-reduction framework captures that distinction. My emphasis is that “measured” should mean controlled execution of the reduction—not uncertainty about whether to complete it.

The protective-exit issue should remain separate. The dated $255.29 weekly SuperTrend reference was only $8.03 below the supplied close, against $22.50 of daily ATR. Neither distance caps loss. A confirmed weekly break of the recalculated boundary should trigger a risk review, while portfolio-loss, concentration, liquidity, and event-risk breaches operate independently and may require action before the weekly close. Conservative Analyst, if the caller requires a protective-exit framework that cannot be established, reducing further is appropriate. Neutral Analyst, you are equally right that the absence of a numerical stop does not automatically require liquidation under a mandate that permits stress-based management. We cannot invent that mandate—or a defensible stop price—from the missing portfolio information.

On macro and sentiment, I accept both warnings against manufactured corroboration. Headline-only funding concerns, repeated social commentary, and falling prices are not three independent confirmations of financing failure. Six bullish versus four bearish labels among only ten labeled messages cannot establish broad conviction, and missing Reddit coverage further limits confidence. The supplied prediction-market snapshot priced an October hold at 70% and a 25-basis-point hike at 28%, with the latter up 13 percentage points over the week. These are contract prices, not official forecasts. They undermine reliance on imminent easing; they do not prove tightening or customer-financing failure. Healthy optical demand can coexist with valuation compression, but stabilizing financing conditions could also improve the outlook.

Both of you now allow reassessment before annual free cash flow turns positive. That is important, and I would make the standard explicitly testable rather than indefinitely cautious. Confirm COHR’s FY2027 first-quarter earnings timing through investor relations. At the next verified disclosure, test the working-capital explanation, remaining investment commitments, available funding, forward-EPS basis, and measurable cash-conversion milestones. Delivery timing, customer commitments, and cancellation provisions matter where disclosed. A reassuring narrative is insufficient, but we should not require unavailable contract-level detail or completed investment payback before recognizing credible improvement. Improving price participation would strengthen that evidence; a bounce alone would not.

Execution should follow the trader’s plan under normal liquidity. Refresh COHR’s quote, spread, depth, and earnings calendar. If the existing position exceeds the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Monitor fills and reassess the pace if actual limits or verified event timing require faster reduction. Do not wait for $285.00; that would require approximately an 8.2% recovery from the supplied reference before addressing exposure already judged excessive. The $263.32 October 14, 2026 close is dated, not a live quote, guaranteed fill, or minimum sale price. Missing holdings and risk-budget information prevent an exact share recommendation.

My recommendation remains SELL COHR where exposure exceeds the applicable ceiling. If already within it, do not add; if unowned, do not initiate; do not open a fresh short. A failed residual thesis or binding portfolio constraint can justify further reduction or a complete exit. Released capacity need not be immediately redeployed, especially into another financing-sensitive holding.

The aggressive choice is not maximum exposure to every innovation story. It is accepting the possibility of selling near a temporary low to correct excessive exposure, while remaining willing to recognize a productive investment transition before every historical ratio looks comfortable. COHR’s operating growth gives that transition substance. Its cash conversion does not yet justify a full allocation. Sell the excess now, retain only what both the thesis and the caller’s constraints support, and let new evidence—not fear of missing a rebound or fear of all uncertainty—determine the next decision. Aggressive Analyst: I remain firmly in favor of SELL COHR to the applicable risk-budgeted underweight. The aggressive choice is to reduce exposure despite the possibility of a sharp rebound—not to keep a full allocation simply because the growth story is compelling. But I also reject turning unresolved funding questions into an automatic liquidation thesis. COHR has enough demonstrated operating progress to make limited participation worth considering where the caller’s actual objectives, loss capacity, and investment thesis support it.

Conservative Analyst, your distinction between a productive project and an attractive common-equity investment is exactly right—and it strengthens the sell decision. Shareholders receive the economics left after financing costs, obligations, and any dilution, not merely the benefits of higher shipments. With $80 million of annual operating cash flow against $1.103 billion of capital expenditure, we cannot assume that impressive revenue growth translates into equally impressive shareholder returns. That is why COHR does not currently deserve a full allocation.

Where I challenge your caution is in how much uncertainty must disappear before a residual investment becomes defensible. You explicitly do not require completed investment payback, so the standard should be whether the transition can be credibly underwritten, not whether it has already succeeded. Revenue grew 22.5%, calculated gross profit grew 30.6%, and annual gross margin reached 37.5%. The implied June quarter showed 33.7% revenue growth and a 38.5% gross margin. Those figures do not establish incremental returns on capital, but they give the transition thesis substantive operating support.

A smaller position does not validate that thesis. It is a way to express a thesis whose potential reward remains meaningful but whose critical assumptions remain unresolved. No amount of position reduction rescues an investment without a rationale; equally, incomplete proof does not erase genuine operating evidence. COHR’s photonics platform could benefit from increasing bandwidth requirements and capacity constraints. The supplied information does not establish a durable moat, quantify the AI contribution, or prove that new capacity will earn attractive returns. Nevertheless, those opportunities deserve more weight than a purely defensive assessment might give them.

Neutral Analyst, your criticism of my static cash-flow sensitivities is fair. A successful transition could combine better operating cash generation, working-capital normalization, and lower expansion spending. It need not involve one dramatic adjustment. The useful comparison is that operating-cash-flow margin fell from approximately 10.9% in FY2025 to 1.1% in FY2026, while capital expenditure rose from 7.6% to 15.5% of revenue. Both sides of the cash equation moved adversely. A credible recovery can address them together, but the supplied evidence does not yet establish that recovery.

That is the central reason to sell excess exposure now. Capital expenditure does not explain the operating-cash-flow collapse because operating cash flow is measured before that expenditure. Conversely, progressively negative quarterly free cash flow does not establish that investment returns are deteriorating. We should neither dismiss the funding burden as “just growth spending” nor declare the investment program unsuccessful. The return-seeking response is to reduce the capital committed to that unresolved bridge while preserving only exposure that can survive a disappointing outcome.

Conservative Analyst, monitoring cannot prevent an earnings gap, and I am not presenting it as protection. A residual holding represents genuine risk acceptance. Its loss capacity must be established before the event, not discovered afterward. But the absence of portfolio information establishes neither permission to retain half a standard allocation nor a requirement to liquidate. It calls for conditional sizing guidance. We should not substitute an assumed capital-preservation mandate for an unknown mandate, any more than I should assume the caller prioritizes maximum growth.

On liquidity, your funding-runway warning is important. COHR’s $1.162 billion of cash and 2.43× current ratio are relevant counterweights, not a demonstrated runway. The sequential cash decline and increase in current liabilities warrant scrutiny, particularly because much of the current-asset growth was noncash and its composition is unavailable. Dividing cash by the annual free-cash-flow deficit would ignore investment timing, obligations, and financing availability. Likewise, the $1.477 billion of net financing inflows cannot be classified entirely as debt. The unanswered question is what funding remains available, on what terms, and against which commitments—not whether the available figures prove distress.

Both of you are right to demand equal discipline around the valuation illustrations. Approximately $351.34 under the supplied forward EPS and a 25× multiple is not evidence of an attractive expected return. Approximately $168.64 under a 20% EPS haircut and a 15× multiple is not a central forecast. Neither has an established probability, and neither bounds possible prices. The downside scenario can still constrain exposure without being the most likely outcome. The upside scenario matters only after binding risk requirements are satisfied; it cannot compensate for breaching them.

The stronger objection to a full allocation is that the reported 18.7× forward P/E depends on approximately $14.05 of EPS without a defined forecast period or accounting basis. We cannot confidently call COHR inexpensive using an unresolved denominator. Direct drawdown and event-gap stresses should therefore complement valuation sensitivities. That avoids making the entire risk assessment depend on the same earnings uncertainty that weakens the apparent bargain.

Conservative Analyst, rebound risk is indeed different for a short seller and a long holder reducing exposure. For the latter, it is primarily opportunity cost rather than an additional trading loss. But opportunity cost still matters within permitted risk capacity. Weekly and monthly SuperTrend remain UP, daily Z-score is −2.05, and the longer-window OBV comparison offers potential positive divergence. Those observations do not validate funding economics or establish a floor. They do make complete liquidation a materially different decision from trimming an oversized long.

At the same time, Neutral Analyst, I am not using those signals to declare the residual attractive by themselves. COHR is below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, recent OBV declined, and no supplied TD-9 setup is complete. The October 14 close was only $1.42 above the session low. That daily evidence argues against postponing necessary trimming for a favorable rebound. Taken together, the technicals support decisive exposure reduction without a fresh short after the approximately 22.2% decline—not an unconditional hold or a confirmed bottom.

The exit framework must remain separate from that technical interpretation. The historical $255.29 weekly SuperTrend boundary is not a standing protective stop. Its $8.03 distance from the supplied close was small relative to $22.50 of daily ATR, and neither figure caps loss. A confirmed weekly break of the recalculated boundary should trigger a risk review. Portfolio-loss, concentration, liquidity, and event-risk breaches must operate independently, with responsibility for checking them and acting explicitly assigned. If the caller requires a protective-exit framework that cannot be established, further reduction is appropriate.

On macro and sentiment, supporting evidence should influence scenario assessment without masquerading as confirmation. The supplied prediction-market snapshot priced an October hold at 70% and a 25-basis-point hike at 28%; it did not establish inevitable tightening. A hold, however, is not an easing catalyst. Headline-based yield concerns could matter to valuation and customer investment economics, but official macro observations were unavailable. Similarly, six bullish versus four bearish labels among only ten labeled messages cannot establish broad conviction. Repeated headlines, social commentary, and falling prices are not independent proof of financing failure. My sell case does not require such proof.

Neutral Analyst, your warning against repeatedly selling on unchanged annual cash-flow figures is particularly valuable. Those figures did not deteriorate in the October 7–14 comparison, and I am not claiming a newly verified weekly operating collapse. Once the planned reduction is completed, repeating the same deficit should not mechanically ratchet the allocation toward zero. But a missed, pre-agreed disclosure milestone can become new decision-relevant evidence: if an explanation expected to substantiate the residual thesis remains unavailable, the thesis has not earned additional confidence. Changes in price risk, correlations, or the caller’s loss capacity can also justify another sizing decision without a new annual cash-flow number.

That makes the next review consequential. Confirm COHR’s FY2027 first-quarter earnings timing through investor relations and assess retained event exposure beforehand. Test disclosures for a working-capital reconciliation, remaining investment commitments, identified funding capacity and terms, a consistent forward-EPS basis, and measurable cash-conversion milestones. Do not demand confidential contract detail or completed payback. Do demand enough disclosed evidence to distinguish a funded investment transition from an attractive narrative. Credible improvement could justify reconsideration before annual free cash flow turns positive; that would be a new decision, not permission to add today.

For sizing, retain the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the exposure permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. The assigned budget must account for simultaneous losses in other optical and AI-infrastructure holdings. Half a standard allocation is neither 0.5% of the portfolio nor an optimal holding. It is a ceiling, not a target or a minimum.

For execution, refresh COHR’s quote, spread, depth, and earnings calendar. If exposure exceeds that ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Monitor actual fills and reassess the pace if portfolio limits or verified event timing require faster action. Do not wait for $285.00. The supplied October 14, 2026 close of $263.32 is a dated reference, not a live quote, guaranteed fill, or minimum sale condition. Missing holdings and risk information prevent an exact share count, dollar amount, or defensible protective-stop price.

My recommendation remains SELL COHR where the existing position exceeds the applicable ceiling. If already within it, do not add; if unowned, do not initiate; do not open a fresh short. Further reduction or a complete exit remains available if actual constraints or a failed residual thesis require it. Released capacity need not be immediately redeployed, especially into another financing-sensitive holding.

The aggressive edge is accepting rebound regret to correct excessive exposure, while remaining willing to recognize a productive investment transition before every historical ratio looks comfortable. COHR’s operating recovery gives that possibility substance. Its unresolved cash conversion and funding economics do not currently justify a full allocation. Sell the excess now, retain only what the thesis and verified loss capacity support, and make the next change depend on evidence rather than either fear of missing out or fear of all uncertainty. Aggressive Analyst: I support SELL COHR to the applicable risk-budgeted underweight. The aggressive decision is to accept the risk of selling before a sharp rebound rather than leave excessive capital committed to unresolved cash conversion and funding economics. But that conviction should not turn into an automatic march toward liquidation. COHR’s operating progress is substantial enough that abandoning all participation also requires justification.

Conservative Analyst, your strongest challenge is that the residual must survive delayed improvement. Agreed—but survival means the caller can tolerate the loss and any funding uncertainty, not that the investment thesis must succeed under every stress. Monitoring cannot prevent an earnings gap. A properly assigned loss budget can establish whether the caller can afford one. Where that affordability has not been verified, we cannot declare a residual position suitable. Equally, missing portfolio information does not establish that zero exposure is the right allocation.

Where I challenge your conclusion is the willingness to accept a potentially higher re-entry price as the routine cost of stronger evidence. That is a legitimate conservative preference, but it can be expensive for a growth-oriented investor. COHR recorded two consecutive years of revenue growth above 20%, while FY2026 calculated gross profit increased 30.6% and annual gross margin reached 37.5%. Those are demonstrated operating achievements, not just capacity headlines. They do not prove attractive incremental returns on capital, but they provide a substantive basis for evaluating a limited transition investment before its cash payoff is complete. I would not make that case depend on the implied June-quarter figures, an unverified AI revenue contribution, or an asserted competitive moat.

Neutral Analyst, you correctly separate business funding, common-equity returns, and portfolio affordability. But timing matters too. Waiting for uncertainty to narrow can mean paying more for the same opportunity; it can also prevent a bad investment. We cannot establish which outcome will occur here. My argument is not that a smaller position creates attractive expected returns—it does not—but that incomplete proof need not disqualify a credible growth thesis from receiving any capital. The aggressive approach accepts some transition risk within verified limits, rather than requiring the investment to resemble a mature cash generator before considering participation.

The strongest reason to sell excess exposure remains the cash-flow bridge. FY2026 statement-derived FCF deteriorated by $1.216 billion from FY2025. Approximately $554 million of that deterioration came from lower operating cash flow, and $662 million came from higher capital expenditure. In other words, almost half the deterioration occurred before the additional investment spending was deducted. That defeats the simplistic defense that negative FCF is merely the price of attractive expansion. It also identifies two separate questions management needs to answer: why operating cash conversion weakened, and what the expanded investment program will produce for shareholders.

On scenario consistency, both of you make an important point, but consistency must apply in both directions. A constructive case cannot assume sharply lower investment while leaving capacity-dependent earnings untouched. However, declining new expansion spending and rising shipments are not inherently contradictory: previously installed capacity could support greater output as utilization increases. That mechanism would need evidence about commissioning, utilization, remaining commitments, and working capital. It is a hypothesis, not something the supplied reports establish.

Likewise, an adverse scenario should have a causal structure. Delayed customer shipments could postpone collections while committed investment continues, increasing funding needs. That is a coherent stress. Automatically adding severe margin compression, punitive financing, and unavoidable dilution merely because each is possible would not be a disciplined central case. Conservative Analyst, your timed sources-and-uses assessment is therefore useful precisely because it can distinguish a manageable delay from a funding gap. Committed financing should be separated from prospective transactions, and the consequences of delayed funding should be explicit.

The liquidity evidence does not settle that assessment. COHR’s $1.162 billion of cash and 2.43× current ratio are June observations, not confirmation of October funding availability. The sequential cash decline and rising current liabilities warrant scrutiny, particularly given the unidentified composition of noncash current assets. But they do not establish distress. Nor can the $1.477 billion of net financing inflows be classified entirely as debt or assumed to entail unavoidable dilution. We need updated usable liquidity, material obligations, and funding terms—not a runway calculation produced by dividing historical cash by historical FCF.

Neutral Analyst, your distinction between an operating commitment and a data-feed omission deserves to govern the next review. A company missing its stated cash-conversion milestone would be adverse operating evidence. Our vendor failing to return a schedule would be an information limitation. Either can constrain the exposure we can responsibly defend, but they are not the same event. Similarly, the changed net-income extracts do not establish a restatement. The annual cash-flow figures were unchanged during the supplied weekly comparison. Once the initial reduction is completed, repeating those figures should not mechanically generate another sale. Further action should follow a fresh thesis or risk assessment.

On valuation, I reject both an automatic bargain argument and an automatic liquidation argument. The reported 18.7× forward P/E depends on approximately $14.05 of EPS without a defined forecast period or accounting basis. That is insufficient to establish a margin of safety. The approximately $351.34 upside illustration and $168.64 downside illustration are arithmetic scenarios, not targets, probability-weighted outcomes, or trading boundaries. The downside can constrain position size without being our central forecast; the upside can inform the cost of liquidation without proving attractive expected returns. Direct drawdown and event-gap stresses should complement both.

The technical evidence favors completing the reduction, not waiting for a more comfortable sale. COHR is below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, recent OBV declined, and none of the TD-9 setups is complete. But weekly and monthly SuperTrend remain UP, daily Z-score is −2.05, and the longer-window OBV comparison offers potential positive divergence. Conservative Analyst, those signals do not protect the residual capital. They nevertheless matter when deciding whether to liquidate discretionary exposure immediately. Neutral Analyst, they do not independently establish an attractive long. Together, they support trimming excess exposure without chasing a fresh short after the approximately 22.2% decline.

Macro and sentiment remain supporting evidence. COHR’s own funding requirements and customers’ AI-project financing are different exposures, even if both respond to interest rates. Funding-fear headlines do not establish a COHR financing shortfall, and negative COHR FCF does not establish customer cancellations. The supplied prediction-market snapshot priced an October hold at 70% and a 25-basis-point hike at 28%; those are contract prices, not official forecasts. They offer little basis for relying on imminent easing, but do not prove tightening. Likewise, six bullish versus four bearish labels among ten labeled social messages cannot establish broad conviction or capitulation. The low-confidence sentiment report should not decide the trade.

For sizing, use the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the exposure permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. That budget must account for simultaneous losses in other optical and AI-infrastructure holdings. Half a standard allocation is not necessarily 0.5% of the portfolio, an optimal holding, or permission to buy toward it. A permissible allocation still needs a testable investment thesis.

For execution, refresh COHR’s quote, spread, depth, and earnings calendar. If above the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That is half the excess, not half the entire holding. Monitor fills and reassess the pace if binding limits or verified event timing require faster action. Do not wait for $285.00. The supplied October 14, 2026 close of $263.32 is a dated reference—not a live quote, guaranteed fill, or minimum sale condition.

For retained exposure, assign responsibility for checking limits and acting on breaches. Use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger, not the historical $255.29 reference as a protective stop. The supplied $22.50 ATR highlights volatility; neither ATR nor weekly confirmation caps losses. Portfolio-loss, concentration, liquidity, and event-risk rules must operate independently. Confirm COHR’s FY2027 first-quarter earnings timing through investor relations before deciding how much event exposure to retain.

At that review, require evidence that can test the transition: a working-capital reconciliation, remaining investment commitments, identified funding capacity, a consistent forward-EPS basis, and measurable cash-conversion progress. Credible improvement could justify reconsideration before annual FCF turns positive. A reassuring narrative alone should not extend the holding indefinitely.

My recommendation remains SELL COHR where existing exposure exceeds the applicable ceiling. If already within it, do not add; if unowned, do not initiate; do not open a fresh short. Further reduction or a complete exit remains appropriate if actual constraints or a failed residual thesis require it. Missing holdings and risk information prevent an exact share count or defensible protective-stop price.

The aggressive edge is selective risk acceptance, not maximum exposure. Sell the excess now despite rebound risk. Where the caller’s verified loss capacity and a testable thesis permit it, retain limited participation in a potentially productive investment transition. COHR’s growth makes that risk worth evaluating; its unresolved cash economics make a full allocation unjustified.

Conservative Analyst¶

Conservative Analyst: I support SELL COHR, but I would challenge the Aggressive Analyst’s statement that a smaller long, rather than a complete exit, is necessarily the sensible outcome. Your proposed 0.5× ceiling correctly allows lower exposure, and that flexibility matters. Preserving participation is optional; meeting the firm’s loss, liquidity, and concentration limits is not. I am not advocating automatic liquidation, but we cannot establish that any particular residual holding is appropriate without the portfolio context. No Neutral Analyst argument has been provided, so I will address the possible case for waiting without attributing that position to anyone.

The strongest reason to reduce COHR is not simply its negative free cash flow. It is the deterioration in operating cash generation before capital expenditure. Revenue growth of 22.5% and improving gross margins are encouraging, but operating cash flow fell from $634 million to $80 million. Calling the investment cycle attractive does not explain that collapse. Temporary working-capital absorption could explain some of it, but assuming that cash will reverse promptly amounts to making another forecast. Until the supporting schedules establish the cause, the conservative response is to limit exposure rather than fund that assumption with the firm’s risk capacity.

I would also put more weight on liquidity quality than the headline current ratio suggests. COHR’s 2.43× current ratio is reassuring in isolation, but cash fell 27.1% between March and June while current liabilities increased 35.1%. Much of the annual current-asset growth was noncash, with its composition unavailable. These figures do not establish insolvency or imminent funding trouble. They do mean that aggregate balance-sheet coverage is not enough to dismiss financing risk. The $1.477 billion of net financing inflows also requires a breakdown: it cannot all be labeled new debt, but its costs, obligations, and possible dilution cannot simply be ignored.

Your valuation analysis is useful, but I would take the downside stress further. A 20% forward-EPS reduction at an unchanged multiple tests only one source of loss. Financing pressure could plausibly reduce both expected earnings and the multiple investors will pay. Using the supplied forward EPS solely for illustration, a 20% haircut combined with a 15× multiple produces approximately $168.64, roughly 36% below the dated $263.32 reference. That is not a target, probability estimate, or worst-case boundary. It demonstrates why an apparently moderate forward P/E does not provide dependable protection when both the earnings definition and its achievability remain unresolved. The vendor discrepancies warrant reconciliation, not accusations of accounting misconduct.

On the technical side, I agree that a fresh short is unattractive, but that does not make retaining a long low-risk. COHR’s daily Z-score of −2.05 and potential longer-window OBV divergence increase rebound risk. They do not establish a floor. RSI of 39.30 is not conventionally oversold, the TD-9 setups are incomplete, and recent OBV declined alongside price. The approximately 22.2% decline is a historical loss, not evidence that the remaining downside has become small. These conditions support avoiding a chased short while still reducing excess existing exposure.

If the case for waiting rests on weekly and monthly SuperTrend remaining UP, I would distinguish trend classification from capital protection. The supplied weekly boundary was only $8.03 below the close, compared with daily ATR of $22.50. ATR is neither a maximum move nor a probability estimate, but it makes clear that the nearby boundary is not a dependable loss limit. A confirmed break of the recalculated weekly SuperTrend should trigger a risk review; it should not be the only circumstance that permits further selling. Portfolio-loss or concentration breaches must be addressed independently, potentially before the weekly close. The dated $255.29 reference is not a fixed protective stop.

I would also resist waiting for earnings merely because the next disclosure might settle these questions. It might, but an adverse disclosure can produce a gap before the portfolio can respond. Confirm COHR’s FY2027 first-quarter release and call timing through investor relations before deciding how much exposure to carry through that event. Likewise, the macro and sentiment reports support caution without proving a bearish outcome. Official macro observations were unavailable, the news was headline-only, and the retail sample was small and repetitive. Neither the 28% rate-hike contract price nor the 60/40 bullish split among ten labeled posts is strong enough to justify additional risk. No confirmed order cancellations are needed for valuation compression to hurt COHR.

My adjustment would therefore be to make the residual allocation explicitly risk-budget-driven. Use the lowest of 0.5× the portfolio’s standard COHR allocation, the position allowed by the firm’s downside-stress budget, and applicable sector-concentration and liquidity limits. For a simple stress check, the permitted portfolio-loss fraction divided by an assumed COHR drawdown gives a corresponding weight ceiling, before applying those other constraints. That is a scenario tool, not a guarantee against larger losses. Also assess aggregate optical and AI-infrastructure exposure: several holdings can respond to the same financing shock even when each individual weight appears modest.

For execution, the proposed phased reduction is reasonable under normal liquidity, but it should not become an inflexible waiting period. Refresh COHR’s quote, spread, depth, and event calendar. If above the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using executable, refreshed limit orders. Monitor fills; an unfilled limit order has not reduced exposure. If portfolio limits are already breached, reassess the pace rather than automatically waiting through the schedule. Do not require a rebound to $285.00, and do not use $263.32 as a minimum sale price—it is the supplied October 14, 2026 reference, not a live quote.

If COHR is already within all applicable limits, do not add merely to reach the ceiling. If unowned, do not initiate, and do not open a fresh short. Restoring exposure should require a defined forward-EPS basis, an explanation for weak operating cash flow, evidence of investment returns and funded demand, and improving market participation—not simply a bounce through one reference level.

My recommendation remains SELL COHR to an underweight, or lower if the portfolio’s actual constraints require it. Missing some rebound is an opportunity cost we can knowingly accept. Carrying an inadequately controlled residual position is a capital risk we should not accept by default. Conservative Analyst: I remain in favor of SELL COHR to a risk-budgeted underweight, or lower if the firm’s actual constraints require it. Both of you now distinguish exposure reduction from a prediction of further price declines, and that is appropriate. Our remaining disagreement is about what earns the right to stay in the portfolio. An allocation can be permissible under a ceiling without being attractive enough to retain. Passing a risk limit is necessary; it is not an investment thesis.

Aggressive Analyst, your withdrawal of the informational-advantage argument is welcome. I also accept that complete liquidation has an opportunity cost. But for a capital-preservation mandate, potential missed appreciation and potential capital loss do not have equal standing. We should consider rebound participation when choosing among exposures that satisfy our risk requirements—not use it to relax those requirements. COHR’s 22.5% revenue growth and improving gross margins establish a credible operating recovery. They do not yet establish that the incremental investment will generate adequate cash returns for common shareholders.

Neutral Analyst, your observation that the implied June quarter produced approximately $70 million of the year’s $80 million in operating cash flow is relevant. However, I would resist treating that concentration as meaningful reassurance without the underlying reconciliation. Against approximately $556 million of capital expenditure, the implied quarter still produced approximately negative $486 million of free cash flow. The supplied quarterly estimates deteriorated from negative $58 million to negative $96 million, negative $383 million, and negative $486 million. That does not prove the investment cycle will fail, but it makes “cash generation is beginning to recover” an insufficient reason to carry additional exposure.

Aggressive Analyst, your sensitivity showing negative $469 million of annual free cash flow even if operating cash flow returned to $634 million is useful. I would take its implication further: we need to understand both sides of the cash equation. Which expenditures are discretionary expansion, which are necessary to maintain competitiveness, and what commitments remain? We cannot assume FY2026 capital spending will persist indefinitely, but we also cannot assume it can be reduced quickly without impairing growth. A sustainable COHR thesis needs a credible route from investment to cash generation, including the funding required during the transition.

On liquidity, neither of you should interpret my caution as a hidden insolvency forecast. COHR’s $1.162 billion of cash and 2.43× current ratio are meaningful counterweights. Nevertheless, the current ratio cannot answer how readily noncash assets will convert into funds available to meet obligations. Cash declined 27.1% sequentially while current liabilities increased 35.1%, and the composition of much of the current-asset growth remains unavailable. Missing financing schedules do not prove punitive terms or unavoidable dilution. But missing information cannot be replaced with favorable assumptions when deciding position size. I would want the financing breakdown, maturity schedule, preferred-capital obligations, and expected cash requirements before treating liquidity as a reason to retain more COHR.

You both correctly insist that the approximately $168.64 downside illustration is not a forecast. I agree. Where I push back is any implication that an unassigned probability makes that scenario unimportant to sizing. A loss scenario can constrain exposure without being our central expectation. The approximately $351.34 upside illustration cannot offset a downside outcome that would violate the firm’s mandate. Equally, we should not choose arbitrary extreme assumptions merely to force liquidation. Use transparent, mandate-approved stresses, and recognize that the roughly 36% drawdown illustration is neither a maximum loss nor a reliable valuation boundary.

Because the forward-EPS definition remains unresolved, I would also test COHR using direct price-drawdown and event-gap scenarios rather than relying exclusively on earnings-multiple arithmetic. Otherwise, the risk model inherits the same uncertain earnings denominator that undermines the valuation argument. The reported 18.7× forward P/E does not provide dependable protection when the forecast period, accounting basis, and estimate history are missing.

That leads to an important refinement of your sizing agreement. The applicable ceiling should remain the lowest of 0.5× the portfolio’s standard COHR allocation, the stress-budget allowance, and applicable concentration and liquidity limits. But the stress allowance must use the loss budget actually assigned to COHR after considering other exposures. We cannot give every optical or AI-infrastructure holding the entire portfolio’s acceptable loss budget independently. Several small positions can breach the aggregate limit together. Also, half a standard allocation established under different volatility conditions may still be too large. It is a ceiling, not evidence that the remaining position is conservative.

Neutral Analyst, I accept your distinction between daily deterioration and an unconfirmed higher-timeframe reversal. I am not recommending an automatic exit because COHR is below its moving averages, nor because it briefly crosses an old indicator value. But weekly and monthly SuperTrend remaining UP cannot establish that a residual holding meets the firm’s capital-protection requirements. Likewise, the daily Z-score of −2.05 and potential longer-window OBV divergence support rebound risk, not a floor. These price-derived signals should not be treated as independent evidence that funding economics are sound. They help explain why a fresh short is unattractive; they do not independently justify retaining a long.

The missing protective-stop specification remains an operational issue. The dated $255.29 weekly SuperTrend boundary was only $8.03 below the supplied close, versus $22.50 of daily ATR. Neither distance defines maximum loss, and weekly confirmation permits exposure to intervening moves and gaps. Use a confirmed weekly break of the recalculated boundary as a risk-review trigger, but establish portfolio-loss and event-risk escalation rules separately. If the mandate requires a defensible protective-exit framework and one cannot be established, reduce exposure rather than substitute a weekly indicator for that framework.

On macro and sentiment, I agree with keeping them secondary. The headline-only news, unavailable official macro series, and small social sample do not establish a financing crisis. But uncertainty cuts both ways: they also cannot support a dependable easing or rebound catalyst. An unchanged policy rate would not itself guarantee favorable customer funding or renewed multiple expansion. We do not need confirmed COHR order cancellations to recognize that healthy demand can coexist with poor shareholder cash returns.

Aggressive Analyst, I agree that reassessment should not require every historical ratio to become ideal or annual free cash flow to turn positive first. My objection is to accepting an explanation without enough evidence to test it. A more constructive review could occur earlier if disclosures reconcile working-capital absorption, identify remaining investment commitments, clarify available funding, and establish measurable cash-conversion milestones. Funded demand should mean more than sold-out-capacity headlines: delivery timing, cancellation provisions, and customer commitments matter where disclosed. A reassuring narrative or a share-price bounce alone would not meet that threshold.

For execution, retain the proposed phasing under normal liquidity: refresh COHR’s quote, spread, depth, and earnings calendar; sell half the excess above the applicable ceiling in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That is half the excess, not half the entire holding. Monitor actual fills. If portfolio limits are already breached or the verified earnings timing creates unacceptable event exposure, reassess the pace rather than mechanically waiting through the schedule. Do not require a rebound to $285.00. The supplied $263.32 October 14, 2026 close is a dated reference, not a live quote, guaranteed fill, or minimum sale price.

My recommendation remains SELL COHR where exposure exceeds the genuinely stress-tested ceiling. If already within that ceiling, do not add merely to reach it; if unowned, do not initiate; do not open a fresh short. A complete exit is available if actual constraints require it, but the supplied evidence does not establish it as the universal default. Released capacity need not be immediately redeployed into another holding exposed to the same financing shock.

We agree that COHR’s growth opportunity deserves respect. My conservative distinction is that credible growth makes the investment worth monitoring; demonstrated funding capacity and tolerable portfolio losses determine how much capital it deserves today. Accepting some rebound opportunity cost is preferable to allowing an optional residual holding to become an inadequately controlled risk. Conservative Analyst: I remain in favor of SELL COHR to a risk-budgeted underweight, or lower if the caller’s actual constraints require it. We agree on reducing excessive exposure. Where I still challenge both of you is the suggestion that a plausible transition thesis, a small position, and regular monitoring together establish an acceptable residual investment. They may support one, but only if the funding requirements and potential portfolio losses are sufficiently understood. Monitoring cannot prevent an earnings gap, and a small allocation is not necessarily small relative to the portfolio’s remaining risk capacity.

Aggressive Analyst, your strongest counterargument is COHR’s genuine operating progress. Revenue growth of 22.5% and gross-margin improvement to 37.5% deserve substantial weight. But better gross margins do not establish adequate returns on incremental capital. Capital expenditure consumes cash upfront, while depreciation generally enters earnings over time. Consequently, improving reported manufacturing economics can coexist with heavy investment requirements and disappointing shareholder cash returns. The supplied reports do not provide enough information to establish incremental investment returns. Your transition thesis remains plausible, but its critical steps—cash conversion, investment payback, and sufficient funding during the interval—are still hypotheses.

That is not an argument for waiting until every investment has paid back. It is a question of what funds the interval before it does. COHR generated $80 million of annual operating cash flow against $1.103 billion of capital expenditure. The implied June quarter generated approximately $70 million against approximately $556 million of investment. Even if the expansion ultimately succeeds, the timing and cost of financing can affect the return available to common shareholders. A productive project and an attractive common-equity investment are not automatically the same thing.

Neutral Analyst, I accept your distinction between increasing cash consumption and deteriorating investment returns. The progressively negative quarterly FCF estimates do not prove that the investment program is failing. Likewise, the negative $469 million sensitivity is a funding stress, not normalized cash flow. But those qualifications should not make the observed funding burden less important. We need neither a failure forecast nor a normalized earnings estimate to recognize that substantial cash requirements must be met before the hoped-for improvement arrives. The aggressive analyst’s breakeven calculations help identify the scale of that challenge; they do not establish that improvement must come entirely from either higher operating cash flow or lower investment.

Both of you are also correct that the caller’s mandate has not been supplied. I am not asserting that every investor must prioritize capital preservation above all opportunity cost. I am presenting the conservative recommendation: do not resolve missing objectives and loss-capacity information in favor of retaining discretionary growth risk. Verify the actual constraints before declaring a residual allocation suitable. That does not require automatic liquidation, but neither does the absence of a known prohibition establish permission to retain COHR at half a standard allocation.

On liquidity, I agree that $1.162 billion of cash and a 2.43× current ratio are meaningful counterweights. They do not establish distress, and I am not treating them as though they do. However, they also do not establish a reliable funding runway. Dividing year-end cash by an annual or quarterly FCF deficit would be misleading without understanding investment timing, working-capital movements, financing availability, and obligations. The $1.477 billion of net financing inflows needs reconciliation—not classification entirely as debt. The relevant conservative question is whether available funding covers reasonably stressed cash requirements on acceptable terms, not merely whether aggregate current assets exceed current liabilities.

Aggressive Analyst, your opportunity-cost argument is legitimate, but its evidentiary standard needs to match the downside discussion. The approximately $351.34 upside illustration shows what one earnings-and-multiple combination produces; it does not establish that retaining COHR offers an attractive expected return. The approximately $168.64 downside illustration likewise does not establish a central forecast. Neither scenario has an assigned probability, and neither bounds possible outcomes. For sizing, I would therefore prioritize transparent direct-drawdown and event-gap stresses alongside valuation sensitivities, rather than letting the unresolved forward-EPS definition determine the entire risk assessment.

The applicable COHR ceiling should remain the lowest of 0.5× the caller’s standard COHR allocation, the exposure permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. In a simple unlevered stress calculation, the assigned portfolio-loss fraction divided by the assumed COHR drawdown gives a corresponding weight ceiling. That is a scenario calculation, not a maximum-loss guarantee. Crucially, the assigned budget must reflect simultaneous losses elsewhere. Optical and AI-infrastructure holdings cannot each be allocated the same supposedly available portfolio loss capacity.

Neutral Analyst, I agree that daily weakness is not a confirmed higher-timeframe reversal. Weekly and monthly SuperTrend remain UP, while the daily Z-score of −2.05 and potential longer-window OBV divergence make a rebound plausible. But rebound risk has different implications for a short seller and an existing long holder. For the short seller, it can create additional losses; for the long holder reducing exposure, it primarily creates opportunity cost. That distinction supports avoiding a fresh short without making continued long exposure the default. RSI of 39.30, incomplete TD-9 setups, and declining recent OBV do not establish exhaustion.

The protective-exit issue remains separate. The historical $255.29 weekly SuperTrend reference is not a standing loss limit, particularly against the supplied $22.50 ATR. Use a confirmed weekly break of the recalculated boundary as a risk-review trigger, not as the only permission to sell further. I accept that a numerical stop is not universally required. But a stress-managed residual position needs explicit escalation rules, event-risk limits, and responsibility for acting when those limits are breached. “We will monitor it” is not an adequate substitute, and no stop framework eliminates gap risk.

I would keep macro and sentiment secondary, as you both recommend. Headline-only financing fears, repeated social commentary, and the same falling share price are not independent evidence of financing failure. The prediction-market snapshot does not prove tightening, and official macro observations were unavailable. Nevertheless, neither a policy hold nor stabilizing sentiment guarantees affordable customer funding or improved COHR cash conversion. Those developments could help; they should not be necessary assumptions supporting today’s residual allocation.

For execution, retain the trader’s phasing under normal liquidity, but not as an inflexible waiting period. Refresh COHR’s quote, spread, depth, and earnings calendar. If exposure exceeds the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Monitor fills and reassess the pace if portfolio limits or verified earnings timing require faster reduction. That means half the excess, not half the entire holding. Do not wait for $285.00, and do not treat the supplied October 14, 2026 close of $263.32 as a live quote, guaranteed fill, or minimum sale price.

For reassessment, I do not require confidential contract-level detail, completed investment payback, or positive annual FCF before recognizing improvement. I do require enough disclosed evidence to test the thesis: a working-capital bridge, remaining investment commitments, identified funding capacity, a consistent forward-EPS basis, and measurable cash-conversion milestones. Confirm COHR’s FY2027 first-quarter earnings timing through investor relations and review retained event exposure beforehand. If essential information remains unavailable, that is not proof of distress—but the allocation should reflect the uncertainty rather than assume favorable answers.

My recommendation remains SELL COHR where exposure exceeds the genuinely stress-tested ceiling. If already within it, do not add merely to reach it; if unowned, do not initiate; do not open a fresh short. Further reduction or a complete exit remains appropriate if actual constraints or a failed residual thesis require it, not as a universal default.

COHR’s operating recovery makes the opportunity credible. It does not make participation compulsory. The conservative adjustment is to preserve capital first, retain only exposure supported by both a testable thesis and verified loss capacity, and accept that stronger evidence may come with a higher re-entry price. That opportunity cost is preferable to treating unresolved funding requirements as an affordable risk before affordability has actually been established. Conservative Analyst: I remain in favor of SELL COHR to a risk-budgeted underweight, or lower if the caller’s actual constraints require it. We agree on the initial reduction, so I will not manufacture disagreement about the transaction. My concern is what happens afterward: a plausible growth thesis, a smaller holding, and regular monitoring do not by themselves establish that the remaining exposure is affordable. The residual position must withstand delayed improvement, not merely benefit if the anticipated transition arrives on schedule.

Aggressive Analyst, I accept your distinction between credibly underwriting a transition and waiting until it has already succeeded. But what makes this transition sufficiently underwritten today? COHR’s 22.5% revenue growth, 30.6% calculated gross-profit growth, and 37.5% annual gross margin establish substantial operating progress. They do not establish the cash return on newly invested capital. The implied June-quarter figures are encouraging, but they remain derived figures, and the supplied information cannot isolate the AI contribution or establish incremental investment returns. Those limitations do not erase the growth evidence; they limit how much capital that evidence can justify.

Neutral Analyst, you are right that recovery could combine working-capital normalization, higher operating profitability, and lower expansion spending. My challenge is whether those assumptions remain consistent when considered together. Lower capital expenditure might conserve cash but constrain the capacity supporting the earnings forecast. Continued rapid growth might improve profitability while requiring additional working capital. Customer delays could weaken cash collections while previously committed investment continues. These are conditional risks, not established developments. Nevertheless, a credible residual thesis needs to survive a coherent combination of disappointments, rather than borrowing the most favorable assumption from each separate scenario.

The observed cash burden remains the starting point: COHR generated $80 million of annual operating cash flow against $1.103 billion of capital expenditure, producing statement-derived FCF of negative $1.023 billion. Capital expenditure cannot explain the operating-cash-flow decline because it is deducted afterward. Equally, those figures do not prove that the investment program will fail. I agree with both of you that the unchanged October 7–14 cash-flow extracts are not a newly verified weekly deterioration and should not mechanically trigger successive sales toward zero.

However, completing the initial reduction does not make the remaining allocation permanently justified. Changes in volatility, correlated portfolio exposure, available loss capacity, or the failure of a previously specified milestone can warrant another decision without a new annual cash-flow figure. That is different from repeatedly counting the same deficit as new evidence.

Neutral Analyst, your request for an operational definition of “sufficiently understood” is reasonable. Before defending a material residual COHR position, I would want enough disclosed information to construct a timed sources-and-uses assessment: remaining investment commitments, maintenance versus expansion spending where available, working-capital requirements, material financing obligations, usable liquidity, and identified funding capacity. If future financing is necessary, distinguish committed availability from a prospective transaction and assess what happens if that transaction is delayed or its terms worsen. This does not require confidential contract details or completed investment payback. It requires understanding what funds the interval before the expected payoff.

COHR’s $1.162 billion of cash and 2.43× current ratio are meaningful counterweights, but they cannot answer that funding question alone. Cash declined 27.1% sequentially while current liabilities increased 35.1%, and much of the annual current-asset growth was noncash, with its composition unavailable. Those observations do not establish distress. Nor should the $1.477 billion of net financing inflows be classified entirely as debt or assumed to entail unavoidable dilution. My objection is narrower: the supplied information does not yet establish funding capacity under stress, and the allocation should reflect that uncertainty.

Aggressive Analyst, your upside illustration makes the cost of liquidation visible, but it does not demonstrate an attractive expected return. The same discipline applies to the downside illustration. Neither has an established probability, and neither bounds possible COHR prices. With approximately $14.05 of forward EPS lacking a defined forecast period and accounting basis, the reported 18.7× forward P/E cannot provide a dependable margin of safety. Direct drawdown and event-gap stresses are therefore important complements to earnings-and-multiple arithmetic. Otherwise, the risk assessment inherits the same unresolved denominator as the valuation thesis.

You are both correct that the caller’s mandate is unknown. I am not imposing a universal capital-preservation mandate or asserting that every residual holding should be eliminated. I am advocating the lower-risk adjustment: do not resolve missing objectives and loss-capacity information in favor of discretionary exposure. Half a standard COHR allocation is a provisional ceiling, not a presumption of suitability.

Use the lowest of 0.5× the caller’s standard COHR allocation, the exposure permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. For a simple unlevered long, the assigned portfolio-loss fraction divided by an assumed COHR drawdown provides one weight ceiling—not a maximum-loss guarantee. That assigned budget must already account for simultaneous losses in any other optical and AI-infrastructure holdings. Several individually modest positions can still consume the same risk capacity together.

On technicals, I agree that weekly and monthly SuperTrend remaining UP, the daily Z-score of −2.05, and potential longer-window OBV divergence leave meaningful rebound potential. But rebound potential has different consequences for a short seller and an existing long holder reducing exposure. For the latter, it primarily creates opportunity cost. It does not protect the remaining capital. COHR is still below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, recent OBV declined, and the TD-9 setups are incomplete. That combination supports reducing excess exposure without waiting for a bounce, while avoiding a fresh short—not an automatic full exit or an unconditional residual hold.

The exit framework must operate independently. The historical $255.29 weekly SuperTrend boundary is not a standing protective stop. Its $8.03 distance from the supplied close was small relative to the $22.50 daily ATR, and neither figure caps loss. Use a confirmed weekly break of the recalculated boundary as a risk-review trigger. Portfolio-loss, concentration, liquidity, and event-risk breaches can require action earlier. A stress-managed holding also needs an identified decision-maker and explicit escalation rules; “we will monitor it” is not sufficient protection against an earnings gap.

I would keep macro and sentiment subordinate to that analysis. Headline-only financing concerns, repeated social commentary, and falling prices are not independent confirmations of financing failure. The supplied 70% October hold and 28% hike contract prices are not official forecasts. But neither a policy hold nor improved sentiment establishes cheaper customer funding or better COHR cash conversion. Those are possible aids to recovery, not assumptions on which today’s residual allocation should depend.

For execution, retain the proposed phasing under normal liquidity. Refresh COHR’s quote, spread, depth, and earnings calendar. If the existing position exceeds the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That means half the excess, not half the entire holding. Monitor fills and reassess the pace if actual portfolio limits or verified earnings timing require faster reduction. Do not wait for $285.00. The supplied October 14, 2026 close of $263.32 is a dated reference, not a live quote, guaranteed fill, or minimum sale price.

Before retaining earnings exposure, confirm COHR’s FY2027 first-quarter release and call timing through investor relations. Set the review criteria beforehand: a working-capital reconciliation, remaining investment commitments, identified funding capacity, a consistent forward-EPS basis, and measurable cash-conversion milestones. Credible improvement could justify reassessment before annual FCF becomes positive. But a reassuring explanation without evidence that can be tested should not automatically extend the holding period.

My recommendation remains SELL COHR wherever exposure exceeds the applicable ceiling. If already within it, do not add merely to reach it; if unowned, do not initiate; do not open a fresh short. Further reduction or a complete exit remains appropriate if actual constraints or a failed residual thesis require it, not as a universal default. Missing portfolio information prevents an exact share count or defensible protective-stop price.

COHR’s operating recovery makes participation worth evaluating, not compulsory. The conservative distinction is to retain only exposure supported by both a testable investment thesis and established loss capacity. Accepting some rebound opportunity cost is preferable to discovering after an adverse event that the supposedly affordable residual position depended on several favorable assumptions arriving together. Conservative Analyst: I continue to recommend SELL COHR to a risk-budgeted underweight, or lower if actual portfolio constraints require it. We agree on the initial reduction. My remaining concern is that “limited participation in a credible transition” can become the default before we have established whether the remaining exposure is adequately supported. Rejecting automatic liquidation does not, by itself, justify retaining a position.

Aggressive Analyst, you are right that waiting for stronger evidence can mean paying a higher re-entry price. But a higher price is not necessarily a worse investment if the funding uncertainty, earnings-definition problems, and potential shareholder obligations have narrowed materially. Conversely, early participation is not necessarily advantageous simply because it precedes confirmation. We do not have enough information to quantify that trade-off. From a conservative perspective, accepting possible rebound opportunity cost is preferable to assuming that buying—or retaining—uncertainty cheaply will be rewarded.

I am not dismissing COHR’s operating achievements. Revenue growth of 22.5%, calculated gross-profit growth of 30.6%, and annual gross margin of 37.5% provide substantive support for the business recovery. My question is narrower: what presently connects that recovery to adequate cash returns for common shareholders? Operating cash flow fell from $634 million to $80 million before capital expenditure, while investment spending increased to $1.103 billion. Your cash-flow bridge correctly identifies two problems, not one. Improving manufacturing economics cannot substitute for explaining the operating-cash-flow decline.

Your installed-capacity argument is plausible: previously completed investment could support higher shipments while new expansion spending declines. I accept that those developments are not inherently contradictory. But commissioning schedules, utilization, remaining commitments, and associated working-capital requirements are precisely the missing evidence. Until those connections can be tested, that mechanism supports a conditional thesis—not confidence that the funding burden is about to ease.

Neutral Analyst, I agree that business funding and portfolio loss tolerance are different questions. I am not requiring COHR to avoid equity losses under stress. I am asking whether the retained position remains tolerable if the business stays solvent but the investment transition takes longer or financing economics disappoint. COHR need not approach insolvency for common shareholders to experience substantial losses. A company can successfully fund expansion while delivering an unattractive return to its existing equity holders.

I also agree that adverse assumptions should not simply be stacked. A coherent stress, however, can produce several adverse effects from one cause. If customer shipments or collections are delayed while committed investment continues, cash requirements could rise just as investors reduce earnings expectations and the multiple they will pay. That does not require assuming punitive financing, unavoidable dilution, and severe margin compression simultaneously. It is a linked scenario worth testing, not a prediction that those developments are occurring.

That is why I would make the sources-and-uses review central to retaining material COHR exposure. Identify the timing of remaining investment commitments, material obligations, usable liquidity, and committed funding. Separate available financing from a transaction management might seek later. Then ask what happens if operating improvement or prospective financing arrives later than expected. This is not a demand for completed investment payback; it is an assessment of what funds the interval before that payoff.

The June figures—$1.162 billion of cash and a 2.43× current ratio—are meaningful counterweights, but they do not establish October funding availability. The sequential cash decline and rising current liabilities warrant scrutiny without proving distress. Likewise, the $1.477 billion of net financing inflows cannot be classified entirely as debt. We need updated information and a financing reconciliation, not either a comfortable-runway assumption or an impending-crisis narrative.

Aggressive Analyst, an assigned loss budget helps establish affordability, but it does not cap realized losses. A stress assumption is not a hedge. If COHR gaps beyond the selected drawdown or correlated holdings decline together, actual portfolio losses can exceed the planned allowance. That matters particularly when the apparently modest residual is measured against an allocation established under quieter conditions. Half a standard allocation can still be excessive relative to the portfolio’s remaining risk capacity.

I would therefore retain the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the weight permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. For a simple unlevered long, dividing the assigned portfolio-loss fraction by an assumed COHR drawdown fraction provides one stress-based weight ceiling—not a maximum-loss guarantee. The assigned budget must already account for simultaneous losses elsewhere. Missing holdings, portfolio value, and risk limits prevent an exact share recommendation.

On valuation, the unresolved approximately $14.05 forward-EPS denominator remains a significant weakness. Neither the reported 18.7× forward P/E nor the illustrative $351.34 upside establishes an attractive expected return. The approximately $168.64 downside illustration is not a forecast either. Direct drawdown and event-gap stresses should complement those calculations so that sizing does not depend entirely on the same uncertain earnings basis that weakens the apparent valuation bargain.

Neutral Analyst, your distinction between a missed company commitment and a missing vendor schedule is important. Our research deadline is not management guidance. The supplied evidence does not establish a restatement or a newly missed cash-conversion commitment, and unchanged annual cash-flow figures should not mechanically generate successive sales. But an unresolved research limitation can still restrict the exposure we can responsibly approve. First seek the filings and company disclosures; if essential information remains unavailable, describe that as uncertainty—not operating deterioration—and reassess the residual accordingly.

On technicals, I accept that weekly and monthly SuperTrend remaining UP, the daily Z-score of −2.05, and potential longer-window OBV divergence matter for execution and rebound opportunity cost. They do not protect retained capital. COHR remains below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, recent OBV declined, and the TD-9 setups are incomplete. That supports completing necessary exposure reduction without waiting for a bounce, while avoiding a fresh short after the approximately 22.2% decline.

The exit framework must remain independent. Use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger, not the historical $255.29 reference as a fixed protective stop. The supplied $22.50 ATR highlights substantial volatility; neither ATR nor weekly confirmation caps losses. Portfolio-loss, concentration, liquidity, and event-risk rules can require action earlier, with responsibility for checking limits and acting clearly assigned.

I would keep macro and sentiment secondary. COHR’s funding needs and customer-project financing are separate exposures, although a common rate shock could affect both. Headline-only concerns do not establish either a COHR funding shortfall or customer cancellations. The prediction-market prices are not official forecasts, and the small, repetitive social sample cannot establish broad conviction. Neither offers a dependable catalyst on which to base today’s residual allocation.

For execution, obtain refreshed COHR quotes, spreads, depth, and earnings timing. If exposure exceeds the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That is half the excess, not half the entire holding. Monitor fills and recalculate remaining excess as positions and portfolio values change. Reassess the pace if binding limits or verified event timing require faster reduction. Do not wait for $285.00; the supplied October 14, 2026 close of $263.32 is a dated reference, not a live quote or minimum sale price.

Before retaining earnings exposure, confirm COHR’s FY2027 first-quarter release and call timing through investor relations. Make the next review consequential: test the working-capital reconciliation, remaining investment commitments, funding capacity, forward-EPS basis, and measurable cash-conversion milestones. Credible improvement can justify reassessment before annual FCF becomes positive. A reassuring narrative alone should not automatically extend the holding period.

My recommendation remains SELL COHR wherever exposure exceeds the applicable ceiling. If already within it, do not add merely to reach it; if unowned, do not initiate; do not open a fresh short. Further reduction or a complete exit remains appropriate if actual constraints or a failed residual thesis require it, not as a universal default.

COHR’s growth makes participation worth evaluating. It does not make participation compulsory. The conservative adjustment is to retain only what a testable investment thesis and established loss capacity jointly support—and accept possible rebound regret rather than discover after an adverse event that the residual was affordable only under favorable assumptions.

Neutral Analyst¶

Neutral Analyst: I support SELL COHR to a risk-budgeted underweight, but I would frame it as an exposure adjustment, not a high-conviction prediction of another leg down. Both of you make a stronger case for reducing an oversized position than for forecasting COHR’s next price move. That distinction matters: we can act on inadequate cash conversion without assuming the growth thesis has failed, and preserve limited participation without treating a rebound as inevitable.

Aggressive Analyst, your strongest argument is that capital expenditure does not explain the entire cash problem. Operating cash flow fell from $634 million to $80 million before subtracting $1.103 billion of capital spending. That warrants a smaller allocation. Where I challenge you is the suggestion that we are acting before the market has fully recognized the problem. After COHR’s approximately 22.2% decline, we cannot establish how much uncertainty is already reflected in the price. We lack a reliable estimate-revision history, a defined forward-EPS basis, and verified customer-funding information. Selling excess exposure is defensible; claiming an informational advantage over the market is not established.

I would also distinguish unresolved cash economics from demonstrated deterioration in investment returns. COHR’s 22.5% revenue growth and improvement in annual gross margin to 37.5% are substantial counterevidence to an entirely negative operating assessment. The implied June quarter generated approximately $70 million of the year’s $80 million in operating cash flow. That does not establish recovery—particularly against approximately $556 million of quarterly capital expenditure—but it deserves monitoring rather than assuming the annual cash weakness will continue unchanged. We need the working-capital bridge and investment-payback disclosures to distinguish temporary cash absorption from a persistent problem. Neither explanation should be presumed.

Conservative Analyst, I agree with your correction that preserving a residual COHR holding is optional. A smaller long is not automatically appropriate merely because it preserves upside. But your framework also needs protection against becoming excessively defensive in practice. COHR’s $1.162 billion of cash and 2.43× current ratio do not eliminate financing risk, especially given the sequential cash decline and rising current liabilities. Equally, those figures do not establish an imminent liquidity crisis. Missing debt, preferred-capital, and financing schedules justify tighter limits and further investigation; they should not silently become assumptions of unfavorable financing terms or unavoidable dilution. You are not recommending automatic liquidation, and I would preserve that distinction.

Your combined earnings-and-multiple stress is useful, but I would challenge how much decision weight it receives. Approximately $168.64 follows mechanically from a 20% haircut to the supplied forward EPS and a 15× multiple. The aggressive analyst’s approximately $351.34 upside illustration follows from achieving that EPS at 25×. Neither is a probability-weighted outcome, and both depend on an earnings definition we have not reconciled. The downside scenario belongs in position sizing, not as an implied central forecast. The upside scenario belongs in assessing opportunity cost, not as proof that retaining COHR offers an attractive expected return. We should not average these illustrations into a price target.

On technicals, Aggressive Analyst, I would not make your hypothetical neutral argument that an intact weekly uptrend requires waiting before trimming. COHR is below its supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined. That supports reducing excess exposure now. But Conservative Analyst, daily weakness should not overwhelm the distinction between a damaged daily setup and a confirmed higher-timeframe reversal. Weekly and monthly SuperTrend remain UP, while the daily Z-score of −2.05 and potential longer-window OBV divergence leave meaningful rebound risk. Neither set of indicators cancels the other. Together, they support measured reduction rather than either a blanket exit or a fresh short.

The volatility reinforces that conclusion. COHR’s $22.50 ATR is approximately 8.5% of the supplied close, although it is neither a maximum move nor a loss forecast. The dated weekly SuperTrend reference at $255.29 was only $8.03 below that close. That is not enough distance to treat the line as dependable capital protection. A confirmed weekly break of the recalculated boundary should prompt a risk review, while portfolio-loss and concentration breaches should be addressed independently, potentially before that weekly close. Conversely, an intraday dip through an old reference should not automatically determine the fate of a longer-horizon residual holding.

I would challenge both of you to keep macro and sentiment evidence in a supporting role. Higher yields and customer-financing pressures are credible channels through which COHR could suffer even with healthy optical demand. Stabilizing rates and demonstrably funded spending could improve that outlook. But official macro observations were unavailable, the news was headline-only, and the supplied prediction-market snapshot still priced an October hold at 70% alongside a 28% chance of a 25-basis-point hike. That is a reason not to rely on imminent easing, not proof that tightening will occur. Likewise, ten labeled social posts cannot establish broad conviction. Repeated selloff headlines, bearish commentary, and falling prices should not be counted as independent confirmations of a financing failure.

My sizing adjustment would combine your approaches rather than choose between them. The applicable COHR ceiling should be the lowest of half the caller’s standard COHR allocation, the weight allowed by the caller’s downside-stress budget, and applicable concentration and liquidity limits. Half the standard allocation is not necessarily 0.5% of the portfolio, and it is not an instruction to sell half the entire holding. For illustration, a 1% portfolio weight experiencing a 36% decline would contribute approximately 0.36 percentage points of portfolio loss before losses elsewhere. That scenario is not a maximum-loss boundary. It must be assessed alongside correlated optical and AI-infrastructure exposures; several individually modest positions can still represent one large financing-sensitive bet.

For execution, I would retain the trader’s phased schedule under normal liquidity. First refresh COHR’s quote, spread, depth, and earnings calendar. If the position exceeds its applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Do not require a rebound to $285.00. The supplied $263.32 October 14, 2026 close is a dated reference, not a minimum sale price. Monitor fills, because an unfilled order has not reduced exposure. Accelerate or otherwise reassess the schedule if actual portfolio limits require it, rather than allowing phasing to become an excuse for delay.

For the remaining COHR exposure, I would avoid both automatic re-entry and an indefinite demand for perfect evidence. A bounce alone should not justify restoring the allocation. A later reassessment should consider a reconciled forward-EPS definition, an explanation for weak operating cash flow, credible evidence of funded demand and investment returns, and improving price participation. We need evidence that uncertainty is narrowing—not necessarily every historical ratio already looking ideal. Confirm the FY2027 first-quarter earnings timing through investor relations before deciding how much event risk to retain. Any released risk capacity need not be immediately redeployed, especially into holdings exposed to the same financing shock.

My recommendation remains SELL COHR where an existing position exceeds the applicable risk ceiling. If already within that ceiling, do not add merely to reach it; if unowned, do not initiate, and do not open a fresh short. A complete exit remains available if actual portfolio constraints require it, but it is not established as the default by the supplied evidence. This approach accepts some rebound opportunity cost while limiting unresolved cash-flow and financing exposure—the more defensible balance when operating growth is credible but its conversion into shareholder cash remains unproven. Neutral Analyst: I continue to support SELL COHR to a risk-budgeted underweight. But the remaining disagreement is about what justifies retaining exposure, not whether cash generation is weak. Aggressive Analyst, conviction should attach to correcting excessive exposure—not to an unproven forecast of further declines. Conservative Analyst, a residual position needs an investment rationale, but uncertainty alone does not establish that liquidation offers the best prospective outcome. A moderate strategy is not an arbitrary compromise between you; it separates the sizing decision we can make now from the operating diagnosis that remains unresolved.

Aggressive Analyst, your negative $469 million free-cash-flow sensitivity is useful: restoring operating cash flow to $634 million would still leave a substantial deficit if capital expenditure remained $1.103 billion. My challenge is how that calculation informs the decision. It holds investment at FY2026’s elevated level while restoring operating cash flow only to the prior year’s amount. That is a funding stress, not an estimate of normalized cash generation. You acknowledge that it is not a forecast; we should preserve that distinction when deciding how much additional selling the evidence warrants after the initial reduction.

Conservative Analyst, your response correctly identifies the missing questions: maintenance versus expansion spending, remaining commitments, and the consequences of slowing investment. But four progressively worse quarterly FCF estimates demonstrate increasing cash consumption, not necessarily deteriorating investment returns. We lack the schedules needed to distinguish those possibilities. Equally, my earlier observation that the implied June quarter generated approximately $70 million of annual operating cash flow should not be treated as evidence of an established recovery. Against approximately $556 million of capital expenditure, it remains insufficient reassurance. Neither interpretation earns the right to become our base case yet.

Where I push back more directly on the conservative position is the mandate assumption. You correctly argue that missed appreciation and capital loss have different standing under a capital-preservation mandate. But no actual mandate has been supplied. We should not impose that preference universally, just as we should not assume the caller prioritizes aggressive growth. COHR’s 22.5% revenue growth, 30.6% calculated gross-profit growth, and annual gross-margin improvement to 37.5% are substantive operating evidence. They can support a conditional, limited investment thesis—not merely a place on a watchlist—provided the caller’s objectives and loss capacity permit it.

That does not mean an existing COHR holding deserves preferential treatment simply because it is already owned. Conservative Analyst, you are right that passing a risk limit is necessary but insufficient. The residual thesis should explicitly connect growing revenue and margins to a plausible, testable route toward cash returns. “We might get a bounce” is not enough. Conversely, requiring completed investment payback before allowing any exposure could exclude the very transition an investor intends to capture. The appropriate middle ground is a smaller, reviewable exposure supported by milestones, rather than either indefinite patience or a demand for complete proof.

On liquidity, I think both of you have reached the right factual boundary. COHR’s $1.162 billion of cash and 2.43× current ratio matter, but neither answers how quickly noncash assets become spendable funds. The sequential cash decline and increase in current liabilities also matter, but do not establish distress. The $1.477 billion of net financing inflows needs a financing and capital-structure reconciliation; it cannot be assumed to be entirely debt or evidence of unavoidable dilution. Information gaps justify limiting exposure. They should not be counted repeatedly as separate, demonstrated adverse events.

I also support the conservative proposal to use direct drawdown and event-gap stresses alongside valuation scenarios. The approximately $168.64 downside illustration and $351.34 upside illustration are not the endpoints of an estimated trading range. Both depend on an unresolved forward-EPS definition, neither has an established probability, and COHR can trade outside either figure. Use the downside exercise to test portfolio tolerance and the upside exercise to recognize opportunity cost. Neither establishes expected return, and averaging them would not produce a defensible target.

Technically, the supplied evidence still favors measured reduction. COHR is below the verified $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined. That argues against waiting for a favorable rebound before correcting an oversized position. But weekly and monthly SuperTrend remain UP, while the daily Z-score of −2.05 and potential longer-window OBV divergence leave meaningful rebound risk. Those observations do not validate funding economics, as the Conservative Analyst correctly notes. They do affect the opportunity cost and execution risk of selling everything immediately. They support neither an unconditional hold nor a chased short.

The protective-exit question needs a separate answer. COHR’s supplied $22.50 ATR—approximately 8.5% of the dated close—makes an arbitrarily tight stop vulnerable to ordinary volatility. It also does not define a maximum loss. Use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger, not the historical $255.29 value as a standing protective stop. Portfolio-loss, concentration, and event-risk limits must operate independently. A stop order would not eliminate gap risk; equally, the absence of a numerical stop does not automatically require liquidation if the caller permits a position managed through stress limits and explicit escalation rules.

On macro and sentiment, I would caution both of you against letting several descriptions of the same selloff become multiple confirmations of the thesis. Headline-only funding concerns, repeated social commentary, and falling prices are not independent proof of financing failure. The supplied prediction-market snapshot priced an October hold at 70% and a 25-basis-point hike at 28%; it argues against relying on imminent easing, not for assuming tightening. Rising yields could pressure valuation and customer funding even with healthy optical demand. Stabilizing yields and demonstrably funded investment could improve the outlook. Official macro data were unavailable, so these remain conditional channels rather than verified explanations.

For sizing, retain the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the exposure permitted by COHR’s assigned stress-loss budget, and applicable concentration and liquidity limits. Half the standard allocation is a provisional ceiling, not evidence of an optimal weight, and certainly not an instruction to buy toward it. The stress budget must account for simultaneous losses in other optical and AI-infrastructure holdings. Several small positions can still constitute one large financing-sensitive exposure. Released capacity need not be immediately redeployed; replacing COHR with a highly correlated holding may change the ticker without meaningfully diversifying the risk.

Execution should remain practical. Refresh COHR’s quote, spread, depth, and earnings calendar first. If the existing position exceeds its applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. Monitor actual fills. Reassess the pace if a portfolio breach or verified earnings timing makes that schedule inappropriate. Do not require a rebound to $285.00, and do not treat the supplied October 14, 2026 close of $263.32 as a live quote, guaranteed fill, or minimum sale price. Missing holdings, portfolio value, standard allocation, and risk limits prevent an exact share recommendation.

Finally, make reassessment time-bound without demanding perfect evidence. Confirm COHR’s FY2027 first-quarter earnings timing through investor relations and review any retained event exposure beforehand. Subsequent disclosures should be tested for a working-capital bridge, remaining investment commitments, funding capacity, a defined forward-EPS basis, and measurable cash-conversion milestones. Improving participation would strengthen that evidence; a bounce alone would not. Continued unexplained cash weakness or deteriorating funded demand could justify further reduction before a weekly trend reversal. Credible improvement could justify reviewing the ceiling before annual FCF becomes positive—but would be a new decision, not permission to add now.

My recommendation remains SELL COHR where an existing holding exceeds the applicable ceiling. If already within it, do not add merely to reach that ceiling; if unowned, do not initiate, and do not open a fresh short. A complete exit remains available when actual constraints or a failed residual thesis require it, but it is not the universal conclusion supported by this snapshot. That preserves a defensible balance: reduce unresolved cash-flow and financing exposure now, while leaving room for credible operating growth to earn greater confidence later. Neutral Analyst: I still support SELL COHR to a risk-budgeted underweight, but I would make the distinction sharper: the allocation ceiling controls how much exposure is permissible; the investment thesis determines whether any exposure is worth retaining. Aggressive Analyst, a smaller position does not validate the growth transition. Conservative Analyst, unresolved funding questions do not establish that liquidation offers the best prospective outcome. Neither conclusion follows automatically from the evidence.

Aggressive Analyst, COHR’s operating recovery gives your residual thesis substance. Revenue growth of 22.5%, calculated gross-profit growth of 30.6%, and annual gross margin of 37.5% are meaningful achievements. But the crucial bridge is still missing: those results do not establish that the newly committed investment will earn adequate returns for common shareholders. The supplied segment information also cannot tell us how much of that growth comes specifically from AI infrastructure. I would retain your transition thesis only as a testable possibility—not treat improving manufacturing economics as evidence that the investment payoff is already underway.

Your cash-flow breakeven calculations are useful, but they should define questions rather than become hurdles that COHR must clear through one dramatic adjustment. At unchanged capital expenditure, operating cash flow would need substantial improvement; at restored prior-year operating cash flow, investment would need substantial reduction. In practice, a credible transition could involve some combination of working-capital normalization, higher operating profitability, and declining expansion spending. We cannot assume that combination will occur, but neither should we assess the investment solely through static alternatives.

That qualification does not diminish the observed problem. COHR generated $80 million of operating cash flow against $1.103 billion of capital expenditure, producing statement-derived FCF of negative $1.023 billion. It supports reducing excessive exposure now. However, the annual cash-flow figures were unchanged in the October 7–14 comparison. We are responding to an unresolved funding burden, not a newly verified weekly deterioration in operations. Once the planned reduction is completed, repeating the same annual figures should not mechanically become an argument for another reduction without reassessing the residual thesis and portfolio constraints.

Conservative Analyst, your strongest point is that monitoring cannot prevent an earnings gap. I agree. But “funding requirements must be sufficiently understood” needs an operational definition. You are not demanding perfect information, yet an undefined standard could become an indefinite veto on retaining exposure. A workable threshold would identify the material obligations, available funding, remaining investment commitments, and cash-conversion milestones needed to support the position. If essential information remains unavailable at the agreed review, that can justify further reduction. It should not silently become an assumption that unfavorable financing is inevitable.

The same balance applies to liquidity. COHR’s $1.162 billion of cash and 2.43× current ratio are relevant counterweights, while the sequential cash decline and rising current liabilities warrant caution. Neither establishes a dependable funding runway or imminent distress. I agree that dividing cash by an annual FCF deficit would be misleading. Likewise, the $1.477 billion of net financing inflows cannot be classified entirely as debt. The decision should reflect uncertainty about financing economics without counting every missing schedule as a separate adverse event.

On valuation, neither of your illustrative outcomes deserves special forecasting status. Approximately $351.34 makes the opportunity cost of liquidation visible; approximately $168.64 demonstrates the vulnerability to simultaneous earnings disappointment and multiple compression. Neither establishes expected return, and neither bounds possible prices. With the reported 18.7× forward P/E dependent on an undefined forecast period and accounting basis, direct price-drawdown and event-gap stresses are sensible complements. They avoid making the entire risk assessment depend on the same unresolved EPS denominator that weakens the valuation case.

Conservative Analyst, you correctly distinguish rebound risk for a short seller from opportunity cost for a seller reducing a long. But opportunity cost still matters when the caller’s objectives include growth. It cannot override a binding risk limit; it can influence discretionary exposure and execution within those limits. That is why I would not dismiss COHR’s intact weekly and monthly SuperTrend signals, daily Z-score of −2.05, and potential longer-window OBV divergence merely because they do not validate funding economics. They answer a different question.

At the same time, Aggressive Analyst, those signals do not make a residual long inherently attractive. COHR remains below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined. None of the supplied TD-9 setups is complete. The combined evidence supports reducing excess exposure without waiting for a rebound, while avoiding a fresh short after the approximately 22.2% decline. It does not provide a confirmed bottom or a confirmed bearish reversal across all timeframes.

I would also keep macro and sentiment from deciding an otherwise unresolved argument. Higher yields could compress COHR’s valuation and weaken customer investment economics without any confirmed order cancellations. Stabilizing yields and demonstrably funded spending could improve the outlook. But official macro observations were unavailable, and the news was headline-only. The supplied 70% October hold and 28% hike contract prices do not establish either cheaper funding or inevitable tightening. Similarly, ten labeled social posts and overlapping selloff headlines cannot establish broad investor conviction. These sources support scenario planning, not a high-confidence causal diagnosis.

For sizing, use the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the weight permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. Half the standard allocation is neither 0.5% of the portfolio nor an optimal holding. In a simple unlevered stress, the assigned portfolio-loss fraction divided by an assumed COHR drawdown gives a corresponding weight ceiling, but not a maximum-loss guarantee. That assigned budget must already account for simultaneous losses in other optical and AI-infrastructure exposures.

Execution should retain the proposed phasing under normal liquidity. Refresh COHR’s quote, spread, depth, and earnings calendar. If above the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That means half the excess, not half the entire holding. Monitor fills and reassess the pace if actual limits or verified event timing require faster action. Do not wait for $285.00. The supplied October 14, 2026 close of $263.32 is a dated reference, not a live quote, guaranteed fill, or minimum sale price.

For any residual COHR holding, establish explicit responsibility for checking limits and acting on breaches. Use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger, not the historical $255.29 value as a standing protective stop. Portfolio-loss, concentration, liquidity, and event-risk limits must operate independently. The supplied $22.50 ATR highlights volatility; it neither identifies a defensible stop by itself nor caps potential loss. We cannot specify shares or a protective-exit price without the missing portfolio and risk information.

Finally, make the next review consequential rather than ceremonial. Confirm COHR’s FY2027 first-quarter earnings timing through investor relations and assess retained event exposure beforehand. Test subsequent disclosures for a working-capital reconciliation, remaining investment commitments, funding capacity, a consistent forward-EPS basis, and measurable cash-conversion progress. Credible improvement could justify reconsidering the ceiling before annual FCF turns positive. Continued unexplained cash weakness, deteriorating funded demand, or failure to substantiate the residual thesis could justify further selling before a weekly trend reversal.

My recommendation remains SELL COHR where an existing position exceeds the applicable ceiling. If already within it, do not add merely to reach it; if unowned, do not initiate; do not open a fresh short. A complete exit remains appropriate if actual constraints or a failed investment thesis require it, not as the universal default. Released capacity need not be immediately redeployed into another financing-sensitive holding.

The balanced approach is not to split the difference between optimism and caution. It is to reduce the exposure the evidence no longer supports, retain only what a testable thesis and actual loss capacity justify, and specify what would change that judgment. That preserves potential participation without allowing either fear of missing a rebound or fear of all uncertainty to control the decision. Neutral Analyst: I support SELL COHR to a risk-budgeted underweight based on the supplied October 14, 2026 snapshot. But I would separate three questions that can otherwise become tangled: can COHR fund its investment transition, does the common equity offer an attractive prospective return, and can the caller afford the exposure? Strong operating growth does not answer all three. Neither does negative free cash flow. The initial reduction is defensible; the residual holding needs its own justification.

Aggressive Analyst, your transition thesis has substantive support. Revenue growth of 22.5%, calculated gross-profit growth of 30.6%, and annual gross margin of 37.5% are not merely optimistic headlines. Where I would restrain your argument is the step from improving manufacturing economics to worthwhile common-equity participation. Additional working capital, financing costs, capital obligations, and possible dilution can absorb some of the benefit. Those outcomes are not established, but neither are the returns remaining for common shareholders. A smaller COHR position makes that uncertainty more affordable; it does not establish attractive expected returns.

Your strongest sell argument remains the operating-cash-flow decline, not capital expenditure alone. COHR generated $80 million of operating cash flow against $1.103 billion of capital expenditure, producing statement-derived FCF of negative $1.023 billion. Calling all of that “growth investment” would overlook the deterioration before capital expenditure. However, I would not turn your breakeven sensitivities into a requirement that cash flow improve through one dramatic adjustment. A credible transition could combine better collections, higher operating profitability, and a tapering of expansion spending. The missing question is whether those changes fit a realistic timetable.

Conservative Analyst, your request for a timed sources-and-uses assessment is the most useful refinement in this round. Funding must cover the interval before investment pays off, not merely look sufficient after success arrives. But I would distinguish a transition that remains fundable under stress from an equity investment that avoids losses under stress. The former is a business-financing question; the latter is not something an ordinary COHR long can promise. The portfolio must be able to tolerate a disappointing outcome, rather than requiring the company to be insulated from every combined shock.

Your coherent-scenario challenge is also right. We should not assume sharply lower capital expenditure while leaving the capacity-dependent earnings forecast untouched. Nor should we assume rapid growth releases working capital automatically. But consistency matters in the adverse case too: customer delays, expensive financing, margin pressure, and continued investment commitments should be linked through an explicit scenario, not simply stacked because each is possible. The objective is a demanding, economically coherent stress—not a collection of unrelated worst cases designed to force liquidation.

COHR’s liquidity evidence supports neither complacency nor a distress conclusion. The June balance sheet showed $1.162 billion of cash and a 2.43× current ratio, alongside weakening sequential cash and current-liability trends. Those are historical balance-sheet observations, not confirmation of October funding availability. The $1.477 billion of net financing inflows also needs reconciliation; it cannot all be classified as debt. I would want updated usable liquidity, material obligations, and committed funding identified before assigning much confidence to either a comfortable-runway argument or an impending-funding-problem argument.

I would challenge both of you on how disclosure milestones are interpreted. A company missing its own stated cash-conversion commitment is different from our data feed failing to provide a schedule. Either can limit the exposure we can responsibly defend, but only the former establishes a missed operating commitment. Likewise, the changed net-income extracts with unchanged EPS do not establish a restatement. The annual cash-flow figures were unchanged during the supplied weekly comparison. After the initial reduction, further selling should reflect a fresh assessment—not repeated presentation of the same uncertainty as new deterioration.

On valuation, I agree that the reported 18.7× forward P/E is not a dependable margin of safety while the approximately $14.05 EPS denominator lacks a defined period and accounting basis. The approximately $351.34 upside and $168.64 downside illustrations do not resolve that problem. Neither has an established probability, and neither bounds possible COHR prices. Direct drawdown and earnings-gap stresses are therefore sensible complements. The upside illustration can inform opportunity cost after risk limits are satisfied; it cannot offset a downside outcome that breaches those limits.

The technical evidence supports the trader’s measured reduction rather than either extreme. COHR is below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined. That argues against making necessary trimming conditional on a rebound. Yet weekly and monthly SuperTrend remain UP, while the daily Z-score of −2.05 and potential longer-window OBV divergence leave rebound potential. Conservative Analyst, those signals do not protect capital, but they remain relevant to discretionary execution and opportunity cost. Aggressive Analyst, they do not independently establish that the residual long is attractive.

I would also keep COHR’s own funding needs separate from customers’ AI-project financing. They may respond to the same rate environment, but sector funding-fear headlines do not establish a COHR financing shortfall, and COHR’s negative FCF does not establish customer cancellations. Higher yields could pressure both valuation and spending economics; stabilizing yields could help without solving cash conversion. Official macro observations were unavailable, and the supplied 70% hold and 28% hike contract prices are not official forecasts. The small, repetitive social sample is similarly supporting evidence, not a reason to override the financial analysis.

For sizing, retain the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the exposure allowed by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. That is a ceiling, not an optimal weight or an instruction to buy. The assigned budget must account for simultaneous losses in other optical and AI-infrastructure holdings. A simple unlevered stress calculation can divide the assigned portfolio-loss allowance by an assumed COHR drawdown to obtain a weight ceiling, but the selected drawdown is not a maximum-loss guarantee. Missing portfolio information prevents an exact share recommendation.

For execution, keep the proposed phasing under normal liquidity. Refresh COHR’s quote, spread, depth, and earnings calendar. If above the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That is half the excess, not half the entire holding. Monitor actual fills and reassess the pace if portfolio limits or verified event timing require faster action. Do not wait for $285.00, and do not treat the supplied $263.32 close as a live quote, guaranteed fill, or minimum sale condition.

For retained COHR exposure, use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger—not the dated $255.29 reference as a protective stop. The supplied $22.50 ATR highlights substantial volatility; it does not cap losses or determine a defensible stop by itself. Portfolio-loss, concentration, liquidity, and event-risk rules must operate independently, with responsibility for acting clearly assigned. Confirm the FY2027 first-quarter earnings timing through investor relations before deciding how much event exposure to retain.

At that review, test the working-capital explanation, remaining investment commitments, available funding, forward-EPS basis, and measurable cash-conversion progress. Credible improvement could justify reconsideration before annual FCF becomes positive; a reassuring narrative alone should not extend the holding indefinitely. Released capacity need not be immediately redeployed, particularly into another holding exposed to the same financing shock.

My recommendation remains SELL COHR where the existing position exceeds the applicable ceiling. If already within it, do not add; if unowned, do not initiate, and do not open a fresh short. Further reduction or a complete exit remains appropriate if actual constraints or a failed residual thesis require it. The balanced strategy is not to retain exposure merely to avoid rebound regret, or eliminate it merely to avoid uncertainty. It is to reduce unsupported exposure now and let a testable investment thesis and actual loss capacity determine what remains. Neutral Analyst: I remain in favor of SELL COHR to a risk-budgeted underweight using the supplied October 14, 2026 snapshot. We have largely converged on the initial transaction. The remaining disagreement is whether limited exposure is worth retaining—not whether COHR’s cash conversion deserves scrutiny. My adjustment is to make that residual decision explicit rather than let either “preserve participation” or “wait for stronger evidence” become the default.

Aggressive Analyst, your strongest argument is the cash-flow bridge. Your weaker argument is that avoiding a potentially higher re-entry price gives early participation an advantage. Sometimes it does; sometimes the higher price purchases substantially better information and lower financing uncertainty. We cannot quantify that trade-off here. COHR’s approximately 22.2% decline does not establish cheapness, and genuine operating progress does not establish attractive expected returns at the supplied valuation. You acknowledge those limitations, but they should meaningfully constrain how much weight rebound opportunity cost receives.

That said, Conservative Analyst, the operating recovery deserves more than recognition as a reason to monitor COHR. Revenue growth of 22.5%, calculated gross-profit growth of 30.6%, and annual gross margin of 37.5% can support a conditional investment thesis before completed investment payback. They do not justify a full allocation, but neither should the absence of completed cash returns automatically disqualify a transition investment. The appropriate question is whether the remaining assumptions are testable and affordable—not whether uncertainty has disappeared.

The cash evidence nevertheless supports reducing excessive exposure now. Operating cash flow fell from $634 million to $80 million before subtracting $1.103 billion of capital expenditure. Statement-derived FCF was negative $1.023 billion. That defeats the simple defense that negative cash flow is merely attractive expansion spending. But it does not distinguish temporary working-capital absorption from a persistent cash-conversion problem. Nor were those annual cash-flow figures newly deteriorating during the supplied weekly comparison. After completing the initial reduction, we should not repeatedly present the same deficit as fresh evidence for another sale.

Conservative Analyst, your timed sources-and-uses assessment is the right next step, but I would sharpen its purpose. We need to identify the peak cumulative funding requirement during the transition, not just compare one year’s cash balance with one year’s FCF deficit. Annual totals can conceal a short-term funding mismatch; they can also exaggerate persistent cash consumption if investment is concentrated in a particular period. Separate committed investment, potentially deferrable expansion, material obligations, usable liquidity, and committed financing. Then test delayed shipments or collections while existing commitments continue.

Aggressive Analyst, your installed-capacity argument belongs in the constructive version of that same assessment. Previously completed investment could support rising shipments while new expansion spending declines. That is economically plausible, but commissioning schedules, utilization, working-capital needs, and remaining commitments must support it. We cannot simultaneously assume lower investment and unchanged capacity-dependent earnings without explaining the connection. Equally, the adverse case should link its assumptions rather than simply accumulate every possible negative outcome.

COHR’s June cash balance of $1.162 billion and current ratio of 2.43× are relevant counterweights, not verified October funding availability. The sequential cash decline and rising current liabilities warrant investigation without establishing distress. Likewise, the $1.477 billion of net financing inflows cannot all be classified as debt. Both of you should resist turning incomplete financing information into either a comfortable-runway assumption or an impending-crisis narrative.

On valuation, I would stop treating the illustrative upside and downside prices as competing anchors. The approximately $351.34 and $168.64 calculations demonstrate sensitivity; they do not establish expected return, probabilities, or trading boundaries. The more important issue is that the reported 18.7× forward P/E depends on approximately $14.05 of EPS without a defined forecast period or accounting basis. Until that denominator is reconciled, direct drawdown and event-gap stresses should complement—not merely repeat—the earnings-and-multiple analysis.

The technical evidence supports measured execution, not a resolution of the fundamental debate. COHR is below the supplied $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined. That argues against waiting for a rebound before correcting excessive exposure. Yet weekly and monthly SuperTrend remain UP, daily Z-score is −2.05, and the longer-window OBV comparison offers potential positive divergence. Those observations leave rebound potential without establishing a bottom. They support avoiding a fresh short and considering the opportunity cost of discretionary liquidation; they do not independently justify retaining a long.

I would also challenge both of you to look beyond the policy-rate headline when assessing financing conditions. A Federal Reserve hold does not guarantee unchanged long-term yields or customer funding costs, just as a hike contract price does not establish tightening. The supplied 70% hold and 28% hike prices are market-contract observations, not official forecasts. With official macro observations unavailable, verified yields, financing terms, and funded customer commitments matter more than a single policy narrative. The small, repetitive social sample should remain secondary. COHR’s own financing needs and customers’ project financing are related exposures, not interchangeable evidence.

For sizing, retain the lowest applicable ceiling: 0.5× the caller’s standard COHR allocation, the weight permitted by COHR’s assigned stress-loss budget, and applicable volatility, concentration, and liquidity limits. Neither analyst can establish that half a standard allocation is optimal from this information; it is a provisional ceiling. Under a simple unlevered stress, the assigned portfolio-loss fraction divided by the assumed COHR drawdown gives one weight constraint. That calculation is not a hedge or a maximum-loss guarantee. It also must account for simultaneous losses in other optical and AI-infrastructure holdings rather than allocating the same available loss capacity repeatedly.

For execution, keep the proposed phasing under normal liquidity. Refresh COHR’s quote, spread, depth, and earnings calendar. If exposure exceeds the applicable ceiling, sell half the excess in the next liquid session and the remainder over the following one to three liquid sessions using refreshed, executable limit orders. That means half the excess, not half the entire holding. Monitor fills and recalculate remaining excess as positions and portfolio values change. Phasing reduces dependence on one execution moment, but extends time at risk; accelerate or otherwise reassess it if binding limits or verified event timing require. Do not wait for $285.00. The supplied $263.32 close is a dated reference, not a live quote, guaranteed fill, or minimum sale condition.

For retained COHR exposure, use a confirmed weekly break of the recalculated weekly SuperTrend boundary as a risk-review trigger—not the historical $255.29 reference as a fixed protective stop. The supplied $22.50 ATR, approximately 8.5% of the dated close, highlights volatility without capping losses. Portfolio-loss, concentration, liquidity, and event-risk rules must operate independently, with responsibility for acting clearly assigned. Missing holdings, portfolio value, and risk limits prevent an exact share count or defensible numerical protective-stop recommendation.

Finally, make reassessment consequential. Confirm COHR’s FY2027 first-quarter release and call timing through investor relations, then review retained event exposure beforehand. Test disclosures for a working-capital reconciliation, remaining investment commitments, funding capacity, a consistent forward-EPS basis, and measurable cash-conversion progress. A missing vendor schedule is not a missed company commitment, although unresolved essential information can still constrain exposure. Credible improvement could justify reconsideration before annual FCF becomes positive; a reassuring narrative or price bounce alone should not.

My recommendation remains SELL COHR where an existing position exceeds the applicable ceiling. If already within it, do not add or mechanically sell further merely because the same annual figures remain weak; reassess the residual thesis and actual constraints. If unowned, do not initiate, and do not open a fresh short. A complete exit remains appropriate if binding limits or a failed thesis require it. Released capacity need not be immediately redeployed into another financing-sensitive holding.

The moderate strategy does not promise the best return in every outcome. It reduces exposure to unresolved cash economics now, preserves only participation that has an investment rationale and demonstrable loss capacity, and specifies what evidence would change the decision. That is more sustainable than either paying any price to avoid rebound regret or demanding that uncertainty disappear before allowing any participation.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Cap any retained COHR long at the lowest of 0.5× the caller’s standard COHR allocation, its assigned stress-budget allowance, and applicable volatility, concentration and liquidity limits. After refreshing execution data, sell half of any excess in the next liquid session and the remainder over 1–3 liquid sessions using executable limit orders, without requiring a rebound to $285. Do not buy toward the ceiling, initiate if unowned, or open a fresh short. Over 3–6 months, review at the next verified FY2027 first-quarter disclosure and on risk breaches; the dated $255.29 weekly SuperTrend is a review reference, not a fixed stop, especially with $22.50 daily ATR.

Investment Thesis: COHR warrants an underweight, not an automatic exit: the demonstrated cash-generation shortfall outweighs the prospective investment payoff, but substantial operating growth and intact higher-timeframe trends limit conviction in complete liquidation. The trader’s selling proposal implements an exposure reduction rather than a universal instruction to exit. The aggressive analyst supplies the strongest fundamental argument, the conservative analyst improves the risk constraints, and the neutral analyst correctly distinguishes unresolved information from demonstrated operating deterioration.

The decisive evidence is that FY2026 operating cash flow fell from $634 million to $80 million before capital expenditure. Statement-derived FCF equals $80 million minus $1.103 billion, or negative $1.023 billion; growth capex alone therefore cannot explain the cash weakness. Net financing inflows of $1.477 billion accompanied this shortfall, but their debt, equity and other components and common-shareholder costs are unknown. The implied June quarter generated approximately $70 million of operating cash flow against $556 million of capex, leaving negative $486 million of FCF—not proof of a durable recovery. The provider’s approximately negative $650 million FCF conflicts with the statement calculation, although both show cash consumption.

The countercase is substantive: FY2026 revenue grew 22.5% to $7.118 billion, gross profit grew 30.6%, and gross margin reached 37.5%. June cash of $1.162 billion and a 2.43× current ratio argue against assuming distress, but do not establish October usable liquidity or funding runway. These facts support considering a limited, testable transition investment where the caller’s objectives and loss capacity permit it; they do not establish adequate returns on incremental capital. Changed net-income extracts with unchanged EPS do not prove a restatement, and unchanged annual cash-flow data during the weekly comparison are not a fresh operating deterioration.

COHR’s technical evidence supports trimming without waiting for a rebound: the verified $263.32 October 14, 2026 close is below the $293.97 200-day and $303.43 50-day averages, RSI is 39.30, and recent OBV declined. Conversely, weekly and monthly SuperTrend remain UP, daily Z-score is -2.05, and longer-window OBV offers potential positive divergence. After an approximately 22.2% decline, these conditions argue against chasing a fresh short, not for assuming a bottom. Sparse social commentary and qualified macro observations receive little decision weight.

Required price-target calculation: I adopt a conditional valuation planning target of USD 210.80, using the report’s supplied forward EPS of $14.05355 × its illustrated 15× P/E = $210.80325, rounded to $210.80. Relative to the verified close, $210.80 / $263.32 - 1 implies approximately 19.9% downside. Selecting the lower multiple from the report’s sensitivity analysis reflects unresolved cash conversion and funding economics while retaining the full supplied EPS rather than imposing an additional earnings haircut. This is a manager-selected scenario-based objective, not an analyst consensus, verified fair value, probability-weighted forecast or downside boundary. The EPS period and accounting basis are missing, and no peer evidence validates 15×; consequently, confidence in this numerical target is low even though the exposure-reduction decision has medium confidence. The reported 18.7× forward P/E and 63.9× trailing P/E do not establish a dependable margin of safety.

Apply actual holdings and risk limits: 0.5× standard allocation is neither 0.5% of the portfolio nor an instruction to sell half the entire holding. For a simple unlevered long, COHR’s assigned portfolio-loss fraction divided by an assumed drawdown fraction supplies one stress-based weight ceiling; account for simultaneous losses in related holdings and recognize that losses can exceed the stress. Refresh quotes, spreads, depth and event timing, monitor fills and remaining excess, and accelerate reductions if binding limits require it. A confirmed weekly break of the recalculated SuperTrend boundary triggers review, while portfolio-loss and event-risk limits operate independently. The dated $255.29 line and $22.50 ATR do not cap losses. Holdings and risk-budget information are insufficient for an exact share count or defensible numerical protective stop.

Confirm the next FY2027 first-quarter release timing; its date is not supplied. Reconsider increasing exposure only after a working-capital/operating-cash-flow reconciliation, a timed funding sources-and-uses assessment covering remaining capex and material obligations, financing and common-shareholder attribution details, a period-specific EPS basis, and measurable cash-conversion progress supported by funded shipments. Improving price participation should confirm execution, not substitute for valuation; positive annual FCF need not already have arrived. Re-underwrite at the then-current price before rebuilding in 0.25× standard-allocation increments within actual limits. If new disclosures show continuing severe cash burn without a credible funded improvement path, reduce the residual ceiling to 0.25×; material funding stress, sustained demand/margin deterioration or binding portfolio constraints can justify exit. Do not mechanically repeat sales on unchanged historical figures or confuse a missing vendor schedule with a missed company commitment.

Current Price: 263.32

Price Target: 210.8

Confidence: Medium

Time Horizon: 3-6 months